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Counterfeit drugs threaten public health and present unique and complex challenges to 
the criminal justice system and the field of forensic science.  Theft of intellectual property in the 
pharmaceutical industry has caused sickness and death, and it is necessary that the perpetrators 
of these crimes are brought to justice.  In some cases, threats to health and safety are short term; 
in others they are long term.  This research describes these threats in detail. 
The problem is complex, and there are many important factors that need to be considered 
to successfully address the problem.  Public-health challenges, drug-development challenges, 
legal challenges, issues of public policy, and financial considerations are all important aspects of 
the problem that need to be understood.  This research describes these details so that appropriate 
solutions can be proposed. 
The field of forensic science struggles to establish analytical methods to identity 
composition and establish provenance of counterfeit goods.  No method has been shown to be 
universally applied to achieve this goal.  The use of field-portable instruments to detect and 
v 
identify counterfeits in the field is important emerging technology.  These instruments must work 
quickly and accurately.  This research defines the challenges faced by the field of forensic 
science and proposes methods that may be used to address these challenges.  This will enable 
forensic scientists to provide support to law enforcement and other members of the criminal 
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CHAPTER 1:  INTRODUCTION 
Counterfeit and substandard drugs present unique and complex challenges to the fields of 
forensic science and criminal justice.  These goods seriously threaten public health and safety.  
Analytical testing can be challenging because forensic analysis of counterfeit drugs typically 
goes beyond more traditional pharmaceutical methods of drug analysis.  Criminal justice and 
law-enforcement organizations are being forced to evaluate current policies and practices so 
successful investigation and adjudication in these types of cases is possible.  The internet has 
made it possible to easily access these drugs even in places like the United States that have a 
well-controlled legitimate pharmaceutical supply chain.  The problem is multidimensional and 
incorporates matters of law, science, criminal justice, public health, and public policy.  There is a 
need to delineate the integral aspects of the counterfeit drug trade if an effective solution is to be 
proposed. 
Detection and identification of counterfeit drugs is a critical step in the process of 
addressing the counterfeit-drug problem.  The ability to individualize is the foundation of the 
discipline of criminalistics and typically the goal of the forensic scientist.  Classification is also 
important. (De Forest, Gaensslen, & Lee, 1983)  Scientific testing performed to achieve these 
goals must use methods that work accurately and reliably.  Analytical testing of counterfeit drugs 
in the field is usually performed to differentiate an authentic from a non-authentic article and to 
classify these goods.  This capability has value and may help determine source or origin.  In 
situations where evidence will be used court, technologies and methods used must meet the 
standards of admissibility of scientific evidence.  Historically, results of tests performed using 
field instruments were used in a presumptive manner (Fedchak, 2014) to support investigations 
and for probable cause.  More recently, the need to collect court-admissible data in the field is 
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desirable because it may save time and money in the long term.  Another significant advantage 
of the use of diagnostic field tests is the ability to deal with ‘‘dissipating evidence’’ such as 
gunshot residue or explosive traces on the hands of suspects. (Almog, 2006)  When analyzing 
counterfeit drugs, additional considerations make the forensic testing of these goods in the field 
important.  This testing is unique and challenging. 
When analyzing a drug in a pharmaceutical setting to confirm identity, infrared or mass 
spectra may be collected from the sample and used for identification.  An additional routine test 
may then be used to quantify the amount of drug present or establish its distribution throughout 
the final dosage form.  Once the tablet is identified and quantified using standard test methods 
that were developed during the drug-development process, analysis is usually complete.  When 
analyzing counterfeit drugs in a forensic setting, however, identification of the active 
pharmaceutical ingredient (API) is likely only one of many steps in the analytical work flow.  
Analysis of counterfeits may begin with the evaluation of packaging used.  A comparison of 
coatings on laminates used for both dosage form and bulk packaging may serve as a means for 
differentiation.  Physical comparisons of markings and other sample features may also be used 
for this purpose.  Once inside the packaging, physical and chemical characteristics of the dosage 
form may then be evaluated.  If the API is present, further testing is likely required.  Counterfeits 
may have the proper API in the wrong dosage or solid-state form.  Solid-state form of the API is 
important for a variety of reasons.  An example is polymorphism where different polymorphs of 
the same chemical may exhibit different bioavailability.  The polymorphic form created during 
manufacture may also have legal significance because one polymorphic form may be covered 
under patent whereas others may not.  In the case of different solid-state hydrates of the API, the 
wrong hydration level may result in under dosing tablets when hydration levels are too high, or 
3 
over dosing tablets when hydration levels are too low.  In addition dosages and solid-state form 
differences, particle size or distribution throughout the dosage form may be different, or residual 
solvents present may be different.  These differences may be used as points of comparison 
amongst samples.  When evaluating counterfeits, the inactive ingredients may be different from 
the authentic versions of the drug and need to be identified and characterized.  Foreign particles 
present in the counterfeit versions may serve as an additional feature for differentiation and 
identification.  In these cases, non-routine methods of analysis need to be employed. 
The analytical testing of counterfeit drugs is also unique because it is typically the goal of 
the forensic scientist to establish provenance when counterfeit drugs are presented for analysis.  
No method or combination of methods has been shown to be universally applied to achieve this 
goal.  Attempts are usually made to link samples to each other using some chemical or physical 
marker present in the sample. (Alabdalla, 2005; Lopatka & Vallat, 2011; Ortiz, et al., 2011)  
These attempts have been extended to the sourcing of illicit drugs as well.  Creating these links 
between samples is important.  Counterfeiters are frequently members of terrorist organizations 
or organized crime groups. (United Nations Office on Drugs and Crime, 2014)  Establishing 
distribution chains and linking samples from different geographic locations may help bring 
justice.  This justice may be important criminally, for example, in cases when counterfeits cause 
harm or death; or they may be important in civil cases where patent-infringement violations have 
cost brand owners significant costs for which they seek compensation.  A significant limitation 
of all methods currently used to establish provenance is in the limited number of samples 
available for analysis for any given study. (Pérez-Bernal, Amigo, Fernández-Torres, Bello, & 
Callejón-Mochón, 2011)  Testing of samples in the field and creation of a mechanism for law-
enforcement agencies from different locations to share this data would be very valuable, and 
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would provide the forensic scientist with access to larger numbers of samples.  These shared data 
could be used for comparisons, to evaluate trends, and perform other types of data review useful 
in establishing provenance.  
The counterfeit-drug problem is also complex because of both the patenting system and 
laws governing patented drugs.  In the United States, patents are granted through the United 
Stated Patent and Trademark Office (USPTO) and are integrated within the development 
lifecycle of pharmaceutical innovators and generic manufacturers.  The United States patenting 
system as applied to the pharmaceutical industry was completely redefined by The Drug Price 
Competition and Restoration Act of 1984, also known as the Hatch-Waxman Act.   This law was 
designed to protect rights of innovators, while at the same time allowing for generic drugs to 
come to the market as quickly as possible.  It fundamentally changed the patenting system in the 
United States and has had a significant impact on patenting of pharmaceutically relevant 
compounds, drug development, the Food and Drug Administration (FDA) regulatory process, 
pharmaceutical litigation, patent protection, and patent enforcement.  It is important that the 
patenting and drug development processes, and specifically the impact of the Hatch-Waxman 
Act on these processes, is understood.   The impact of counterfeit drugs on criminal justice and 
forensic science are directly related to both patenting and drug development. 
While it is important to understand the patenting processing and its integration with drug 
development, understanding the value of patents is also important.  Patents are granted because 
the patented invention will provide a benefit to society.  This is especially true in the 
pharmaceutical industry.  Drugs patented in the United States are developed and tested in 
accordance with FDA guidelines with the intention of bringing the patented invention to the 
market in the form of a new drug.  Without these patented inventions, society loses and the 
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future of pharmaceutical development is challenged.  Pharmaceutical innovation is an important 
part of society.  It helps cure and treat disease, and improves quality of life.  New drugs will be 
needed to remedy the health problems being created and perpetuated by the presence and 
proliferation of counterfeit and substandard drugs in many regions of the world.  In places like 
Africa and Asia, anti-infective medicines containing sub-therapeutic amounts of API are 
commonly encountered.  These bogus drugs, whether counterfeit or substandard, increase the 
risk of the spread of resistance of disease to available drugs. (Newton, et al., 2006)  Sub-
therapeutic amounts of drug promote resistance.  This factor, coupled with other issues that 
indicate diseases like malaria are impacted by environmental change (Siraj, et al., 2014), makes 
the counterfeit-drug problem even more troubling. 
The future of pharmaceutical innovation is in question.  The drug-development life cycle 
is long, risky, and expensive.  It seems fair to question the future of pharmaceutical innovation 
and the development of new medicines in a global environment where intellectual property (IP) 
rights are not protected and enforced.  These rights are an inherent aspect of the counterfeit-drug 
problem.  Therefore, it is important that the role patents and protection of patent rights play both 
nationally and internationally are understood. 
Counterfeit drugs present challenges to practitioners of law and justice.  Identification 
and prosecution of criminals responsible for the infiltration of counterfeit drugs into the market is 
extremely challenging for a variety of reasons.  For instance, determination of source or origin of 
the drug is not easy, especially considering the global nature of this problem.  In situations where 
determination of source is possible, local laws and jurisdictional issues frequently hamper 
prosecution.  In addition, prosecution of counterfeiters is almost impossible in some regions of 
the world where IP rights are meaningless.  Even in places like the United States, enforcement of 
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IP protection for non-pharmaceutical products can be very difficult and require a level of 
diligence on the part of the brand owner not usually required of victims of crimes.  While some 
relate these cases to being civil cases, IP rights are protected by law and breaking them is a 
criminal activity. (Carruthers & Ariovich, 2004)  For pharmaceutical products, FDA regulations 
highlight the criminal aspect of this problem a little bit better.  While brand owners may have an 
unusual burden to achieve criminal justice, there is, at least, a regulatory, judicial, and legal 
framework in the United States within which these issues may be addressed.  Pharmaceutical 
suppliers governed by FDA must adhere to and work in the United States legal and regulatory 
systems.  Within this jurisdiction, regulations require that suppliers adhere to certain guidelines 
and meet minimum safety, efficacy, and other criteria in order to receive approval to sell 
pharmaceutical drug products to the American consumer.  If these guidelines are not met, laws 
and statutes are in place to ensure that these drug products are not legally available for sale. 
Interestingly, although historically the United States has experienced a tightly controlled 
pharmaceutical supply chain, the FDA appears to be exercising more stringent control over 
manufacturing sites located overseas. (Harris, 2014; Siddiqui & Chatterjee, 2014)  Although 
firms that legally supply drugs to the United States have always been governed by FDA, 
inspections of these facilities are difficult due to geographical location. (Staton, 2012)  In 
February 2014, The New York Times reported that India, the second-largest exporter of over-
the-counter and prescription drugs to the United States, is coming under increased scrutiny by 
American regulators for safety lapses, falsified drug test results, and selling fake medicines.  This 
is important to the American consumer because India's pharmaceutical industry supplies 40 
percent of over-the-counter and generic prescription drugs consumed in the United States. 
(Harris, 2014)  In March 2014, the FDA banned imports from Indian generic manufacturer’s Sun 
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Pharmaceutical Industries Ltd's plant at Karkhadi in the western state of Gujarat, India. (Siddiqui 
& Chatterjee, 2014)  Although the exact reason for the ban was not cited, these recent events 
indicate that the drug problem, specifically quality and counterfeits, is serious. 
Just as importantly, while it is possible to stop sale within the United States in the 
legitimate supply chain, it is very difficult to apply statutes and laws, and enforce these laws 
when they are jurisdictionally unenforceable.  The United States has no jurisdiction in many 
regions of the world where counterfeit drugs are a serious problem.  This situation is further 
complicated by the fact that counterfeit drugs present significant public-health risks, especially in 
less developed and third-world societies where counterfeit drugs are most prolific.  In order to 
address this issue, the role that trade agreements play in enforcement of the goods is important.  
It is not always possible to apply local laws and enforcement in foreign lands where counterfeits 
are produced for sale locally, and methods proposed to stop the proliferation of these goods, 
including trade sanctions must be considered and reviewed. 
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CHAPTER 2.  PROJECT SUMMARY 
Overview 
Counterfeit drugs are a problem for criminal justice.  Theft of IP in the pharmaceutical 
industry has caused sickness and death (Newton, et al., 2006; World Health Organziation, 2008; 
Wondemagegnehu, 1999).  It is necessary that the perpetrators of these crimes are brought to 
justice.  In some cases, threats to health and safety are short term; in others they are long term.  
This research describes these threats in detail. 
The problem is complex, and there are many important factors that need to be considered 
to successfully address the problem.  Public-health challenges, drug-development challenges, 
legal-challenges, and financial considerations are all important aspects that need to be 
understood.  This research details these topics so appropriate solutions to the problem can be 
proposed. 
This project is also important to forensic science.  It defines the challenges faced by the 
field of forensic science and proposes methods that may be used to address these challenges.  
This will enable forensic scientists to provide support to law enforcement and other members of 
the legal system to successfully investigate and adjudicate these crimes. 
This dissertation details and describes the integral aspects of the counterfeit-drug problem 
related to forensic science and the criminal justice system.  It is important to start, therefore, by 
defining the term “counterfeit drug”.  Depending upon the source, the geographic location, and 
the context, this term may have different meanings.  For the purpose of this dissertation, a 
counterfeit drug is one which is deliberately and fraudulently mislabeled with respect to identity 
and/or source.  For instance, a counterfeit VIAGRA® tablet is designed to look as if the tablet 
9 
was manufactured by Pfizer, the brand owner.  The color, size, shape, and tablet markings would 
be such that they give the impression they are an authentic Pfizer VIAGRA tablet.  Figure 1 
(Hensley, 2013) shows the front and back of authentic and counterfeit VIAGRA tablets.  The 
tablets on the left (top and bottom) are counterfeit; the tablets on the right (top and bottom) are 
authentic.  
 
Figure 1.  Counterfeit VIAGRA pills on the left (top and bottom) 
and authentic VIAGRA on the right (top and bottom). 
The problem of counterfeit drugs is also significantly impacted by substandard drugs.  
Substandard drugs are considered in this dissertation.  Sometimes with regard to drugs, the terms 
“counterfeit drug” and “substandard drug” are mistakenly used interchangeably.  Substandard 
drugs include, but are not limited to, illegal imitations, expired drugs repackaged for sale, and 
drugs that have not been stored properly and have may have lost efficacy.  An illegal imitation is 
a drug whose sale is in violation of government regulation (and is, therefore, illegal), but is not a 
counterfeit because the drug is not purported to be the brand name of the patent holder (the drug 
is “generic”).  An example of an illegal imitation is an unregulated generic version of a drug.  
For instance, tablets of sildenafil citrate (VIAGRA) sold within the United States, but that do not 
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analytical testing of non-authentic samples in the field using portable instruments.  In addition, 
the challenges of admissibility as evidence in United States courts of each of these technologies 
for this intended use in the field is presented.  Chapters 12 through 16 detail the aspects of the 
counterfeit-drug trade that impact public health, and therefore, impact forensic science and 
criminal justice.  It is important to describe these roles and processes so that the problem is 
understood and an appropriate solution can be proposed.  Chapter 12 describes the drug-
development process regulated by FDA.  Chapters 13 and 14 describe patents and the patenting 
process as related to the pharmaceutical industry, including a discussion of the Hatch-Waxman 
Act and critical aspects relevant to IP protection and future of the pharmaceutical innovation.  
Chapter 15 describes ways to enforce IP rights including enforceable laws in some jurisdictions, 
and sanctions and trade agreements in others.  Chapter 16 describes funding of pharmaceuticals.  
Chapter 17 summarizes the long-term challenges counterfeit drugs have on public health.  This 
chapter will describe how counterfeit drugs will impact the future of pharmaceutical innovation.  
Finally, the thesis is summarized in Chapter 18.  The value and contribution of this project to 
forensic science and criminal justice is described. 
Research Questions 
The research questions that were answered in this dissertation are as follows: 
(1) To what extent do counterfeit and substandard drugs present a public-health 
problem? 
(2) Is it possible to develop an analytical scheme to identify counterfeit drugs 
using field-portable instrumentation? 
(3) How will failure to protect and enforce IP rights threaten the future of 
pharmaceutical innovation?  
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CHAPTER 3.  TO WHAT EXTENT DO COUNTERFEIT AND SUBSTANDARD DRUGS 
PRESENT A PUBLIC-HEALTH PROBLEM? 
Counterfeit and substandard drugs pose immediate and long-term dangers to public 
health in both developed and developing societies.  The immediate dangers are usually directly 
related to the physical and chemical composition of the drug product.  In some instances, 
poisoning occurs from ingestion; in others, an incorrect dosage of API renders the drug 
ineffective or harmful.  These immediate dangers may even be fatal and will be described in this 
chapter. 
There are at least two long-term dangers counterfeit and substandard drugs pose to public 
health.  The first is the development of resistance to drugs that results from the proliferation of 
counterfeit and substandard drugs; the second is the threat to pharmaceutical innovation that 
these goods present.  The development of drug resistance will be covered within this chapter.  
The threat to pharmaceutical innovation is more complicated, and understanding this threat 
requires an understanding of matters related to criminal justice, regulatory affairs, public health, 
law, and science.  These individual topics will be covered throughout this dissertation, and then 
the threat to pharmaceutical innovation will be covered in chapter 17. 
Immediate Danger of Counterfeit and Substandard Drugs 
The immediate dangers of the counterfeit and substandard drug problem are highlighted 
in the recent actions of the FDA in India.  In February 2014, The New York Times reported that 
India, the second-largest exporter of over-the-counter and prescription drugs to the United States, 
is coming under increased scrutiny by American regulators for safety lapses, falsified drug test 
results, and selling fake medicines.  This is important to the American consumer because India's 
pharmaceutical industry supplies 40 percent of over-the-counter and generic prescription drugs 
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consumed in the United States. (Harris, 2014)  In March 2014, the FDA followed up this report 
by banning imports from Indian generic manufacturer’s Sun Pharmaceutical Industries Ltd's 
plant at Karkhadi in the western state of Gujarat, India. (Siddiqui & Chatterjee, 2014) 
These events are important for a few reasons.  First, they show the importance of the 
issue of drug safety to regulators in the United States.  Larger numbers of drugs are coming from 
overseas where regulators traditionally have been less strict about enforcing drug safety and 
other issues that would be easier to enforce locally at the point of manufacturer.  For example, 
resources available to perform facility inspections overseas have been limited. (Food and Drug 
Administration, 2010; Staton, 2012)  It seems, though, that the threat these goods are posing to 
the American consumer is becoming too great and action at this time is required. (Harris, 2014; 
Siddiqui & Chatterjee, 2014; Staton, 2012)  Second, it shows the amount of control the FDA has 
to protect its regulated drug trade.  Although these plants are not located within the United 
States, they are required to follow FDA guidelines since they will be selling their product within 
the United States.  This is important because regulation, including enforcement, helps to bring 
safety, but is expensive.  Cost is a factor when evaluating the problem of counterfeit drugs.  
Third, India supplies a large percentage of generic prescriptions to the United States market, but 
the amount of innovative medications coming from this region of the world is significantly lower 
than innovation in the United States and Europe.  This is important because the cost of 
innovation is significantly higher than the cost of manufacturing generics.  This is a very 
important aspect with regard to the future of pharmaceutical innovation.  These details will be 
discussed in later chapters. 
While these recent events are important and show there is a need to address the 
counterfeit-drug problem in the United States, there are no geographical limits to the immediate 
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dangers of counterfeit and substandard drugs.  In fact, you are much more likely to encounter a 
counterfeit drug outside of the United States than you are within its borders.  The record of 
public harm due to counterfeit and substandard drugs throughout the world is well established. 
Some of these instances have been summarized below. 
In 2004, an otherwise healthy 22-year-old Argentinean woman being treated for a mild 
case of anemia died after the seventh injection of a ten-injection treatment with a toxic 
counterfeit iron supplement.  Subsequent analysis showed that instead of iron sorbitol, the API in 
AstraZeneca’s legitimate Yectafer®, the counterfeit samples contained a different iron derivative 
in a concentration three times as high as in the original product.  This caused fatal liver failure.  
Authorities managed to prosecute several members of the counterfeit drug’s distribution chain, 
but those who actually produced the drug were never identified or caught. (Loewy, 2007)  On a 
larger scale, over 100 people in Panama died as a result of taking toxic counterfeit glycerin in 
2006.  These deaths were directly linked to a Chinese manufacturer that made and exported 
diethylene glycol as 99.5% pure glycerin.  This toxic solution of diethylene glycol was 
unwittingly mixed into 260,000 bottles of cold medicine. (Bogdanich & Hooker, 2007) 
Death due to the lack of the proper dosage of API in counterfeit and substandard drugs is 
also documented.  In February 2005, a 23-year-old man presented with a fever to a rural hospital 
in eastern Burma where he was diagnosed as having uncomplicated hyperparasitaemic 
falciparum malaria by microscopy (4.2% infected red blood cells).  He was treated with oral 
artesunate, labeled as made by Guilin Pharmaceutical (Guangxi, People’s Republic of China), 4 
mg/kg once a day, the treatment of choice in this region.  On the third night the young Burmese 
man became unconscious and was transferred to another hospital where he was found to be in a 
coma (Glasgow Coma Score = 3/15), with renal failure and a higher parasitaemia (5.5% infected 
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red blood cells).  He was perfused with intravenous fluids, received an injection of intravenous 
artesunate (2.4 mg/kg) and was transferred to a third hospital where he died within 12 hours of 
arrival from cerebral malaria.  The amount of artesumate in the tablet was determined to be 10 
mg, rather than the purported dosage of 50 mg. (Newton, et al., 2006)  These authors refer to this 
death and others like it as manslaughter.  They present as part of their evidence published 
research showing that artemisinin derivatives were used in this region to treat malaria, and not 
one of 600 patients prospectively studied with ≥4% parasitaemia had died. 
These examples resulted in immediate harm to either the patient or the public in regions 
outside of the jurisdiction of the United States.  These counterfeit or substandard samples are 
either poison or ineffective and lead to harm, disease, or death.  There are many more examples 
throughout the world, but it is important to note that in many cases, instances are not reported, or 
the details of the event are not reported well for various reasons. (Cockburn, Newton, Agyarko, 
Akunyili, & White, 2005) 
In the United States, the situation is usually identified and reported more quickly than in 
other regions of the world.  Recent events related to counterfeit versions of the drug Avastin® in 
the United States were reported and mitigated almost immediately.  Other examples of 
substandard or counterfeit drugs in the United States market are usually responded to with 
similar expediency. (Pills for birth control seized as counterfeit, 1984; Wax, 1995) 
One significant challenge to FDA regulators, though, is in management of drugs in the 
United States market that are the product of a global supply chain.  The recent events related to 
more stringent control in India are evidence of this fact. (Siddiqui & Chatterjee, 2014)  In 
addition, the inability to effectively manage this supply chain resulted in substandard versions of 
16 
the drug heparin infiltrating the highly regulated pharmaceutical market in the United States.  
The consequences were fatal. 
In January 2008, the United States Centers for Disease Control and Prevention began a 
nationwide investigation of severe adverse reactions that were first detected in a single 
hemodialysis facility.  Preliminary findings suggested that heparin was a possible cause of the 
reactions. (Blossom, et al., 2008)  Ultimately, a total of 785 adverse-reaction reports including 81 
deaths in the United States were associated with the contamination of heparin.  Intensive 
investigations, inspections, testing, and chemical analysis related to Baxter’s heparin identified a 
previously unknown contaminant, oversulfated chondroitin sulfate.  Oversulfated chondroitin 
sulfate is a modified form of chondroitin sulfate and was detected in samples of heparin crude 
materials, heparin API’s, and finished heparin drug products. 
Chondroitin sulfate is a naturally occurring in animal cartilage and is often used as a 
dietary supplement and in supplements to treat arthritic joints.  Oversulfated chondroitin sulfate, 
however, doesn’t occur naturally and was created by chemical modification of chondroitin 
sulfate.  The production of crude material for the production of heparin starts with the isolation 
of heparin from pig intestines.  Many of those pigs come from rural farms in China, with the 
intestines initially processed at unregulated small workshops. (Labadie, 2012)  During this crisis, 
it was found that the United States Pharmacopeia (USP) testing monograph for unfractionated 
heparin sodium did not detect the presence of oversulfated chondroitin sulfate in heparin.  New 
tests and specifications have since been developed by the FDA and the USP and put in place to 
not only detect the contaminant oversulfated chondroitin sulfate, but also to improve assurance 
of quality and purity of the drug product. (Keire, et al., 2011) 
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Long-Term Danger of Counterfeit and Other Substandard Drugs 
Drug Resistance 
Counterfeit drugs also present long-term challenges to public health.  They allow for the 
development of resistance to current medications.  Frequently, this type of situation occurs in 
regions of the world where reports indicate that as much as, if not more than, half of prescription 
drugs are suspected to be counterfeits.  It has been reported that counterfeit artesunate (artesunate 
is one of a number of drugs used for the treatment of malaria) comprises between 33% and 53% 
of the supply of this drug in mainland Southeast Asia. (Senior, 2008)  Anti-infective medicines 
containing sub-therapeutic amounts of API, whether counterfeit or substandard, increase the risk 
of spreading resistance to the drug. (Shakoor, Raylor, & Behrens, 1997)  The recent discovery of 
fake artesunate containing small quantities of API (Fernández, et al., 2006; Newton, Green, 
Fernández, Day, & White, 2006) raises the likelihood that these counterfeits will facilitate the 
selection and spread of Plasmodium falciparum parasites resistant to artemisinin derivatives. 
(Newton, et al., 2006) 
Unfortunately, poor-quality drugs are rarely mentioned as important in the evolution of 
drug resistance. This is in part due to the fact that differentiating the relative roles of widespread 
unregulated use of inadequate anti-infectives from poor drug quality is very difficult in these 
geographical regions. (Newton, Green, Fernández, Day, & White, 2006)  According to World 
Health Organization (WHO) data, malaria infected around 219 million people in 2010, killing 
around 660,000 of them - the vast majority in sub-Saharan Africa.  Robust figures are hard to 
establish for a disease that affects mainly poor communities in rural areas of developing 
countries, and some global health experts say the annual malaria death toll could be double that. 
(Kelland, 2014) 
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Aside from malaria, other diseases are reported to develop resistance due to 
counterfeiting.  The high prevalence of substandard chloramphenicol and cotrimoxazole in 
Burma could well have contributed to the high frequency of typhoid antibiotic resistance. (Shwe, 
Nyein, & Yi, 2002)  Poor quality rifampicin and pyrazinamide (Wondemagegnehu, 1999) are 
also likely to be fueling the spread of multidrug-resistant mycobacterium tuberculosis.  Loss of 
these medicines would likely lead to therapeutic failure.  The need for the development of new 
anti-infectives is indicated, when so few new ones are being produced. (Trouiller, et al., 2001) 
This observation is especially problematic when considering results of a recent study of 
global warming and the occurrence of malaria at higher elevations.  These authors reported that 
future global warming could lead to a significant increase in malaria cases in densely populated 
regions of Africa and South America unless disease monitoring and control efforts are increased. 
(Siraj, et al., 2014)  In a study of the mosquito-borne disease that infects around 220 million 
people a year, researchers from Britain and the United States found what they describe as the 
first hard evidence that malaria creeps to higher elevations during warmer years and back down 
to lower altitudes when temperatures cool. (Kelland, 2014)  This in turn "suggests that with 
progressive global warming, malaria will creep up the mountains and spread to new high-altitude 
areas." (Neuhauser, 2014)  People who live in these areas have no protective immunity because 
they are not used to being exposed to malaria, so they will be particularly vulnerable to more 
severe and fatal cases of infection. (Kelland, 2014) 
For their study, Siraj and colleagues analyzed data from Ethiopia and Colombia, looking 
at malaria case records from the Antioquia region of western Colombia from 1990 to 2005 and 
from the Debre Zeit area of central Ethiopia from 1993 to 2005.  By excluding other factors that 
influence malaria case numbers, such as mosquito-control programs, resistance to anti-malarial 
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drugs and fluctuations in rainfall, they found that the median altitude of malaria cases shifted to 
higher levels in warmer years and back to lower levels in cooler years.  The authors purport that 
a clear, unambiguous signal that can only be explained by temperature changes.  They state this 
is indisputable evidence of a climate effect.  The researchers noted that their work was limited to 
two countries on two continents, and suggested it should be replicated in more countries with 
malaria in highland regions before more general trends are assumed. (Siraj, et al., 2014) 
It is clear that both counterfeit and substandard drugs have a negative impact on public 
health and, therefore, are a problem for both the forensic scientist and other practitioners within 
the criminal justice system.  
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CHAPTER 4.  FORENSIC SCIENCE AND COUNTERFEIT DRUGS 
The Role of the Forensic Scientist in the Counterfeit-Drug Problem 
The threat posed by counterfeit drugs to public health and safety was established in the 
previous chapters.  These goods are manufactured and distributed by individuals and criminal 
organizations that need to be identified and brought to justice. (United Nations Office on Drugs 
and Crime, 2014)  Executing this capability relies upon the practice of good forensic science.  
Counterfeit samples need to be identified using methods of analysis that are admissible in court.  
Classification of these samples provides useful information that may be used in an investigative 
manner to establish provenance and identify counterfeiting groups or organizations.  It is 
important that this capability be performed in the field so that decisions about a sample’s 
authenticity may be made without delay.  Frequently and for various reasons, counterfeit drugs 
are sold in foreign countries distant from their manufacture site. (Dean, 2013)  If a Customs 
agent were able to rapidly and reliably establish authenticity, the import of these goods to the 
target nation could be denied before infiltration of these illicit goods into the local supply chain 
occurs. 
Literature Review with Regard to Analytical Testing of Counterfeit Goods 
A review of the scientific literature shows that a method to routinely identify counterfeit 
drugs has not been described.  In addition, although attempts were successful in some specific 
instances, a method for the routine analysis of counterfeit goods or drugs to determine 
provenance is yet to be established.  Finally, there is a lack of discussion in the literature with 
regard to the analysis of counterfeit goods in the field.  Virtually all of the literature describing 
counterfeits references lab-based methods.  Most are used to detect, identify and quantify the 
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pigments contained within ink samples suspected to be used to produce the notes.  The 
conclusion drawn by the authors was that the bank note was consistent with being made using 
inks from the suspect sample, but no attempts were made to individualize the inks to the bank 
notes. (Acampora, Ferranti, Malorni, & Milone, 1991)  Hida, Mitsui and Minami performed x-
ray fluorescence (xrf) and microscopy to analyze counterfeit coins.  The counterfeit coins tested, 
just like the authentic coins, were comprised primarily of copper and nickel.  The amount of 
copper and nickel present was higher in the counterfeit coins.  In addition, the authors noted that 
chromium, manganese, iron, nickel, and zinc profiles of the counterfeit coins were quantitatively 
more variable than what was observed in the authentic coins. (Hida, Mitsui, & Minami, 1997)  
Hida, Sato, Sugawara and Mitsui described analysis of counterfeit coins using xrf and x-ray 
diffraction (xrd).  Using statistical methods, these authors were able to cluster the coins into three 
groups.  One group included 250 counterfeit coins, the second group included 27 counterfeit 
coins and the third group included the four authentic coins analyzed. (Hida, Sato, Sugawara, & 
Mitsui, 2001)  This same year, Hida and Mitsui described xrf testing of prepaid turnpike and 
subway cards.  They developed a multivariate statistical method to categorize 200 authentic 
subway cards into at least four different groups.  This same method was then applied to 20 
counterfeit turnpike cards, as well as 12 authentic turnpike cards.  Using this multivariate 
statistical method, this group of 32 cards was divided into three groups.  One was comprised of 
the 20 counterfeit cards plus one authentic card; the other 11 authentic cards were divided into 
two groups. (Hida & Mitsui, 2001)  Bartle and Watling used laser ablation-inductively coupled 
plasma-mass spectrometry (LA-ICP-MS) to analyze the isotope distribution profiles of porcelain.  
From this work, they concluded that LA-ICP-MS can be used to identify and classify Oriental 
porcelains and establish their origin of country.  They furthered their conclusion by stating that 
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minor variations in the spectral fingerprints of porcelains from the same country can be attributed 
to variations in production methods both over time and between individual potters.  This 
indicated to them a potential to further provenance Oriental porcelains to specific production 
kilns. (Bartle & Watling, 2007)  Sugawara used polarized infrared radiation to differentiate 
counterfeit Japanese passports from authentic samples.  When unpolarized radiation was used, 
the authentic samples were indistinguishable from the counterfeits.  When polarized radiation 
was used, however, peak ratios were used for successful differentiation. (Sugawara, 2007)  
Sugawara also successfully applied confocal-type laser microscopy to Japanese passports with 
the goal of differentiating authentic samples from counterfeits. (Sugawara, Passport examination 
by a confocal-type laser profile microscope, 2008)  Suzuki used the acoustic characteristics of 
500-yen coins to differentiate authentic coins from counterfeits.  The author concluded that this 
simple and rapid technique can not only be used to differentiate authentic from counterfeit coins, 
but also that the method may be applied to the classification of counterfeit coins if databases of 
coins were developed. (Suzuki, 2008)  LaPorte and colleagues used microscopy to analyze the 
printing defects in envelopes.  These authors concluded that their study corroborates previous 
assertions that assessments to determine whether two or more items may have a common origin 
can be based upon the evaluation of printing defects. (LaPorte, Stephens, & Beuchel, 2010)  
Pérez-Bernal and colleagues performed principal component analysis (PCA) on metallic 
distribution data from the ash of tobacco from different brands and types of cigarettes.  This data 
indicates it may be possible to use this type of analysis to assess the brand of tobacco used for 
manufacture of cigarettes.  These authors state that a limitation of their study is in the number of 
different types of tobacco analyzed, as well as in the number of different brands of cigarettes 
analyzed. (Pérez-Bernal, Amigo, Fernández-Torres, Bello, & Callejón-Mochón, 2011)  Romão et 
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al. used electrospray ambient ionization-mass spectrometry (EASI-MS) and showed this 
technique may be successfully applied as a fast and non-destructive screening tool for 
documents, specifically for Brazilian vehicle registration. (Romão, et al., 2012)  Brzezinksi and 
Craft summarized analysis performed on seized samples of counterfeit toothpaste.  These 
samples were analyzed to determine the number of microorganisms present.  Although the 
authors showed the samples contained high numbers of microorganisms, they were not able to 
assign all samples to either a manufacturing site or method of manufacture. (Brzezinski & Craft, 
2012)  Cao, Gao, Fan, and Yan presented an automatic and efficient detection algorithm for 
copy-move forgery for digital counterfeits. (Cao, Gao, Fan, & Yang, 2012)  Nam and colleagues 
used liquid chromatography-mass spectrometry-mass spectrometry (LC-MS-MS) to detect 
corticosteroids in cosmetic creams.  The method allowed for the analysis of large numbers of 
samples in a short period of time.  As a result of this work, illegal steroids were detected in four 
different cosmetic products and resulted in these products being withdrawn from local markets. 
(Nam, Keun, Lee, & Lee, 2012)  Božičević and colleagues used micro Raman spectroscopy to 
identify a common origin of toner-printed counterfeit banknotes.  Their results show that micro-
Raman spectroscopy can be successfully applied as a method for the analysis of color toner 
printed counterfeits, such as banknotes and documents, in some instances. (Božičević, Gajović, 
& Zjakić, 2012).  Baechler and colleagues applied chemometric methods to data from visual 
markers to classify false identity documents.  Their method generated low error rates and was 
concluded to be able to link documents to a common source or to differentiate them. (Baechler, 
et al., 2013) 
With regard to the analysis of counterfeit drugs, most of the literature relevant to the field 
of forensic science describes methods and techniques for the identification and/or quantitative 
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analysis of the API and other ingredients present in the counterfeit drug.   Alabdalla discussed 
the analysis of counterfeit samples of Captagon®, a drug product containing the API 
fenethylline, using GC-MS.  This drug is commonly abused in the country of Jordan and 
throughout the Middle East.  The author concluded that the comparison of chromatographic 
patterns is useful in establishing links between samples under investigation.  In addition, the 
author concluded that profound similarities of chromatographic profiles support the assumption 
that samples could have a common origin, or at least have been produced by the same 
manufacturer. (Alabdalla, 2005)  Baer, Gurny, and Margot used near-infrared (NIR) analysis to 
evaluate cellulose and lactose.  Although they state it may be possible to use this type of analysis 
to source ecstasy tablets, their data is preliminary and the intra- and inter-variability of 
compression batches using this method is unknown. (Baer, Gurny, & Margot, 2007)  
Soltaninejad and colleagues discussed the analysis of counterfeit buprenorphine using GC-MS 
and liquid chromatography (LC) with a diode array detector.  These authors showed that the 
counterfeited samples analyzed were derived from illicit heroin.  Due to the therapeutic and 
metabolic differences between buprenorphine and heroin derivatives, the authors concluded that 
the use of counterfeit buprenorphine leads opiate abusers to serious health risks. (Soltaninejad, 
Faryadi, Akhgari, & Bahmanabadi, 2007)  Venhuis, Blok-Tip and de Kaste used high-
performance liquid chromatography (HPLC) with a diode-array detector fitted with a mass 
spectrometer (MS) detector to analyze three different types of seized natural aphrodisiacs.  All 
three types of samples contained analogs of prescribed erectile dysfunction drugs.  Although 
there was nothing unusual about the analysis, this study is interesting because these drugs were 
likely designed to circumvent patents by using unpatented analogs.  In addition, they are being 
used as natural supplements and, therefore, were also likely designed to circumvent regulatory 
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requirements. (Venhuis, Blok-Tip, & de Kaste, 2008)  Been et al. used NIR and Raman to 
propose a strategy for the classification of counterfeit medicine. (Been, Roggo, Degardin, 
Esseiva, & Margot, 2011)  Kauppila and colleagues purport the use of desorption atmospheric 
pressure photoionization-mass spectrometry (DAPPI-MS) as a screening tool for drug samples.  
A primary advantage of the DAPPI-MS technique compared with GC-MS is speed.  Their 
research showed the DAPPI-MS technique could be used to identify controlled substances within 
drug samples within seconds. (Kauppila, et al., 2011)  Lopatka and Vallat evaluated surface 
granularity of tablets to differentiate different samples from each other.  They purport that this 
type of analysis contains valuable information with regard to production batch identity. (Lopatka 
& Vallat, 2011)  Samms et al. used direct-analysis-in-real-time – time-of-flight – mass 
spectrometry (DART-TOF-MS) to analyze street samples of Xanax®.  The authors propose this 
as a new method to identify API’s. (Samms, Jiang, Dixon, Houck, & Mozayani, 2011)  Jung et 
al. propose a method for quick and reliable identification of counterfeit VIAGRA® and Cialis® 
using image processing and statistical analysis.  Although this method seems useful, one of the 
concerns about the technique is that there is potential for a large number of false positives if 
tablet discoloration occurs. (Jung, Ortiz, Limberger, & Mayorga, 2012)  Logan and colleagues 
used a variety of techniques including thin-layer chromatography, GC-MS, HPLC, and liquid 
chromatography – time-of-flight – mass spectrometry (LC-TOF-MS) to characterize a variety of 
different types of samples including counterfeits.  It is important to note that no counterfeit 
samples analyzed as part of this study contained any active ingredient. (Logan, Reinhold, Xu, & 
Diamond, 2012)  Park and Ayn summarized quantitative analysis of sildenafil and tadalafil using 
high-performance liquid chromatography-ultraviolet spectroscopy (HPLC-UV) analysis 
performed on counterfeit drugs seized in Korea.  One hundred five samples were analyzed.  
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More than half contained more than the prescription dose of sildenafil and tadalafil. (Park & 
Ahn, 2012)  Patterson et al. developed and described an electrospray ionization-liquid 
chromatography-mass spectrometry (ESI-LC-MS) analytical method used to differentiate 
sildenafil from its vardenafil analog.  This work is valuable because these compounds are 
difficult to differentiate using more common MS methods due to similarity in the fragmentation 
patterns of the two compounds when analyzed using a quadrupole MS. (Patterson, Mabe, 
Mitchell, & Cory, 2012)  Ortiz et al. used attenuated total reflection (ATR) Fourier-transform 
infrared spectroscopy (FT-IR) with PCA analysis to classify seized samples of Cialis and 
VIAGRA.  The PCA applied to ATR-FTIR data allowed grouping samples according to their 
different chemical profiles, distinguishing successfully between authentic and counterfeits 
samples.  In addition, PCA scores inserted counterfeit drugs from different seizures in the same 
cluster, suggesting a common illicit source for these medicines. (Ortiz, et al., 2013)  Mariotti and 
colleagues evaluated the trends in counterfeit amphetamine-type simulants after prohibition of 
these goods in Brazil.  These authors concluded that visual inspection and the physical 
characteristics like average mass were useful in indicating forgery.  However, they stated that 
this analysis is limited and alone these measurements were not reliable to distinguish between 
authentic and counterfeit samples.  For some samples they recommended additional analysis 
using GC-MS.  For others they recommended other methods including PCA of ATR-FT-IR data. 
(de Cássia Mariotti, Ortiz, Sousa, Fröehlich, & Limberger, 2013)  Ortiz and colleagues used 
chemometrics applied to UPLC-MS to analyze counterfeit samples of drugs used to treat erectile 
dysfunction. (Ortiz, et al., 2013)  Anzanello et al. proposed a framework for selecting the 
analytical techniques providing the most conclusive data for categorizing seized drugs into 
authentic and unauthentic classes.  With regard to VIAGRA and Cialis, these authors proposed 
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the use of data from UPLC–MS, physical dimensions, and ATR FT-IR. (Anzanello, Ortiz, 
Limberger, & Mariotti, 2014) 
This literature review shows that there is a need for an analytical scheme to rapidly and 
reliably identify counterfeit drugs and establish provenance using methods of analysis that work 
well.  Infrared, Raman, and gas chromatograpy-mass spectrometry (GC-MS) are methods that 
are routinely used to physically and chemically characterize drugs and drug products.  
Investigation of these methods for this use is proposed.  Ideally, this scheme would be applied 
using field-portable instruments in order to rapidly and reliably identify these goods at their port 
of entry.  The scope of this dissertation includes an attempt to establish such an analytical 
scheme using field-portable instrumentation.  Ultimately, the data collected in the field should be 
used to create a database of counterfeit drugs analyzed in order to provide forensic scientists the 
data they need to be able to effectively establish sample provenance. 
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CHAPTER 5.  TESTING IN THE FIELD:  PORTABLE ANALYTICAL 
INSTRUMENTATION 
Design, Performance, and Implementation of Field-Portable Instruments 
It seems appropriate to start this chapter by describing the current state of field-portable 
instrumentation.  It is important that detection and identification of counterfeit drugs is 
performed in the field using methods of analysis that are rapid and reliable.  At Customs check 
points, the ability to detect and identify these goods quickly and accurately will prevent them 
from entering the local supply chain.  It is not always practical or possible to delay entry of cargo 
to wait on results of lab testing.  In fact, border agents typically will only have a few minutes to 
make a go/no-go decision at checkpoints under conditions of high stress. (Pomfret, 2006)  If 
detection and identification can occur in the field, law-enforcement organizations may take 
immediate action to prevent the infiltration of these goods into the market.  It may also help to 
identify counterfeiters, establish provenance, and appropriately adjudicate these cases.  
Significant developments have resulted in the availability of smaller, lighter, and faster 
instruments. (Carrabba, Spencer, Rich, & Rauh, 1990; Lammert, Rockwood, Wang, & Lee, 
2006; Overton, 2010; Reffner & Martoglio, 1995)  In many cases, technology advances have led 
to the availability of handheld measuring devices and spectrometers such as infrared and Raman 
systems. (Smiths Detection, 2014; Wasatch Photonics, 2014)  In the case of GC-MS, portable 
instruments are available that weigh less than 35 pounds. (Smiths Detection, 2014)  These hand-
held and portable instruments are smaller and lighter, but yet generate data that is qualitatively 
comparable to data from laboratory instruments.  There are, however, differences in design, 
performance criteria and implementation between portable and lab-based instruments. 
With regard to design, field portable instruments need to be small, light, rugged, and easy 
to use.  These systems may be hand carried to the site where analysis will be performed.  Large 
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and heavy instruments are not practical or acceptable for this application.  They are expected to 
experience significant wear and tear during transit and at the analysis scene.  Frequently, 
specifications for drop testing and other ruggedization criteria are as critical as the specifications 
for the signal-to-noise ratio of the spectrometer.  Due to the sometimes-precarious environments 
in which these instruments are expected to perform, they must have an easy-to-use software 
interface which generates results-driven answers rather than spectral displays requiring 
significant user interpretation.  Automatic library searching using algorithms tailored to optimize 
results in the field are a significant aspect of these instrument designs.  In addition, sampling and 
other accessories are sometimes required, but are not desirable.  The more complex a field-
portable instrument becomes, the less likely it will become a part of the routine on-scene work 
flow.  There is also a need to minimize impractical consumables.  The more gear that needs to be 
carried to make an instrument perform, the less likely the instrument will be successful in the 
field. 
Performance criteria of field-portable instrumentation, as previously stated, typically 
include specifications for analytical performance as well as for size, weight, and ruggedization.  
Specifications for analytical performance such as signal-to-noise ratio, sensitivity, and levels of 
detection and quantitation will be less stringent than they are for lab-based instrumentation of 
equivalent technologies.  However, instruments will be specified to perform under much more 
extreme environmental conditions than lab-based equivalents.  For instance, specifications may 
be included for performance in cold and hot temperatures, in rainy environments, or even desert-
like conditions.  Field-portable instruments are expected to be drop resistant and specifications 
allow for post-analysis decontamination.  This is a significant factor for instruments intended to 
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be used to detect chemical warfare agents and other toxic chemicals that may be harmful to 
future users of the instrument. 
Ease of implementation of field-portable instruments is also a significant consideration.  
Training requirements should be minimal.  Frequently, the goal is to have non-scientists use 
field-portable instruments.  This translates to a need to minimize modes of operation, simplify 
user interfaces, and generate results-driven answers.  Electronic libraries and the search 
algorithms used to search these databases of spectra are a critical factor when considering the 
potential success of a field-portable instrument.  This is because users in the field do not usually 
have the time available at the scene, or the practical experiences required to process and interpret 
complicated data files.  It is common for field-portable instruments to use library-search 
algorithms designed to identify mixtures rather than use an algorithm like correlation coefficient 
which assumes pure samples.  The ability of the user to separate a mixture sample in the field 
prior to analysis are sometimes limited, so designing the library-search algorithms to compensate 
for this issue during data processing adds value to these systems.  In many ways, field portable 
instruments are only as useful out in the field as the success of their library-search algorithms, 
and the size and quality of the library searched. 
Technologies Evaluated in this Study 
As part of this research, analysis in the field was performed using portable infrared, 
Raman and GC-MS spectrometers. 
Attenuated Total Reflection Infrared Spectroscopy 
Most field-portable mid-infrared systems that are used for rapid analysis in the field 
perform ATR measurements.  This method of infrared analysis is useful in field applications 
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because it requires little-to-no sample preparation.  In addition, ATR spectra are very 
reproducible, which is also useful for field applications. 
Attenuated total reflection occurs when a sample is brought into contact with an internal-
reflection element (IRE) that has a higher refractive index than the sample.  The IRE is also 
referred to as an ATR crystal.  Typical IREs are ZnSe, diamond, and germanium.  ZnSe and 
diamond have refractive indices of 2.4; germanium has a refractive index of 4.0.  If radiation is 
brought through the IRE at an angle greater than the critical angle, the beam will be totally 
internally reflected. 
The critical angle  between two media with different indices of refraction (n1 and n2) 
is defined by the angle whose sin is n1/n2: 
 
For ATR spectroscopy, n1<n2.  A critical angle exists only for radiation traveling through 
a higher-index medium into a lower-index medium.  At angles greater than the critical angle, the 
incident radiation is completely reflected, but there is an electromagnetic field that extends 
beyond the IRE.  This field’s strength decreases as the distance from the IRE surface increases;  
it is referred to as an evanescent wave.  It follows that if an absorbing material is brought into 
contact with the IRE, the evanescent wave will be absorbed at wavelengths where the material 
has an absorption band, and the amount of energy reflected back through the IRE will be 
attenuated. 
The distance the evanescent wave extends past the crystal surface and into any sample in 
contact with the surface can be defined in terms of the depth of penetration.  The depth of 
penetration (dp) is defined as 
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where λ is the wavelength of radiant energy, n1 is the index of refraction of the IRE, n2 the index 
of refraction of the sample, and Θ the angle of incident radiation on the interface.  This depth of 
penetration may essentially be considered the sampling depth. (Reffner & Martoglio, 1995)  
Assuming contact between the IRE and the sample is made, the sampling depth is consistent 
from measurement to measurement.  For field analysis, this is very useful because it makes it 
easier to collect reproducible spectra which can be easily compared with library spectra for 
comparison and identification.  It is important to recognize, though, that transmission spectra are 
not wavelength dependent.  Therefore, comparisons between ATR and transmission spectra 
should allow for expected differences. 
As part of this study, tablet cores were analyzed using a field-portable FT-IR ATR 
spectrometer with a diamond IRE.  In the system used, the diamond sampling area is 1.3 mm x 
0.8 mm.  Less than 1 mg of sample was pressed against the diamond for analysis.  The optical 
engine is designed with a resistively heated wire source, a fiber optic laser diode reference, cube-
corner reflectors, and a thermo-electrically cooled deuterated L-alanine doped triglycine sulfate 
(DLaTGS) detector.  Cube-corner reflectors are mounted on two arms of a double pendulum 
modulator driven by an electromagnetic actuator.  Interferograms are collected by sweeping the 
reflectors over the required optical path difference.  A schematic of this interferometer is shown 
in figure 4.  Both reflectors move synchronously so each reflector travels half the linear distance 
required in a traditional Michelson interferometer. This optical engine is advantageous in field-
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alternating field caused by the electric and magnetic components of the radiation.  During this 
interaction, the electrons of the particle oscillate with the same frequency of the incident 
radiation and thereby produce electromagnetic radiation of the same frequency as the incident 
radiation, but emanating from the particle in all directions.  This appears to be scattered radiation 
and is referred to as Rayleigh scatter.  If, however, the polarizability of the particle, usually a 
molecule, changes rather than remains constant, then the intensity of the scattered radiation 
varies accordingly.  Polarizability is related to the ease of separation of charges in an external 
electrical field.  If one or more normal modes of vibration of a molecule involve changes in the 
polarizability, then the scattered radiation contains this vibrational frequency superimposed upon 
the frequency of the incident radiation.  This is the Raman effect.  For a vibration to be active in 
the Raman effect, the polarizability of the molecule must change during the vibration.  Most 
collisions of the incident photons with the sample molecules are elastic, or Rayleigh.  Raman 
scatter is significantly weaker than Rayleigh scattering. (Willard, Merritt Jr., Dean, & Settle Jr., 
1988)  The use of lasers to generate sufficient Raman signal, coupled with holographic filters to 
reject Rayleigh line scatter enabled significant advances in Raman instrumentation and the field 
portability of these instruments. 
Classical electromagnetic theory predicts the Raman effect, although a quantum 
mechanical treatment is needed for detailed explanation.  According to classical theory, the 
polarization, P, expressed as dipole moment per unit volume, is given equation 3 
 
where E is the magnitude of the electric vector of the electromagnetic field that acts on the 
molecule and α, the polarizability, is the proportionality constant.  Since the magnitude of the 
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electric vector of the electromagnetic field varies with time, t, in a sinusoidal manner, E is 
calculated in accordance with equation 4 
 
and the polarization becomes 
 
The polarizability consists of two parts:  α0, the polarizability when the atoms of a molecule are 
in their equilibrium positions, and a second term that is the sum of the polarizabilities of the 
molecule due to the various rotational and vibrational motions.  Each term of this second part 
varies with the frequency associated with the particular rotation or vibration.  Thus, 
 
where αn is the polarizability associated with the nth rotational or vibrational mode and the rn is 
the maximum displacement of the involved atoms.  Combining equations 5 and 6, the 
polarization becomes 
 
which may be expressed 
 
The first term has the frequency of the incident radiation and is the Rayleigh scattering.  The 
second term is the basis for the Raman effect and represents both the Stokes (v - vn) and anti-
Stokes (v + vn) Raman bands.  As previously mentioned, most collisions of the incident photons 
with the sample molecules result in Rayleigh scatter.  Only a small portion of the excited 
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molecules (10-6 or less) may undergo changes in polarizability during one or more of the normal 
vibration modes, i.e., the Raman effect.  Therefore, holographic filters and their ability to reject 
Rayleigh-line scatter are a significant advancement. 
For their experiment, Carrabba et al. used holographic Bragg diffraction (HBD) filters 
designed for laser-line rejection at 514.5 nm.  The technique for fabricating the HBD filters is 
based upon recording of a hologram in a dichromate gelatin/polymer graft emulsion 
approximately 20-μm thick between transparent plates.  During the recording process, a 
standing-wave pattern generates as set of interference fringes which are recorded in the 
holographic emulsion as successive planes of high and low refractive index.  The planes are 
separated by λ/2, where λ is the wavelength of the recording light in the medium.  When used as 
a filter, only those wavelengths fulfilling the Bragg condition will be diffracted, while other 
wavelengths will be transmitted.  In this way, the filter diffracts at the same wavelength at which 
it was recorded, if recording is carried out at normal incidence.  The holographic images exhibit 
nearly ideal physical properties. (Carrabba, Spencer, Rich, & Rauh, 1990) 
The Raman spectrometer used in this research employs a built-in 785-nm laser with 
f#/1.3 numerical aperture (NA) and volume phase holographic (VPH) grating.  The detector used 
was a back-thinned silicon array CCD with low-noise electronics.  There are some advantages to 
this portable system.  The built-in laser with f#/1.3 NA enables high throughput with minimal 
loss of efficiency.  The VPH grating allows for high diffraction efficiency, minimizes 
polarization effects, and is optimized over a broad range of wavelengths (although there may be 
a tradeoff between maximizing the bandwidth and maximizing the peak efficiency). (Baldry, 
Bland-Hawthorn, & Robertson, 2004)  Rather than having surface structure as in classical 
gratings, VPH gratings diffract light by refractive index modulations within a thin layer of 
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material sandwiched between two glass substrates.  Figure 5 shows a schematic (Kaiser Optical 
Systems, Inc., 2014) of a conventional grating compared with a VPH grating. 
 
Figure 5.  Schematic of diffraction from conventional and VPH 
gratings. 
The intensity of the refractive index modulation and the depth of the grating layer are 
critical parameters in the performance of the grating.  Light is diffracted at angles corresponding 
to the classical grating equation as a function of the incident angle and the frequency of the index 
modulation at the surface of the grating.  The diffraction efficiency, however, is a strong function 
of the relationship between the angle of incidence and angle of diffraction with respect to the 
fringes formed by the refractive-index modulations within the volume of the grating. If these 
relationships satisfy the Bragg condition, which also depends on the depth of the grating volume 
and on the intensity of the grating fringes, then high peak diffraction efficiencies, approaching 
100%, are possible. (Barden, 1998) 
As part of this study, tablet cores were crushed in a mortar and pestle and approximately 
25 mg was transferred to a glass vial.  The sample was analyzed using the Raman spectrometer 
through the glass to evaluate chemical composition.  The resulting Raman spectrum may also be 
sensitive to solid-form differences.  Although approximately 25 mg of sample is present in the 
vial, the analysis spot size was approximately 50 μm for each spectrum collected.   
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Gas Chromtography-Mass Spectrometry 
As part of this study, tablets were analyzed using a field-portable GC-MS to evaluate 
organic volatiles and solvents remaining in the tablet after production (residual solvents).  The 
portable system used employs a low-thermal-mass (LTM) resistively heated capillary column 
directly linked with a miniaturized toroidal ion-trap MS.  This design is advantageous in field-
deployed settings for a few reasons.  The LTM GC column enables fast separation and thermal 
recovery (approximately five minutes between the start of two consecutive injections).  This rate 
of thermal recovery is achieved because only the capillary column of the GC is heated during the 
analysis.  The miniaturized toroidal ion-trap MS minimizes power and vacuum requirements, 
making the technology amenable for field analysis. 
Ion-trap MS systems, by virtue of their simplicity, are ideal candidates for 
miniaturization.  They are inherently small and have only a few ion optic elements that do not 
require highly precise alignment compared with other types of mass analyzers.  The operating 
pressure for ion traps is higher than for other forms of MS, allowing for less stringent pumping 
requirements.  Furthermore, since the radio frequency (rf) trapping voltage is inversely 
proportional to the square of the analyzer radial dimension, a modest decrease in analyzer size 
results in a large reduction in operating voltage and, hence, lower power requirements. 
(Lammert, Rockwood, Wang, & Lee, 2006)  A primary challenge for ion traps, especially when 
maximizing reduction in size, is the management of ion-ion repulsions in the trap.  The toroidal-
ion-trap design increases trapping volume and, therefore, minimizes these ion-ion repulsions. 
The toroidal ion trap can be viewed as a conventional three-dimensional ion trap cross 
section that has been rotated on an edge through space.  Figure 6 shows the geometry of the 
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power requirements.  The ability to operate at higher pressures, as well as the reduction in power 
requirements are the primary advances that enabled field portability. 
In this study, tablets were gently crushed and then heated in a vial for headspace analysis.  
Gases and volatiles in the headspace were sampled using solid-phase microextraction (SPME).  
Samples were thermally desorbed from the SPME upon injection into the GC-MS system.  Fast 
separation (less than three minutes) was performed on the GC.  Analytes eluted directly from the 
column into the ionization chamber of the toroidal ion-trap MS.  An rf trapping field was 
applied, and resonance ejection was achieved by applying a voltage of known frequency to the 
filament end cap and increasing the amplitude of the rf trapping field such that the frequency of 
the ion becomes the same as that applied to the end cap (mass-selective instability scan).  
Dynamic-ionization optimized the number of ions in the trap for each analyte.  Dynamic 
ionization control is a feature that adjusts the filament current in real time to optimize the number 
of ions being generated.  This prevents space charging and other problems that result from 
overload of the ion trap.  The resulting scanned mass range was from 42 to 500 m/z. 
Chemometric Methods 
When collecting large amounts of chemical data, it can be useful to apply mathematical 
methods to extract useful chemical information.  As part of this research, the chemometric 
methods of PCA and canonical variate analysis (CVA) were applied to both the infrared and 
Raman data after autoscaling to investigate the classification and discrimination power of each of 
these methods.  The deconvolution data, specifically the peak positions and areas, also were 
analyzed using hold-one-out cross validation (HOO-CV) PCA-CVA to determine an estimated 
error rate for the classification of sildenafil citrate tablets using each of these methods. 
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As previously stated, data was autoscaled prior to PCA analysis.  Autoscaling is the 
combination of mean centering and variance scaling.  Mean centering is performed by 
calculating the average data vector of all n rows in a data set and subtracting it point by point 
from each vector in the data set. Graphically, mean centering corresponds to a shift in the origin 
of the plot.  Variance scaling is the process of normalizing each column so that the sum of 
squares equals one.  Variance scaling is performed in order to give equal weight or importance to 
all variables (or wavenumbers) in the measured data set, and must be completed after mean 
centering. (Varmuza & Filmozer, 2009) 
Principal Component Analysis 
PCA is a chemometric method that reduces the dimensionality of data based upon the 
variance in the data.  This allows the user to remove the large amounts of data that contain the 
least amount of variance.  As part of this research, the number of starting dimensions was equal 
to the number of wavenumber data points for each spectrum.  For the infrared data, the number 
of original dimensions was 1425; for the Raman data, the number of dimensions was 938. Of 
course this is a highly redundant representation and should be reduced in dimension. (Petraco, 
2014) 
The first PC, i.e., first reduced dimension, is the linear combination of the original 
variables with maximum variance.  The second PC is the linear combination that exhibits the 
second greatest amount of variance, but is orthogonal to the first PC.  Each successive PC 
exhibits less variance than the one before it.  The linear combination of the original variables is 
used to form a set of derived variables, i.e., PC’s.  The matrix form of these derived variables is 
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where the superscript T represents the transpose of APC.  The new data set Z is derived from the 
original variables, but sorted in order of decreasing variance so PC’s containing minimal 
information can be removed.  This allows for the reduction in the number of derived variables 
used without the loss of a significant amount of information from the data. (Varmuza & 
Filmozer, 2009) 
The matrix APC is computed by diagonalizing the p x p maximum likelihood covariance 
matrix (S) of X 
 
where  is the Kronecker product of vectors. 
Canonical Variate Analysis 
For this research, CVA was performed on the derived data computed from PCA.  CVA 
uses a covariance matrix, W-1B, to find the direction of best group separation.  The analysis is 
based on the relationship between-group (B) variance and within-group (W) variance.   
The CVs, ACV, and their eigenvalues, ΛCV, are computed by diagonalizing the covariance 





The non-singular W is inverted using a standard inversion method.  Xi,j represents the j
th 
absorbance response in the ith spectrum and  is the average of all of the spectra in the ith 
sample.  There are ni spectra in sample i.  The eigenproblem for CVA is 
 
and is not symmetric and, therefore, its eigenvectors are not necessarily orthogonal.  Thus as 
opposed to PCA, the CV’s are often not perpendicular.  As a consequence, covariance in the data 
causes the CVA model to fail, which is why spectral data must first undergo PCA.  The last step 
in CVA is the transformation of the data on the basis of the retained CV’s as 
 
Hold-One-Out Cross Validation 
HOO-CV is a method for estimating an algorithm’s error rate (called the estimated error 
rate) for a population of spectra using data from which it was not trained.  HOO-CV was used as 
part of this research to assess the estimated error rates of the mathematical modes created using 
PCA-CVA.  HOO-CV is a useful method to estimate error rates when large data sets are not 
available for testing. (Effron & Tibshirani, 1993)  HOO-CV computes the decision rules using all 
but one of the spectra in the data set.  The HOO-CV estimated error rate is calculated by first 
determining whether the decision rule was correct on a held-out spectrum, x, with true identity, 
y, where ghold-out-x(x) denotes the identity of x assigned by the “hold-one-out” decision rules.  




where the Kronecker delta denotes 1 if y = g(x) and 0 otherwise. 
 
The HOO-CV procedure is repeated for each spectrum in the data set and the results are 




CHAPTER 6.  SAMPLES AND SAMPLING MATRIX 
Sample Procurement 
Testing performed as part of this research was used to develop an analytical scheme to 
rapidly and reliably detect counterfeit drugs in the field.  Attempts were made to procure 
“known” counterfeit drugs for testing.  Many pharmaceutical companies that manufacture drugs 
known to be routinely counterfeited were contacted and requests for samples were made.  
However, no suppliers contacted were willing to provide test samples.  For this reason, samples 
were ordered online from websites offering to sell prescription medication direct to a consumer 
located within the United States without a prescription.  The drug ordered was sildenafil citrate 
100-mg tablets.  No prescription was provided at the time of any online purchase, so it was 
expected that the samples ordered online would be non-authentic versions of Pfizer’s VIAGRA 
100-mg tablets.  This is because prescription medications (like VIAGRA) are not allowed to be 
legally sold within the United States without a prescription.  There are many reported reasons 
this drug is a target of counterfeiters in the United States and around the world, and reports with 
regard to the online purchase of VIAGRA indicate most are fake. (Fiore, 2012)  For comparison, 
sixteen tablets expected to be authentic were purchased in the United States through FDA-
governed pharmacies. 
VIAGRA is not a drug commonly tested in crime labs in the United States.  This is in 
spite of the fact that there are many reports of availability of non-authentic versions, and any 
non-authentic version of this drug sold in the United States is illegal. (35 U.S.C. § 271; Federal 
Food, Drug, and Cosmetic Act, 1938)  The reason non-authentic VIAGRA samples are illegal is 
because they violate FDA regulations, and IP law.  Reasons for this discrepancy are variable and 
include availability of resources within law enforcement, jurisdiction issues, and other 
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enforcement challenges. (Dean, 2013; Faucon & Whalen, 2012; Sen, 2012)  However, it is a 
good drug of choice for inclusion in this testing for a few reasons.  First, VIAGRA is currently 
under patent in the United States. (Ellis & Terret, 2002)  Therefore, any non-authentic sample 
purchased in the United States, by definition, is either an illegal counterfeit or an illegal imitation 
version of the drug.  Second, samples ordered online were purchased from “pharmacies” that 
appeared to be looking for repeat purchasers.  At the time of purchase, each website requested 
contact emails for marketing purposes.  They all also asked for permission to contact the 
purchaser to send a reminder when a “refill” was due.  It was expected, therefore, that tablets 
received would likely contain at least some therapeutic amount of API.  This was valuable from 
an analytical perspective because it required that methods used as part of this scheme be able to 
distinguish samples that were chemically similar to each other.  It would be significantly easier 
to identify counterfeits or imitations if no API or a different API were present in the final dosage 
form. 
Sample Summary 
Websites from which tablets purchased online were ordered were found using various 
search terms and search engines.  Purchases from any website were only made once, i.e., no 
repeat purchases were made from the same website by this researcher.  Table 1 is a summary of 
all samples included in this testing from online purchases and purchases made from FDA-














Singapore (although blister packaging 
identifies country of manufacture as India) 
SING2 
Singapore (although blister packaging 
identifies country of manufacture as India) 
S13 FDA-governed pharmacy in US 
S14 FDA-governed pharmacy in US 
S15 FDA-governed pharmacy in US 
S16 FDA-governed pharmacy in US 
Table 1.  Summary of samples used for analytical testing. 
Sampling Workflow 
Analysis of each sample followed a step-by-step process that included photographic 
documentation, dimensional analysis, and physical/chemical characterization.  The details of 
each method performed will be described in chapters 7 through 10, but the general testing 
process is summarized in figure 7. 
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Figure 7.  Analytical workflow for all test samples. 
Sampling Matrix 
Although attempts were made to analyze at least seven tablets from every sample, this 
was not always possible because in some cases seven tablets were not available for testing.  
Attempts were also made to analyze all seven tablets from each sample for GC-MS analysis.  
This was also not always possible because for some samples, a GC-MS system was not available 
at the time of analysis of that sample, or instrumental problems occurred that prevented analysis.  
Due to the fact that the entire tablet for GC-MS analysis was heated to generate a headspace 
appropriate for sampling, repeat testing at a different time was not an option if instrumental 
problems occurred. 
Clarification of sampling is also necessary for replicate spectra collected from the same 
tablet.  For some Raman spectra collected, there was a file corruption that occurred during data 
transport from the instrument.  Although data for the sample was collected, in some cases, the 
third replicate analysis performed could not be included due to this file corruption. 
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To clarify the exact testing performed, a sample matrix showing all testing performed is 
shown in Tables 2 through 4. 
Summary of All Measurements Performed 
tablet length measurements 210 
tablet width measurements 210 
tablet depth measurements 210 
tablet weight measurements 210 
infrared spectral measurements 231 
Raman spectral measurements 177 
GC-MS measurements 207 
total number of measurements 
(not including photographs) 
1455 
Table 2.  Summary of measurements performed on all samples. 
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Table 3.  Summary of photography and dimensional measurements 
performed on each tablet. 
sample ID sample classification Photographs tablet length tablet width tablet depth tablet weights
S13 T1 Authentic Yes 3 3 3 3
S13 T2 Authentic Yes 3 3 3 3
S13 T3 Authentic Yes 3 3 3 3
S13 T4 Authentic Yes 3 3 3 3
S14 T1 Authentic Yes 3 3 3 3
S14 T2 Authentic Yes 3 3 3 3
S14 T3 Authentic Yes 3 3 3 3
S14 T4 Authentic Yes 3 3 3 3
S15 T1 Authentic Yes 3 3 3 3
S15 T2 Authentic Yes 3 3 3 3
S15 T3 Authentic Yes 3 3 3 3
S15 T4 Authentic Yes 3 3 3 3
S16 T1 Authentic Yes 3 3 3 3
S16 T2 Authentic Yes 3 3 3 3
S16 T3 Authentic Yes 3 3 3 3
S16 T4 Authentic No 0 0 0 0
I1 T1 Illegal Imitation Yes 3 3 3 3
I1 T2 Illegal Imitation Yes 3 3 3 3
I1 T3 Illegal Imitation Yes 3 3 3 3
I1 T4 Illegal Imitation Yes 3 3 3 3
I1 T5 Illegal Imitation Yes 3 3 3 3
I1 T6 Illegal Imitation Yes 3 3 3 3
I1 T7 Illegal Imitation Yes 3 3 3 3
I2 T1 Illegal Imitation Yes 3 3 3 3
I2 T2 Illegal Imitation Yes 3 3 3 3
I2 T3 Illegal Imitation Yes 3 3 3 3
I2 T4 Illegal Imitation Yes 3 3 3 3
I2 T5 Illegal Imitation Yes 3 3 3 3
I2 T6 Illegal Imitation Yes 3 3 3 3
I2 T7 Illegal Imitation Yes 3 3 3 3
I3 T1 Illegal Imitation Yes 3 3 3 3
I3 T2 Illegal Imitation Yes 3 3 3 3
I3 T3 Illegal Imitation Yes 3 3 3 3
I3 T4 Illegal Imitation Yes 3 3 3 3
I3 T5 Illegal Imitation Yes 3 3 3 3
I3 T6 Illegal Imitation Yes 3 3 3 3
I3 T7 Illegal Imitation Yes 3 3 3 3
I4 T1 Illegal Imitation Yes 3 3 3 3
I4 T2 Illegal Imitation Yes 3 3 3 3
I4 T3 Illegal Imitation Yes 3 3 3 3
I4 T4 Illegal Imitation Yes 3 3 3 3
I4 T5 Illegal Imitation Yes 3 3 3 3
I4 T6 Illegal Imitation Yes 3 3 3 3
I4 T7 Illegal Imitation Yes 3 3 3 3
I5 T1 Illegal Imitation Yes 3 3 3 3
I5 T2 Illegal Imitation Yes 3 3 3 3
I5 T3 Illegal Imitation Yes 3 3 3 3
I5 T4 Illegal Imitation Yes 3 3 3 3
I5 T5 Illegal Imitation Yes 3 3 3 3
I5 T6 Illegal Imitation Yes 3 3 3 3
I5 T7 Illegal Imitation Yes 3 3 3 3
S7  T1 Illegal Imitation Yes 0 0 0 0
S7 T2 Illegal Imitation Yes 3 3 3 3
S7 T3 Illegal Imitation Yes 3 3 3 3
S7 T4 Illegal Imitation Yes 0 0 0 0
S7 T5 Illegal Imitation Yes 0 0 0 0
S7 T6 Illegal Imitation Yes 0 0 0 0
S7 T7 Illegal Imitation Yes 3 3 3 3
S7 T8 Illegal Imitation Yes 0 0 0 0
S8 T1 Counterfeit Yes 0 0 0 0
S8 T2 Counterfeit Yes 0 0 0 0
S8 T3 Counterfeit Yes 0 0 0 0
S8 T4 Counterfeit Yes 3 3 3 3
S8 T5 Counterfeit Yes 3 3 3 3
S8 T6 Counterfeit Yes 0 0 0 0
S8 T7 Counterfeit Yes 0 0 0 0
S8 T8 Counterfeit Yes 3 3 3 3
SING1 T1 Illegal Imitation Yes 3 3 3 3
SING1 T2 Illegal Imitation Yes 3 3 3 3
SING1 T3 Illegal Imitation Yes 3 3 3 3
SING1 T4 Illegal Imitation Yes 3 3 3 3
SING1 T5 Illegal Imitation Yes 3 3 3 3
SING1 T6 Illegal Imitation Yes 3 3 3 3
SING1 T7 Illegal Imitation Yes 3 3 3 3
SING2 T1 Illegal Imitation Yes 3 3 3 3
SING2 T2 Illegal Imitation Yes 3 3 3 3
SING2 T3 Illegal Imitation Yes 3 3 3 3
SING2 T4 Illegal Imitation Yes 3 3 3 3
SING2 T5 Illegal Imitation Yes 3 3 3 3
SING2 T6 Illegal Imitation Yes 3 3 3 3
SING2 T7 Illegal Imitation Yes 3 3 3 3
Total Number of Measurements 210 210 210 210
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Table 4.  Summary of infrared, Raman and GC-MS measurements 
performed on each tablet.  
sample ID infrared spectra core Raman spectra core GC‐MS at 60C standard fiber GC‐MS at 60C carboxen fiber GC‐MS at 110C standard fiber GC‐MS at 110C carboxen fiber
S13 T1 3 0 1 1 1 1
S13 T2 3 0 1 1 1 1
S13 T3 0 0 0 0 0 0
S13 T4 3 0 1 1 1 1
S14 T1 3 0 0 0 0 0
S14 T2 3 0 1 1 1 1
S14 T3 3 0 0 0 0 0
S14 T4 3 0 0 0 0 0
S15 T1 3 3 1 1 1 1
S15 T2 3 3 1 1 1 1
S15 T3 3 3 1 1 1 1
S15 T4 3 3 1 1 1 1
S16 T1 3 3 1 1 1 1
S16 T2 3 3 1 1 1 1
S16 T3 3 3 1 1 1 1
S16 T4 0 0 1 1 1 1
I1 T1 3 2 1 0 1 1
I1 T2 3 3 1 0 1 1
I1 T3 3 2 1 0 1 1
I1 T4 3 3 1 0 1 0
I1 T5 3 2 1 0 1 0
I1 T6 3 3 1 0 1 0
I1 T7 3 3 1 0 1 0
I2 T1 3 3 0 1 1 0
I2 T2 3 3 0 1 1 0
I2 T3 3 2 1 0 1 0
I2 T4 3 3 0 1 1 0
I2 T5 3 3 1 0 1 0
I2 T6 3 3 1 0 1 0
I2 T7 3 2 1 0 1 0
I3 T1 3 3 1 1 1 1
I3 T2 3 2 1 1 1 1
I3 T3 3 3 1 1 1 1
I3 T4 3 3 1 1 1 1
I3 T5 3 3 1 1 1 1
I3 T6 3 3 1 1 1 1
I3 T7 3 3 1 1 1 1
I4 T1 3 3 1 1 1 1
I4 T2 3 3 1 1 1 1
I4 T3 3 2 1 1 1 1
I4 T4 3 3 1 1 1 1
I4 T5 3 3 1 1 1 1
I4 T6 3 3 1 1 1 1
I4 T7 3 3 1 1 1 1
I5 T1 3 3 1 1 1 1
I5 T2 3 3 1 1 1 1
I5 T3 3 3 1 1 1 1
I5 T4 3 3 1 1 1 1
I5 T5 3 3 1 1 1 1
I5 T6 3 3 1 1 1 1
I5 T7 3 3 1 1 1 1
S7  T1 3 0 0 0 0 0
S7 T2 3 3 1 0 1 0
S7 T3 3 3 0 0 0 0
S7 T4 3 0 1 1 1 1
S7 T5 3 0 1 1 1 1
S7 T6 0 0 0 0 0 0
S7 T7 3 2 0 0 0 0
S7 T8 3 0 0 0 0 0
S8 T1 3 0 0 1 1 0
S8 T2 0 0 0 0 0 0
S8 T3 3 0 0 0 0 0
S8 T4 3 2 0 0 0 0
S8 T5 3 3 0 0 0 0
S8 T6 3 0 1 1 1 1
S8 T7 3 0 0 0 0 0
S8 T8 3 3 0 1 1 0
SING1 T1 3 3 0 0 0 0
SING1 T2 3 3 1 0 1 0
SING1 T3 3 3 1 0 1 0
SING1 T4 3 3 0 1 1 0
SING1 T5 3 3 0 0 0 0
SING1 T6 3 3 0 1 1 0
SING1 T7 3 3 0 0 0 0
SING2 T1 3 3 1 1 1 1
SING2 T2 3 3 1 1 1 1
SING2 T3 3 3 1 1 1 1
SING2 T4 3 3 1 1 1 1
SING2 T5 3 3 1 1 1 1
SING2 T6 3 3 1 1 1 1
SING2 T7 3 3 1 1 1 1
Total Number of Measurements 231 177 57 50 64 46
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CHAPTER 7.  DIMENSIONAL ANALYSIS AS A TOOL FOR IDENTIFICATION AND 
DIFFERENTIATION OF AUTHENTIC DRUGS 
Introduction 
The manufacture of pharmaceutical tablets is a complicated process.  Raw materials are 
blended together using a variety of solvents, usually at elevated temperatures.  These materials 
are ultimately dried and compressed into tablets of specified physical dimensions.  
Manufacturing equipment such as the die’s used to impress product-specific labeling into the 
tablet also change the physical features of the tablet.  For coated tablets, coating materials and 
the process used to perform the coating may also impart upon the final dosage form 
characteristics that are specific to the manufacturer.  Analysis and comparison of these 
dimensional measurements and other physical and chemical properties between authentic and 
non-authentic samples may sometimes result in the ability to quickly and easily differentiate 
authentic from non-authentic samples. (Jung, Ortiz, Limberger, & Mayorga, 2012)  This data 
may be further used to classify counterfeit drugs providing investigative leads useful in 
establishing source or origin.  They are also amongst the easiest of analyses to perform in the 
field. 
Tablet weight is an important measurement because it is difficult, unless samples are 
manufactured identically using the same types and amounts of ingredients, to generate a 
reproducible tablet weight.  An analytical balance will easily detect these differences, especially 
in cases where tablets might otherwise appear grossly to be the same.  Physical dimensions such 
as length, width, depth, and overall tablet shape may also be different if different manufacturing 
equipment is used to press the final product.  A caliper may be used to measure these properties.  
Tablet color and coating details will also depend upon both the raw materials used, as well as the 
process used to coat the tablet.  Aside from color and chemical composition, coatings may 
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appear and behave differently.  Photographs may be used to document these differences.  In this 
study, photographs of tablets were taken and dimensional measurements were performed to 
determine whether or not it was possible to differentiate between authentic from non-authentic 
samples. 
Experimental Details 
Each tablet was weighed and photographed.  The tablet’s length, width, and depth were 
measured using a digital caliper.  The average weight, length, width, and depth were calculated 
for all tablets of a given sample.  Results were compared for different tablets of the same sample, 
as well as for different samples. 
Photography 
Photographs were taken using a Samsung Galaxy phone with camera, model SCH-1535, 
Android version 4.1.2.  Tablet images were collected from both sides of each tablet at three 
different distances.  Images captured from a distance of 60.4 mm were selected for inclusion in 
this summary.  Magnification was set to 4.0 times, but autofocus was used. 
Tablet Dimensions 
Measurements of tablet length, width, and depth were taken for each tablet using a 
Ferance Construction Co. digital caliper:  For each dimension, three measurements were taken 
for each tablet.  The “AVERAGE” function of Microsoft Excel was used to calculate the tablet’s 
dimension value from the three measured values (Microsoft Excel 2010 running on Windows 7 
Enterprise, Service Pak 1, 64-bit Operating System).  The average dimension and standard 
deviation for each sample was then calculated from the determined values for each tablet of the 
sample using the “AVERAGE” and “STDEV” functions within Microsoft Excel.  From these 
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values, the %RSD was calculated for each sample using Microsoft Excel with the formula 
“=(STDEV/AVERAGE)*100”. 
Tablet Weights 
Tablet weights were measured using two different balances.  The balance used was based 
upon availability at the time of analysis.  Each balance had a readability as low as 0.1 mg.  Both 
balances were under service contracts for calibration at all times measurements were made.  For 
each tablet, sample weight was measured three times.  The balance was tared between 
measurements.  The “AVERAGE” function of Microsoft Excel was applied to the three values to 
determine tablet weight (Microsoft Excel 2010 running on Windows 7 Enterprise, Service Pak 1, 
64-bit Operating System).  The average weight and standard deviation of the sample were then 
calculated from the weights all tablets of the sample using the “AVERAGE” and “STDEV” 
functions within Microsoft Excel.  The %RSD was using Microsoft Excel with the formula 
“=(STDEV/AVERAGE)*100”. 
Results and Discussion 
It was possible to differentiate the authentic samples from all non-authentic samples 
based upon visual observation.  For eight of the nine non-authentic samples, the tablets could 
very easily be distinguished from the authentic samples with the unaided eye.  These eight non-
authentic samples exhibited obvious differences in color, tool-mark impressions, and even shape, 
from the authentic samples.  Weight measurements were also frequently different from each 
other.  The ninth sample, sample S8, was counterfeit and was more similar in general appearance 
than the other eight samples to the authentic samples.  These tablets were still differentiable, 
however, by visual observation, when compared with authentic VIAGRA.  Just like for authentic 
100-mg VIAGRA tablets, the tablets of sample S8 were coated, light-blue tablets.  They were 
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labeled “Pfizer” on one side and “VGR 100” on the reverse side.  Figure 8 shows the front of a 
tablet from sample S8 alongside a tablet of an authentic sample.  Figure 9 shows the back side of 
both tablets.  Although the counterfeit sample is intended to look like an authentic VIAGRA, the 
appearance of this tablet is different from that of authentic VIAGRA when a side-by side 
comparison of the two samples is made.   Aside from size and color, tool-mark impressions 
appeared different between tablets of the authentic samples and the tablets of sample S8.  The 
benefit of having an authentic sample for comparison made this differentiation based upon visual 
observation alone quite easy.  If no authentic for comparison was available, it would have been 
more difficult to identify this tablet as a counterfeit without measuring tablet size and/or weight. 
 
Figure 8.  Front side of a counterfeit VIAGRA tablet (left) 
alongside an authentic VIAGRA tablet (right).  Both tablets are 




Figure 9.  Back side of a counterfeit VIAGRA tablet (left) 
alongside an authentic VIAGRA tablet (right).  Both tablets are 
displayed on the same scale. 
Table 5 summarizes the dimensional analysis for all the samples analyzed.  The tablets of 
sample S8 are slightly larger than the authentic samples in length and width, and weighed 
approximately 100 mg more than did the authentic samples.  Standard deviations were also 
calculated for each measurement of each tablet and are shown in this table.  The relative standard 
deviation (RSD) amongst different tablets of the same samples was always less than 2% for each 
sample.  This shows that for a specific sample, all measured values were consistent from tablet to 
tablet. 
 
Table 5.  Summary of dimensional measurements of samples 
analyzed. 
Sample 
Number Length (mm) St Dev %RSD Width (mm) St Dev %RSD Depth (mm) St Dev %RSD Weight (mg) St Dev %RSD
I1 14.39 0.01521 0.11 10.42 0.01894 0.18 5.57 0.0969 1.74 609.1 7.01 1.15
I2 14.63 0.02085 0.14 10.48 0.01755 0.17 5.36 0.0398 0.74 557.9 5.37 0.96
I3 11.62 0.01357 0.12 11.85 0.02460 0.21 5.35 0.0581 1.09 528.1 4.63 0.88
I4 14.43 0.02175 0.15 10.46 0.00970 0.09 5.66 0.0251 0.44 602.4 7.67 1.27
I5 14.52 0.01538 0.11 10.50 0.00720 0.07 5.10 0.0316 0.62 642.3 4.64 0.72
S13 (authentic) 14.77 0.02722 0.18 10.65 0.07120 0.67 5.77 0.0160 0.28 633.0 10.59 1.67
S14 (authentic) 14.70 0.04787 0.33 10.57 0.02722 0.26 5.79 0.0397 0.69 633.8 9.36 1.48
S15 (authentic) 14.75 0.02331 0.16 10.62 0.00694 0.07 5.77 0.00739 0.13 618.7 12.08 1.95
S16 (authentic) 14.71 0.01644 0.11 10.61 0.01262 0.12 5.78 0.00839 0.15 615.7 5.36 0.87
S7 14.77 0.00839 0.06 10.54 0.01836 0.17 4.82 0.0735 1.52 502.3 7.31 1.45
S8 14.92 0.00839 0.06 10.78 0.01333 0.12 5.68 0.0301 0.53 733.6 5.15 0.70
SING1 11.69 0.01638 0.14 11.92 0.01835 0.15 5.47 0.0507 0.93 541.1 4.49 0.83
SING2 11.72 0.02193 0.19 11.95 0.03173 0.27 5.46 0.0305 0.56 533.2 5.97 1.12
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Although it was possible to distinguish the non-authentic samples from the authentic 
samples, analysis of variance (ANOVA) was applied to the data to determine whether the 
variance could be used to differentiate non-authentic samples that were very similar in 
appearance to each other.  For example, samples I1 and I4 were very similar in dimensional 
measurements and physical appearance to each other.  Using the physical measurements of 
length, width, depth, and weight, t-tests indicate that there is a statistically significant difference 
between I1 and I4 at the 5% level of significance.  However, using the physical measurements of 
length, width, depth, and weight, ANOVA analysis of the four authentic samples indicates there 
is also a statistically significant difference even amongst these authentic samples.  This variance 
in these four authentic samples indicates t-tests and ANOVA analysis of the physical-
measurements data collected from these samples alone is not an appropriate method of 
discrimination. 
The box plots generated from ANOVA analysis of the length measurements of authentic 
samples is shown in figure 10.  The box plots generated from the t-test analysis of the length 
measurements of I1 and I4 re shown in figure 11.  The box plots highlight the median value for 
each sample.  Although only the results from the length measurements are shown, the same 
general amount of variance was observed for the measurements of width, depth, and weight. 
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Figure 11.  Box plots generated from length measurements of 
samples I1 and I4. 




Figure 12.  Images of the front and back of a tablet of I1. 
 
Figure 13.  Images of the front and back of a tablet of I2. 
 
Figure 14.  Images of the front and back of a tablet of I3. 
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Figure 15.  Images of the front and back of a tablet from I4. 
 
Figure 16.  Images of the front and back of a tablet from I5. 
 
Figure 17.  Images of the front and back of a tablet from S7. 
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Figure 18.  Images of the front and back of a tablet from SING1. 
 
Figure 19.  Images of the front and back of a tablet from SING2. 
Summary and Conclusion 
This research shows that detection and identification of all of the non-authentic samples 
was possible based upon visual observation.  In addition, tablet weights and other dimensional 
measurements could be used to differentiate the non-authentic samples from the authentic 
versions.  These measurements were consistent for different tablets of the same sample.  For all 
tablets within a sample, the percent RSD for all measurements of length, width, depth, and 
weight were less than 0.34, 0.68, 1.75 and 1.96, respectively.  T-tests and ANOVA analysis of 
the physical-measurements data collected from these samples alone is not an appropriate method 
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of discrimination.  The within-group variance of these measurements is equal to or greater than 
the between-group variance.  
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CHAPTER 8.  INVESTIGATION AND EVALUATION OF CHEMICAL AND 
PHYSICAL PROPERTIES OF FINAL DOSAGE FORMS USING INFRARED 
SPECTROSCOPY 
Introduction 
Pharmaceutical tablets are typically comprised of active and inactive ingredients blended 
together using specific manufacturing processes.  Specific manufacturing processes are used 
because different processes may alter these ingredients, causing changes in both physical and 
chemical form.  An example of a change in physical form may be the conversion from one solid-
state form of the drug to another; an example of a change in chemical form may be the formation 
of degradation products.  Both the active (and inactive) ingredients may undergo changes in 
solid-state form.  An example of this type of transition is the conversion of a drug substance from 
a crystalline form to an amorphous form. 
Drugs may also sorb water or solvent to form hydrates or solvates.  Some water is sorbed 
interstitially.  This water does not become part of the crystal structure of the drug or incorporate 
itself in the drug chemically.  Water may also be sorbed resulting in differences in crystal 
structure between two hydrated forms of a drug.  In these crystalline hydrates, water is part of the 
drugs crystal lattice.  These hydrates and solvates may or may not desorb during the final 
manufacturing steps. 
Ingredients may also physically or chemically react with each other during tablet 
manufacture or storage.  An example of a physical interaction is the formation of a eutectic.  An 
example of a chemical interaction would be the formation of a degradation product.  These 
interactions may result in tablets that exhibit differences in therapeutic effects, storage stability, 
and physical or chemical composition. 
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When manufacturing processes are well controlled and adhere to regulatory guidelines as 
is typical for an authentic product sold in the United States, the physical and chemical properties 
of the final dosage form is well controlled and reproducible.  The ability to detect and identify 
the physical and chemical form of the final dosage form in a reliable manner is useful, providing 
a compositional fingerprint that is representative of the authentic product and may be used to 
differentiate authentic from non-authentic tablets.  This fingerprint may also be used to classify 
counterfeit drugs, providing investigative leads useful in establishing source or origin. 
Infrared spectroscopy is used to evaluate the chemical and physical form of tablets and 
other drug products.  Data can be evaluated many different ways when applied to the analytical 
challenges associated with counterfeit drugs.  In this study, infrared spectra were compared to 
differentiate authentic from non-authentic samples.  The reproducibility of spectra collected from 
different tablets of a sample was also evaluated.  Spectra were then evaluated to establish 
differences in the relative concentration of the API.  Finally, chemometrics analysis, specifically 
PCA-CVA with HOO-CV, was performed to classify samples and determine an estimated error 
rate for this classification.  Spectra used in this comparison were collected from the core matrix 
of the tablet. 
Experimental Details 
Instrumentation 
Infrared spectra were collected using a HazMatID™ Elite infrared spectrometer (Smiths 
Detection, Danbury, CT).  Performance of the spectrometer was tested at the start and end of 
every work day.  The system always passed performance-test criteria.  The performance test 
method used was the method recommended by the instrument manufacturer.  This test requires 
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that the performance standard meets a minimum library match factor when compared with a 
reference standard spectrum. 
The HazMatID Elite is specifically intended for field use.  Some of the specifications for 
this system, especially those intended to support portability and ruggedization of the instrument, 
are shown in Table 6.  An image of the system is shown in figure 20. 
                    HazMatID Elite Specifications for Portability and Ruggedization 
Compact size 10 5/8 in x 5 5/8 in x 3 1/8 in) 
Weight 2.29 kg 
Operating Environmental 
Temperature 
-20°C to 50°C 
Operating Environmental Humidity 0-100% 
Decontamination IP-67 rated and sealed for decontamination by 
immersion 
User interface 4.3 inches internally bonded LCD color display for high 
visibility in direct sunlight conditions; individually lit 
keypad  
and instructional graphics guide users through the 
operation  
of the device 
Power Rechargeable lithium-ion battery for 4 hours of 
operation;  
compatible with disposable 123A battery 
Repeater RF repeater for extending the wireless data transfer 
range 
Colors Olive drab or yellow 
Wireless Embedded RF modem for 1 km line-of-sight data 
transfer  
and command control;  FIPS 140-2 compliant 
encryption; 
GPS included 
Table 6.  HazMatID Elite specifications for portability and 
ruggedization of importance to this study. 
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Figure 20.  Photograph of HazMatID Elite diamond ATR FT-IR 
spectrometer.  Courtesy of Smiths Detection, Danbury, CT. 
Infrared Method 
Prior to each sample analysis, the diamond IRE was cleaned using a low-lint tissue and, if 
necessary, with an appropriate solvent.  A background spectrum was collected using the default 
method for the instrument set for 8-cm-1 resolution and 32 co-added scans.  Each tablet was 
gently crushed and a small amount of the tablet’s core was pressed against the diamond area until 
the instrument screen displayed in green.  In order for this green readout to appear, the 
absorbance signal level for the spectrum’s largest absorption band must reach a value of at least 
0.11.  A sample spectrum was then collected.  The infrared spectrum was automatically 
calculated and displayed on the screen of the instrument.  For each tablet, three infrared spectra 
from different samples of each tablet’s core were collected. 
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Data Analysis and Chemometrics 
All spectra were then exported from the HazMatID Elite via a USB storage hub and 
transferred to a personal computer.  Each spectrum was opened using the Grams Suite 9.0 
software (Thermo Fisher Scientific, Philadelphia, PA).  Using Grams, a linear multipoint 
baseline correction was performed and corrected to account for diamond uncompensation in the 
spectral region between 2350 cm-1 and 1850 cm-1.  Using the Grams Add-On Excel Exchange 
function, spectra were exported to Microsoft Excel (Microsoft Excel 2010 running on Windows 
7 Enterprise, Service Pak 1, 64-bit Operating System).  Within Microsoft Excel, each spectrum 
was normalized to an area under the curve equal to one.  The normalized spectrum was then 
imported to Grams using the Grams Add-On Excel Exchange.   
The chemometric methods of PCA and CVA were applied to investigate the classification 
and discrimination power of infrared spectroscopy.  Prior to chemometric analysis, the spectral 
region between 2350 cm-1and 1850 cm-1 was deleted from all spectra.  Non-authentic samples 
were sorted into seven groups based upon physical appearance, dimensions, and receipt date; 
authentic samples were categorized into a single group.  The deconvolution data, specifically the 
peak positions and areas, also were analyzed using HOO-CV PCA-CVA to determine an 
estimated error rate for the classification of sildenafil citrate tablets.  
Results and Discussion 
It was possible to differentiate the authentic samples from all non-authentic samples 
using this method.  In most cases, differences in spectra were small but reproducible.  Using 
PCA-CVA, 3D-scores plots were created and visual separation of samples was observed.  This 
observation indicates that not only can infrared spectroscopy be used to differentiate authentic 
from non-authentic samples, but also that this method may be used to sort non-authentic samples 
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and ultimately lead to the establishment of provenance.  Using HOO-CV, an estimated error rate 
of 2.16% was calculated using 12 principal component’s (PC’s).  The error was due to the 
misclassification of samples I1 and I4.  A review of the infrared spectra shows that this 
misclassification is likely due to differing amounts of water in the samples.  Otherwise, the 
spectra were indistinguishable.  It is likely based on all other data collected that these two lots 
share a common origin. 
Figures 21 through 29 show the average infrared spectrum of an authentic sample 
compared with the average spectrum from each of the nine non-authentic samples.  Note that 
with the exception of sample S8, differences in the fingerprint region of the spectra of the non-
authentic samples were small indicating that the chemical composition of the non-authentic 
samples was similar, but not identical to, the chemical composition of the authentic samples.  
Therefore, it was possible to differentiate all non-authentic samples from the authentic ones.  
Sample S8 contained an additional broad absorption band of high intensity that is likely due to 
the presence of calcium sulfate in the sample. 
 
Figure 21.  Infrared spectrum of authentic sample shown in blue 




Figure 22.  Infrared spectrum of authentic sample shown in blue 
compared with non-authentic I2 shown in red (spectra are area 
normalized). 
 
Figure 23.  Infrared spectrum of authentic sample shown in blue 





Figure 24.  Infrared spectrum of authentic sample shown in blue 
compared with non-authentic I4 shown in red (spectra are area 
normalized). 
 
Figure 25.  Infrared spectrum of authentic sample shown in blue 





Figure 26.  Infrared spectrum of authentic sample compared shown 
in blue with non-authentic S7 shown in red (spectra are area 
normalized). 
 
Figure 27.  Infrared spectrum of authentic sample shown in blue 





Figure 28.  Infrared spectrum of authentic sample shown in blue 
compared with non-authentic SING1 shown in red (spectra are 
area normalized). 
 
Figure 29.  Infrared spectrum of authentic sample shown in blue 
compared with non-authentic SING2 shown in red (spectra are 
area normalized). 
Although only the average spectrum for each sample is shown in the preceding nine 
figures, all of the spectra collected from each tablet and from the same sample were consistent 
with each other.  There was some very small variance in the intensities of absorption bands 
within a sample, but there wasn’t a single instance where two spectra from the same sample 
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revealed different absorption bands by visual inspection performed by this researcher.  Figure 30 
shows the 21 spectra collected from the tablet core of the tablets of sample I3.  The variance 
from spectrum to spectrum shown in these figure were typical of the variance observed in spectra 
collected from all tablets of a single sample. 
 
Figure 30.  Twenty-one spectra collected from seven tablets of 
sample I3 (spectra are area normalized). 
Figures 31 and 32 show the standard deviation of the absorbance values of each sample 
plotted as a function of wavenumber.  Figure 31 shows the data in the fingerprint region of the 
spectrum and Figure 32 shows the data in the hydrogen-bonding region of the spectrum.  The 
standard deviation of the absorbance is variable across the spectrum.  Different samples are more 
variable than others in different regions of the spectrum.  This indicates that variance is directly 
related to the physical and chemical compositions of the sample, i.e., absorption bands in some 
samples are more variable than they are in others. This data also indicates that the amount of 
variance is not necessarily indicative of whether or not a sample is authentic.  Although authentic 
sample (S13) shows some of the least variance across the spectrum, it has the greatest amount of 
variance of all samples at 2915 cm-1 and 2850 cm -1.  This observation is consistent with the 
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hypothesis that this sample, although manufactured in a well-controlled manner, has sorbed 
water which causes variance in these two absorption bands. 
 
Figure 31.  Variance expressed as the standard deviation at each 




Figure 32.  Variance expressed as the standard deviation at each 
wavenumber in the hydrogen-bonding region of the spectrum. 
Sample I2 showed the greatest amount of variance of all samples at 1655 cm-1.  Figure 33 
shows an overlay of all of the spectra collected from sample I2.  Note that in this sample, the 
greatest amount of variance is evident in the absorption band at 1655 cm-1.  Figure 34 the same 
overlay expanded to see the absorption band at 1655 cm-1 more clearly.  In this instance, the 
cause of this spectral variance is unknown.  Although the variance in the authentic samples can 
be explained by the presence of different amounts of water, interpretation of variance in the 
infrared spectra in this and some of the other samples was not as straightforward. 
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Figure 33.  All infrared spectra collected from non-authentic 
sample I2 (spectra are area normalized). 
 
Figure 34.  All infrared spectra collected from non-authentic 
sample I2 at 1655 cm-1 (spectra are area normalized) 
From this infrared data, it was also possible to show that eight of the nine non-authentic 
samples contained less than 100 mg of sildenafil citrate, in spite of the fact that all were 
purported to contain 100 mg of this API.  This type of analysis using infrared spectroscopy was 
possible for these samples because tablet weights for these eight samples were measured and 
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were lower than or approximately equal to what they were for the authentic VIAGRA.  
Therefore, the percent by weight of sildenafil citrate in these samples should be equal to or 
higher than for the authentic VIAGRA.  Since the spectra are area normalized and the infrared 
spectra were very similar, absorption bands due only to sildenafil citrate could be reviewed to 
look for relative concentrations of sildenafil citrate.  In all eight of these samples, the absorption 
band due to sildenafil citrate at 1697 cm-1 was lower in intensity than it was for the authentic 
VIAGRA.  Therefore, the non-authentic samples could not contain 100 mg of sildenafil citrate 
(as purported).  This band intensity should be the same or higher than it is for these tablets if they 
did, in fact, contain 100 mg of sildenafil citrate.  It was not possible to determine whether or not 
the ninth non-authentic sample contained less than 100 mg of sildenafil citrate because the tablet 
weight for this sample was significantly higher than for authentic samples and, therefore, the 
absorption band intensity for area normalized spectra should be lower.  In addition, the infrared 
spectrum for this sample was quite different than it was for the authentic sample.  This is also a 
problem when performing this type of analysis because intensities become distorted during 
normalization due to differences in absorption-band intensities due to the presence of different 
chemical functional groups.   Aside from this relative evaluation, no attempts were made to 
determine quantitatively the amount of sildenafil citrate present in these samples using infrared 
spectroscopy or any other technology. 
Figure 35 shows an overlay of the spectrum at this absorbance at 1697 cm-1 for the 
authentic and non-authentic samples.  The spectrum of the authentic sample is shown in red and 
all other spectra shown are of the non-authentic samples (except S8).  For all samples except for 
sample S8, this indicates that less than the purported amount of 100 mg of sildenafil citrate is 
present in the sample. 
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Figure 35.  Spectra of authentic (red) and non-authentic samples 
(except S8) showing the absorption band present due primarily to 
the API sildenafil citrate (spectra are area normalized). 
PCA-CVA showed that it was possible to classify samples based upon their infrared 
spectrum into eight groups (seven non-authentic and one authentic).  HOO-CV was used to 
determine an estimated error rate of 2.16% using 12 PC’s.  Figure 36 shows the 3D-scores plot.  
In this figure, each grouping is colored differently and clustering based upon group assignment 
in three dimensions is evident.  Figure 37 shows the estimated error rates calculated as a function 




Figure 36.  3D-scores plot of infrared data (autoscaled). 
 
Figure 37.  Estimated error rate displayed as a function of the 




The HOO-CV classification table is shown in Table 7.  This data shows that four of the 
five misclassifications occurred between groups 2 (sample I1) and 5 (sample I4).  The spectra for 
these two samples are shown in Figure 38.  It is clear from these two spectra that the primary 
difference between these samples as observed in the infrared spectra is in the water content of the 
samples.  The average spectrum of sample I4 contains less water than the average spectrum of 
sample I1.  This is an important observation because infrared analysis is sensitive to water, and 
drug tablets are known to sorb different amounts of water based upon many factors.  For this 
reason, it is important that when grouping samples together, this fact be considered.  In this 
study, the region of the spectrum sensitive to water was not removed prior to chemometrics 
analysis because water in pharmaceutical tablets may be present due to amorphous API.  Even 
small amounts of amorphous content can cause the sample to sorb more water than a crystalline 
form of the drug. (Sacchetti, 2013)  Amorphous content may be directly related to manufacturing 
process (Hancock & Zografi, 1997) and may provide insight as to the source of the tablets. 
 
Table 7.  HOO-CV estimated error-rate test results for PCA-CVA 
analysis of infrared spectra. 
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Figure 38.  Average infrared spectra of samples I1and I4 (spectra 
area normalized). 
Summary and Conclusion 
This research shows that detection and identification of chemical and physical differences 
in drug tablets using field-portable infrared spectroscopy provides a chemical signature or profile 
that may be used to authenticate product.  PCA-CVA HOO-CV applied to the infrared data 
showed that infrared may also be used to differentiate non-authentic samples from each other.  
This is important because it indicates that infrared analysis performed in the field may be used to 
establish provenance.  A visual comparison of the infrared spectra was used to differentiate non-
authentic from authentic samples.  Infrared spectra were reproducible within different tablets of 
the same sample and may be used as a chemical fingerprint of a specific tablet and sample.  
These spectra may be used to classify samples of unknown origin and provide investigators 
insight into the sample’s manufacturing process and history. 
  
83 
CHAPTER 9.  INVESTIGATION AND EVALUATION OF CHEMICAL AND 
PHYSICAL PROPERTIES OF FINAL DOSAGE FORMS USING RAMAN 
SPECTROSCOPY 
Introduction 
The rationale for using Raman spectroscopy to evaluate counterfeit drugs is the same as 
that for infrared spectroscopy (see chapter 8).  The reason it is useful as a complement to infrared 
spectroscopy is because these two methods have different selection rules.  In order for a 
vibrational mode to be active in the infrared region, the vibration must cause a change in the 
permanent dipole moment of the molecule.  The dipole moment is the product of the charge of 
the dipole and the charge separation difference.  On the other hand, for a vibration to be active in 
the Raman effect, the polarizability of the molecule must change during the vibration.  
Polarizability is the value of the induced dipole moment divided by the strength of the field that 
causes the induced dipole moment. In other words, the electron cloud of the molecule must be 
more readily deformed in one extreme of the vibration than in the other. (Willard, Merritt Jr., 
Dean, & Settle Jr., 1988)  Due to these differences in selection rules, some samples are more 
amenable to infrared analysis and some are more amenable to Raman analysis.  For instance, 
samples in an aqueous dispersant may have limited success when analyzed using infrared 
spectroscopy.  This is due to the strong infrared absorption of water which may overwhelm the 
spectrum and mask the presence of other components in the sample.  When analyzed using 
Raman spectroscopy, water does not generate a strong Raman spectrum and will not usually 
interfere with the Raman measurement of other components in the sample.  On the other hand, 
samples will frequently exhibit a strong fluorescence signal across the Raman spectrum which 
may interfere with spectral interpretation and comparison.  Raman spectroscopy also may cause 
problems when analyzing colored (and some non-colored) samples because the sample may 
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burn.  This is because the sample will absorb the light at the laser wavelength. (Arnó, Frunzi, 
Kittredge, & Sparano, 2014)  This energy is dissipated as heat due to non-radiative emissions. 
(Frunzi, 2014)  In these instances, infrared analysis may be more appropriate.  Lasers are 
required for Raman systems in order to generate a sufficient Raman scatter for detection. 
Raman has a significant advantage in some applications, though.  Raman signal may be 
directly collected from samples through some transparent glass vials and plastic bags.  This 
capability has likely contributed to its success in field-portable applications.  For these reasons, 
infrared and Raman spectroscopy are considered complimentary techniques.  When used 
together, they can provide information that may enable a more complete understanding of the 
chemical and physical properties of the samples. (Otieno-Alego & Speers, 2011) 
Data generated from Raman analysis can be evaluated many different ways when applied 
to the analytical challenges associated with counterfeit drugs.  In this study, Raman spectra were 
compared to differentiate authentic from non-authentic samples.  Reproducibility of spectra 
collected from a single tablet, as well as amongst different tablets of the same sample was also 
evaluated.  Samples were classified and the discrimination potential of Raman as a tool for the 
analysis of counterfeit drugs was evaluated using PCA-CVA HOO-CV. 
Experimental Details 
Instrumentation 
Raman spectra of the core matrices of tablets were collected using a 785L Raman 
spectrometer (Wasatch Photonics, Durham, NC).  Performance of the spectrometer was tested at 
the start and end of every work day by analyzing cyclohexane and verifying peak position.  At all 
times, the system passed this check.  The 785L is a small portable instrument.  However, it is not 
specified for ruggedization.  It was used as part of this study primarily due to its size, portability 
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and performance characteristics.  Some of the specifications for this system that are important 
reasons for its use in this study are shown in Table 8.  Figure 39 is an image of the model of 
Raman instrument used. 
                        Raman 785L Specifications of Importance to this Study 
Compact size 5 in x 6.5 in x 2 in housing 
Weight 1.2 kg 
Laser type 785-nm single-mode laser, diode stabilized with volume Bragg grating
Diffraction grating HD 1624 LP/mm volume phase grating 
Instrument design Lens-based spectrograph 
f/# 1.3 
Interface USB 2.0 
Integration time 1 ms to 2 s 
Resolution 10 cm-1 with 50-μm slit 
Sample spot size <50 μm 
Table 8.  Raman 785L specifications of importance to this study. 
 
 





Approximately 25 mg of gently ground tablet core were transferred to a small, clear, 
glass vial.  The vial was placed in the vial sample chamber of the spectrometer and its position 
was adjusted slightly to maximize signal intensity for each measurement.  A black drape was 
placed over the sampling chamber during scanning to minimize stray light.  Ten scans were 
collected with a resolution of 10 cm-1 and integration time of 1000 milliseconds for each scan.  
The instrument’s Dash software was used to calculate an average of these ten scans.  The laser 
was then turned off and ten dark scans were collected using the same integration time.  The 
system software was used to calculate the average of these ten scans.  The data from the 
spectrometer including each of the individual scans and the average for both the sample spectra 
and the dark-scan spectra were then transferred in a single worksheet to Microsoft Excel.  Using 
Microsoft Excel, the dark spectrum average value at each frequency was subtracted from the 
sample spectrum average value at each frequency.  The subtraction values along with their 
respective frequencies were copied into a new worksheet in Microsoft Excel. 
Data Analysis and Chemometrics 
The “Excel Exchange” function of Thermo Grams was used to convert this worksheet 
data into an *.spc file.  Each *.spc file created was opened in Thermo Grams and then baseline 
corrected using a quintic multipoint baseline correction.  For each tablet, all spectra were 
averaged using the array basic “average” function in Grams.  For each sample, all spectra from 
each tablet of the sample were averaged using the array basic “average” function in Grams.  The 
chemometric methods of PCA and CVA were applied to investigate the classification and 
discrimination power of Raman spectroscopy.  Non-authentic samples were sorted into seven 
groups based upon physical appearance, dimensions, and receipt date; authentic samples were 
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categorized into a single group.  The deconvolution data, specifically the peak positions and 
areas, also were analyzed using HOO-CV PCA-CVA to determine an estimated error rate for the 
classification of sildenafil citrate tablets.  
Results and Discussion 
It was possible to differentiate the authentic samples from all non-authentic samples 
using Raman spectroscopy.  In most cases, differences in spectra were small but reproducible.  
Using PCA-CVA, 3D-scores plots were created and visual separation of samples was not evident 
in these plots.  Although separation was not evident in three dimensions for the Raman data, the 
estimated error rate calculated using HOO-CV was lower than it was for the infrared data and 
calculated to be 0.56% using 14 PC’s.  This lower estimated error rate indicates that Raman 
analysis may be just as useful as infrared analysis to establish provenance.  Not only can Raman 
be used to differentiate authentic from non-authentic samples, but it also may be used to sort 
non-authentic samples and ultimately lead to the establishment of provenance.  Figure 40 shows 
the average spectra collected from two different samples of authentic VIAGRA.  These spectra 
are consistent with each other.  The same bands and were present in each sample across the 
Raman spectrum with very similar band intensities. 
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Figure 40.  Raman spectral averages of samples S15 (red) and S16 
(blue).  Both samples are authentic VIAGRA. 
Figures 41 through 49 show the average Raman spectrum of an authentic sample 
compared with the average spectrum from each of the nine non-authentic samples.  Note that the 
differences between the authentic and non-authentic samples were relatively small.  This 
indicates that the chemical composition of the non-authentic samples was similar but not 
identical to the chemical composition of the authentic samples.  However, the spectra collected 
from different tablets of the same sample were consistent with each other.  It was possible to 




Figure 41.  Raman spectrum of authentic sample (blue) compared 
with non-authentic I1 (red). 
 
Figure 42.  Raman spectrum of authentic sample (blue) compared 




Figure 43.  Raman spectrum of authentic sample (blue) compared 
with non-authentic I3 (red). 
 
Figure 44.  Raman spectrum of authentic sample (blue) compared 




Figure 45.  Raman spectrum of authentic sample (blue) compared 
with non-authentic I5 (red). 
 
Figure 46.  Raman spectrum of authentic sample (blue) compared 




Figure 47.  Raman spectrum of authentic sample (blue) compared 
with non-authentic S8 (red). 
 
Figure 48.  Raman spectrum of authentic sample (blue) compared 




Figure 49.  Raman spectrum of authentic sample (blue) compared 
with non-authentic SING2. 
Although only the average spectrum for each sample is shown in the preceding nine 
figures, all of the spectra collected from each tablet and from the same sample were consistent 
with each other.  There was some variance in the intensities of some of the Raman bands within 
a sample, but there wasn’t a single instance where two spectra from the same sample contained 
different Raman bands. 
PCA-CVA showed that it was possible to classify samples based upon their Raman 
spectrum into eight groups (seven non-authentic and one authentic).  HOO-CV was used to 
determine an estimated error rate of 0.56% using 14 PC’s. 
Figure 50 shows the 3D-scores plot from PCA-CVA.  In this figure each group is colored 
differently and, unlike with the infrared spectra where clustering based upon group assignment 
was evident in three dimensions, no clustering is observed in the Raman data.  However, figure 
51 shows the estimated error rates calculated as a function of number of PC’s for the Raman, and 
even though clustering is not evident in three dimensions, Raman spectroscopy was capable of 
successfully classifying most samples.  This difference in clustering observed in the 3D-scores 
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plots between the infrared (figure 36) and the Raman data (see figure 50) is interesting.  It is 
possible that the reason the separation was not evident in the 3D-scores plot for the Raman data 
is because the Raman analysis spot size (50 μm) is significantly smaller than it is for the infrared 
analysis (1.3 mm x 0.8 mm), but this hypothesis was not tested. 
 




Figure 51.  Estimated error rate displayed as a function of the 
number of PC’s.  An estimated error rate of 0.56% was observed at 
14 PC’s. 
Summary and Conclusion 
This research shows that detection and identification of chemical and physical differences 
in drug tablets using field-portable Raman spectroscopy provides a chemical signature or profile 
that may be used to authenticate product.  PCA-CVA HOO-CV applied to the Raman data 
showed that Raman may be used to distinguish authentic from non-authentic samples, and to 
differentiate non-authentic samples from each other.  This is important because it indicates that 
Raman analysis performed in the field may be used to establish provenance.  A visual 
comparison of the Raman spectra was used to differentiate non-authentic from authentic 
samples.  Raman spectra were reproducible within different tablets of the same sample.  These 
spectra may be used to classify samples of unknown origin and provide investigators insight into 
the sample’s manufacturing process and history.  For example, differences in spectra may result 
from differences in solid-state form of the active or inactive ingredients that are produced during 
manufacture or storage, or may be have different ingredients present that could be linked to 
manufacturer.   
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CHAPTER 10.  INVESTIGATION AND COMPARISON OF ORGANIC VOLATILES 
AND RESIDUAL SOLVENTS IN DRUG PRODUCTS USING GAS 
CHROMATOGRAPHY-MASS SPECTROMETRY 
Introduction 
When pharmaceutical tablets are manufactured, chemicals are present in the finished 
tablet at trace levels.  These chemicals are introduced into the tablet in a variety of ways.  They 
may be present in the raw materials, they may be solvent residues remaining after tablet 
manufacture, or they may even be degradation products that develop during manufacture or 
storage.  These trace chemicals generate a chemical fingerprint that is representative of the tablet.  
They also provide insight about the tablet’s manufacture and storage. 
When manufacturing processes are well controlled and adhere to regulatory guidelines as 
is typical for an authentic product, this chemical fingerprint is well controlled and reproducible.  
The ability to detect and identify these chemicals in a reliable manner is useful, providing a 
chemical fingerprint that is representative of the authentic product and may be used to 
differentiate authentic from non-authentic tablets.  This chemical fingerprint may also be used to 
classify counterfeit drugs, providing investigative leads useful in establishing source or origin. 
GC-MS is useful for detecting and identifying these trace chemicals.  Data generated 
from this type of analysis can be evaluated many different ways when applied to the analytical 
challenges associated with counterfeit drugs.  In this study, total ion chromatograms were 
compared to determine reproducibility amongst different tablets of the same sample.  In addition, 
they were used to differentiate authentic from non-authentic samples.  Samples were heated and 




GC-MS data were collected using a GUARDION™ GC-MS (Smiths Detection, Danbury, 
CT).  The system uses a 5-m long MXT®-5 (Restek Corporation, Bellefonte, PA) resistively 
heated capillary column (inner diameter 0.1 mm, film thickness of 0.4 μm).  This column is a 
crossbond® diphenyl/dimethylpolysiloxane column.  The carrier gas is helium (Leland, South 
Plainfield, NJ) introduced via disposable canister.  Sample collection and introduction to the 
GUARDION was performed via solid-phase microextraction (SPME).  A CUSTODION® 
(Torion Technologies, American Fork, UT) SPME holder was used with a Supelco (St. Louis, 
MO) 23-gauge, 65 μm DMS/DVB fiber assembly. 
Performance of the system was tested at the start and end of every work day and 
periodically throughout the day.  Performance testing evaluates both GC and MS performance.  
To perform this testing, a standard containing 13 chemicals is analyzed.  These 13 chemicals 
have expected retention-time values between 0 and 90 seconds and are spaced across this range.  
GC performance acceptance criteria required that the retention times for all 13 chemicals must be 
the stated +/- 2 seconds.  Retention-time values measured during all performance testing were 




Chemical in Standard CAS Number Stated Retention-Time Value (s) 
Acetone 67-64-1 11.34 
Methylene chloride 75-09-2 13.26 
Methyl-t-butyl ether 163-40-44 15.17 
Heptane 142-82-5 26.25 
Methylcyclohexane 108-87-2 28.92 
Toluene-d8 2037-26-5 32.85 
Perchloroethylene 127-18-4 37.34 
Bromopentafluorobenzene 344-04-7 41.84 
Bromoform 75-25-2 45.14 
1,2-Dibromotetrafluorobenzene 827-08-7 65.94 
Methyl salicylate 119-36-8 72.25 
Tetrabromoethane 79-27-6 79.83 
Tetradecane 629-59-4 85.76 
Table 9.  Chemicals contained within standard sample analyzed 
during performance testing. 
In addition to evaluating the GC, performance testing also evaluates MS performance.  
MS performance includes tests for spectral quality, mass calibration, mass resolution, ion 
statistics, space charge, signal-to-noise ratio, and sensitivity.  The performance-test procedure 
used was the procedure recommended by the instrument manufacturer.  The system did not 
always pass performance-test criteria.  However, the reasons for all failures were due to MS 
performance.  Spectral data, however, were not directly interpreted and compared.  Only GC 
retention-time data was used for comparison.   
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The GUARDION is specifically intended for field use.  Some of the specifications for 
this system, especially those intended to support portability and ruggedization of the instrument, 
are shown in Table 10.  An image of the model of GC-MS instrument used is shown in figure 52. 
                        GUARDION Specifications of Importance to this Study 
Compact size 15.5 in x 15 in x 9 in excluding handle 
Weight 14.6 kg 
GC column MXT-5 column, 5 m, 0.1 mm inner diameter, 0.4 μm film 
thickness 
Carrier gas Helium carrier gas supply, internal disposable cartridge 
Mass spectrometer Toroidal ion trap 
Vacuum system Turbomolecular vacuum pump with diaphragm roughing pump 
Sample collection Solid-phase microextraction 
Hot-zone operation Sealed for operation in the hot zone 
Decontamination Spray/wipe down 
Operating temperature 0⁰C to 45⁰C 
Operating humidity 0% - 95% 
User interface Embedded software with touch-screen 
Data export Full USB support; Ethernet capable; mouse and keyboard capable 
Power Removable, rechargeable Li-ion battery; external power supply 
Mass range 43 m/z - 500 m/z 
Temperature 
programming 
Up to 300⁰C 





Figure 52.  GUARDION GC-MS.  Photograph courtesy of Smiths 
Detection, Danbury, CT. 
Method 
Samples were analyzed using a field-portable toroidal ion-trap GC-MS.  Samples were 
injected directly from the SPME holder into the inlet of the GC-MS.  During analysis, samples 
elute directly from the GC into the ion trap of the MS.  Ionization occurs via electron impact at 
70 eV.  The carrier gas used was helium.  The injector and transfer line temperatures were 
270⁰C.  The column temperature was held at 50⁰C for 10 seconds and then ramped at a rate of 
2⁰C per second to 296⁰C.  The temperature was held at 296⁰C for 47 seconds.  The voltage of the 
MS was scanned continually to detect mass fragments in the range between 43 and 500 atomic 
mass unit’s.  Scan time was approximately 60 milliseconds and continuously performed 
throughout the GC analysis. 
To prepare for GC-MS analysis, each tablet was gently crushed and transferred to a GC-
MS headspace vial.  Samples were heated to 60⁰C and held at this temperature for 20 minutes.  
The headspace was then sampled at 60⁰C for five minutes using the SPME technique.  The 
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sample was then injected directly from the SPME holder into the inlet of the GC-MS.  Sampling 
and analysis was performed two times in immediate succession.  The first sampling used a 
PDMS/DVB SPME sorbent; the second sampling used a carboxen SPME sorbent.  Samples were 
then heated to 110⁰C and held at this temperature for 20 minutes. The same SPME headspace 
sampling and analysis steps performed at 60⁰C were repeated at 110⁰C.  In some instances, 
SPME headspace sampling was performed using only a PDMS/DVB SPME sorbent.  The reason 
both fibers were not always used is because, initially during data collection, the PDMS/DVB 
SPME sorbent was used in duplicate to verify reproducibility.  The carboxen fiber was not used 
during these earlier experiments.  After reproducibility was observed in the first samples 
analyzed, it was deemed to be more important to evaluate the use of the carboxen sorbent during 
the second injection rather than continue to verify reproducibility. 
Results and Discussion 
It was possible to differentiate the authentic samples from all non-authentic samples 
using this method.  In most cases, differences in chromatograms, i.e., chemical fingerprints, 
between the authentic and the non-authentic sample were significant.  An attempt was made to 
average chromatograms to enable quantitation of these visual observations.  Due to many 
instrumental factors including the dynamic ionization that occurs in the instrument during sample 
analysis to optimize MS results, retention-time values from one run to the next are unique.  This 
makes an averaging function impossible to perform without changing retention-time values.  It 
was determined that averaging chromatograms would not be performed. 
Figures 53 through 61 show the chromatogram of an authentic tablet compared with a 
chromatogram from each of the nine non-authentic samples.  A chromatogram (in this context) is 
a display showing all of the chemicals detected during GC-MS analysis.  The x-axis represents 
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the analyte’s retention time, and the y-axis represents abundance.  This study was non 
quantitative, so although relative abundances within a single chromatogram may be used as a 
factor to be evaluated within that single chromatogram, no quantitative assessment of each 
analyte’s concentration within the tablet was or should be performed.  Ideally, each peak in the 
chromatogram is representative of a chemical present in the sample.  In this study, the nature of 
the peak was not important and overlapping peaks were not considered to be a problem.  The 
presence or absence of a peak at a specific retention time was the criteria used for discrimination. 
 
Figure 53.  Chromatogram of authentic sample compared with 




Figure 54.  Chromatogram of authentic sample compared with 
non-authentic I2 (PDMS/DVB SPME sorbent, 60⁰C). 
 
Figure 55.  Chromatogram of authentic sample compared with 




Figure 56.  Chromatogram of authentic sample compared with 
non-authentic I4 (PDMS/DVB SPME sorbent, 60⁰C). 
 
Figure 57.  Chromatogram of authentic sample compared with 




Figure 58.  Chromatogram of authentic sample compared with 
non-authentic S7 (PDMS/DVB SPME sorbent, 60⁰C). 
 
Figure 59.  Chromatogram of authentic sample compared with 




Figure 60.  Chromatogram of authentic sample compared with 
non-authentic SING1 (PDMS/DVB SPME sorbent, 60⁰C). 
 
Figure 61.  Chromatogram of authentic sample compared with 
non-authentic SING2 (PDMS/DVB SPME sorbent, 60⁰C). 
Although only a single chromatogram for each sample is shown in the preceding nine 
figures, it is important to note that all chromatograms generated from each tablet within a sample 
were compared to each other.  In all cases, the chromatogram of each sample was generally 
consistent from tablet to tablet, but was dependent upon SPME sorbent and sample temperature.  
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Therefore, only results generated using the same SPME sorbent and sample temperature were 
used for differentiation. 
Figure 62 shows an overlay of seven chromatograms from seven different tablets of the 
same sample collected using the same SPME sorbent and sample temperature (PDMS/DVB 
SPME sorbent, 60⁰C).  Although peak heights are variable from tablet to tablet, the general 
pattern is consistent across the tablets analyzed.  This type of chromatogram reproducibility was 
typically observed for different tablets of a given sample analyzed using the same conditions. 
 
Figure 62.  Seven chromatograms of seven tablets of sample 
SING2.  Sampling was performed using PDMS/DVC SPME 
sorbent at 60⁰C. 
Chromatogram differences based upon SPME sorbent are expected.  Different SPME 
sorbents, by design, selectively sorb different chemicals differently.  This selective sorption 
accounts for the differences in chromatograms from the same tablet analyzed at the same 
temperature using different SPME sorbents.  As an example, Figure 63 shows the 
chromatograms for sample SING2 collected using two different sorbent materials analyzed at the 
same temperature and under otherwise identical conditions.  Note that the peak intensities for 
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some chemicals across the chromatogram are different.  The most significant differences are 
observed for chemicals with lower boiling point which elute at lower retention times on this GC 
column.  The carboxen fiber is a more aggressive sorbent for these types of chemicals, 
generating patterns with higher concentrations of these chemicals in the chromatogram from the 
same sample analyzed under otherwise identical conditions.  Figure 64 shows replicate analysis 
from the same tablet analyzed under the same conditions using the same SPME sorbent.  Note 
that peak intensities are much more consistent across the entire chromatogram when replicate 
analysis using the same sorbent materials was performed.  These figures show typical behavior 
observed across all samples analyzed. 
 
Figure 63.  Chromatograms of tablet 1 of sample SING2 analyzed 
at the same temperature (60⁰C) using two different SPME sorbents 




Figure 64.  Chromatograms of tablet 2 of sample I2 analyzed at the 
same temperature (60⁰C) using the same SPME sorbent 
(carboxen). 
Differences in chromatograms based upon sample temperature are also expected.  
Temperature will modify the chemical composition of the headspace and, therefore, the resulting 
chromatogram.  Figures 67 shows the types of differences that may be observed based upon 
sampling temperature.  Chromatograms for sample SING2 collected from the same tablet at 
60⁰C and 110⁰C using the PDMS/DVB SPME sorbent are displayed.  Although there is varying 
peak intensities across the chromatograms, the most significant differences lie in the region at 
retention times greater than about 90 seconds, where chemicals present at 110⁰C are completely 
absent in the 60⁰C sample.  This type of difference based upon temperature was consistent 
whether comparisons were made using PDMS/DVB SPME sorbent or carboxen sorbent.  
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Figure 65.  Chromatograms of tablet 1 of sample SING2 analyzed 
at different temperatures (60⁰C and 110⁰C) using the same SPME 
sorbent (PDMS/DVB). 
Summary and Conclusion 
This research shows that detection and identification of organic volatiles and residual 
solvents in drug tablets using field-portable GC-MS provides a chemical signature that can be 
used to authenticate product.  A visual comparison of the chromatograms produced by these 
samples made this a relatively trivial task.  Chromatograms were reproducible within different 
tablets of the same sample and may be used as a chemical fingerprint of a specific tablet and 
sample.  These chemical fingerprints may be used to classify samples of unknown origin and 
provide investigators insight into the sample’s manufacturing process and history. 
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CHAPTER 11.  AN ANALYTICAL SCHEME FOR TESTING OF SUSPECTED 
COUNTERFEIT TABLETS IN THE FIELD 
The data summarized in the preceding chapters shows that differentiating authentic from 
non-authentic samples using many different analytical methods in the field is possible.  The 
choice of method to be used is dependent upon the sample.  In some instances, a visual 
comparison between the authentic and non-authentic samples will suffice.  In others, chemical 
methods must be used to attempt differentiation.  It may be prudent, though, when analyzing 
suspected counterfeit drugs in the field, to measure samples using a combination of methods 
regardless of whether or not a non-authentic sample is detected during the initial examination.  
This is because although individual methods may be used independently to show that a suspect 
sample is not authentic, the real challenge facing forensic scientists is in the sourcing of these 
goods. 
It seems that any attempt at sourcing requires access to data from many different samples 
in order to identify patterns in the date collected from non-authentic samples.  There is a need for 
a database of these samples.  Data collected quickly in the field at border crossings and other 
law-enforcement venues can provide the content for this database and be easily saved in an 
electronic format for review at a later time by members of forensic science and law-enforcement 
organizations.  It is important that the methods used maximize information and minimize testing 
time and difficulty so that the workflow of the field analyst is not too cumbersome.  The results 
presented in the previous chapters of this dissertation show that handheld instruments can be 
used to generate useful data that, if entered into a database, could be retrieved by forensic 
scientists and members of the law-enforcement community to perform important review and 
comparisons that may be used to source counterfeit drugs.  For these reasons, a proposed 
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workflow for the analysis of suspected counterfeit tablets to be used in the field is shown in 
Figure 66. 
 
Figure 66.  Workflow proposed for testing suspected non-authentic 
tablets in the field. 
It is important to highlight that this scheme is intended for field use by non-scientists, and 
is not intended to replace lab-based methods that may be used to establish authenticity.  The 
purpose when performing this scheme in the field is to detect differences between the test sample 
and authentic versions of the sample.  While it is true that if differences are detected a sample 
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The first step of any analytical scheme to be performed in the field to test counterfeits is 
observation and photographic documentation.  All photographs should be taken under the same 
conditions and saved to the database.  Review of the data to establish authenticity from a 
physical examination would likely be manual unless image-analysis methods are developed.  For 
this reason, it may be important to have a second analyst reviewing data in near-real time, 
especially if a non-authentic sample is detected.  This way any conclusions drawn by the field 
analyst are supported by a second analyst.  Tablet color, indicia, and dimensional measurements 
will frequently enable fast and simple differentiation of authentic from non-authentic samples.  
The most significant challenge to this type of analysis is that it requires that the analyst have 
knowledge of the appearance of authentic versions of the drug product.  This may or may not be 
the case.  Determination of whether or not a suspect tablet is indistinguishable from the authentic 
sample is based upon physical appearance, and would be made by the analyst after direct 
comparison of the physical properties of the sample.  Groupings of tablets in the database by the 
forensic scientist based upon visual appearance may be attempted at a later date if determination 
of source or origin is desired.  Measurements may be taken at the time of inspection, but if no 
reference is available for comparison, this step is not necessary.  Photographs captured at the 
same magnification can be reviewed at a later time to determine tablet dimensions, if necessary. 
The next step in the analytical process is to collect infrared spectra from the tablet using a 
field portable ATR FT-IR spectrometer.  A system that uses a larger analysis spot size is 
preferred in order to sample the largest amount of sample during collection of a single spectrum.  
Infrared spectra collected from the tablet’s coating and from its core can be automatically 
searched against electronic databases of library reference spectra to establish a match factor 
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between the spectrum from the test sample and library spectra of authentic samples.  Results are 
fast, and a numerical value is assigned to establish similarity quantitatively.  ATR FT-IR spectra 
are very reproducible for various reasons. (Reffner & Martoglio, 1995)  It would, therefore, be 
appropriate to assign a minimum match factor score to be used to automatically determine that 
the suspect tablet cannot be differentiated from authentic versions using this method.  If the 
match-factor value is met or exceeded, the tablet cannot be differentiated from the authentic 
reference; if the match-factor value is not met, the sample is identified as a non-authentic. The 
instrument could be programmed to generate a real-time pass/fail result to automatically appear 
on the instrument’s results screen at the time of analysis dependent on the sample’s match factor.  
Infrared spectra collected, regardless of whether or not they are displayed on the instrument’s 
result screen, should be stored in an electronic database.  Storage of spectral data in a searchable 
database would allow forensic scientists and law-enforcement personnel performing 
investigations to use the data to generate investigative leads.  This type of review may be used to 
group samples together so that provenance may be established. 
The next step in the analytical process is to perform a Raman measurement of the tablet 
core using a portable Raman spectrometer.  Just like with infrared spectrometry, a Raman 
spectrum collected from the tablet’s core can be automatically searched against electronic 
databases of library reference spectra to establish a match factor between the spectrum from the 
test sample and library spectra of authentic samples.  Results are fast, and a numerical value is 
assigned to establish similarity quantitatively.  Although Raman spectra are generally 
reproducible, differences in peak intensities and other small artifacts of the measurement may be 
observed between spectra.  A minimum match-factor score can be used to automatically 
determine that the suspect tablet cannot be differentiated from authentic versions using this 
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method.  If the match-factor value is met or exceeded, the tablet cannot be differentiated from the 
authentic reference; if the match-factor value is not met, the sample is identified as a non-
authentic. The instrument could be programmed to generate a real-time pass/fail result to 
automatically appear on the instrument’s results screen at the time of analysis.  Raman spectra 
collected, regardless of whether or not they are displayed on the instrument’s result screen, 
should be stored in an electronic database.  Storage of spectral data in a searchable database 
would allow forensic scientists and law-enforcement personnel performing investigations to use 
the data to generate investigative leads.  This type of review may be used to group samples 
together so that provenance may be established. 
The next and final analytical step in the process is GC-MS analysis to determine a 
tablet’s residual-solvent and organic-volatiles profile.  GC-MS is different from the other 
analytical methods proposed as part of this analytical scheme because it requires sample 
preparation that is time consuming (approximately 25 minutes).  In addition, analysis time is on 
the order of minutes rather than seconds.  The ability to establish this profile is powerful, though, 
especially in providing investigative information.  Solvents and volatile compounds detected and 
identified may be used as chemical markers.  These markers can be used to group samples 
together and can provide information about manufacturing methods and processes.  This 
information can be very helpful when establishing provenance. 
Use of all of these methods has value.  Photographs make it possible to easily observe 
differences amongst samples.  Both infrared and Raman methods provide chemical information 
about the sample and can be used to quickly detect non-authentic samples.  Each method 
(infrared and Raman) has its benefits, and while some information interpreted from the data from 
these two methods may be redundant, the methods complement each other well and provide a 
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more complete picture of the nature of the sample.  Performing photography, infrared and Raman 
analysis of a sample may occur in less than five minutes.  It is important to recognize that the 
goal of this field analysis is to detect non-authentic samples.  It is not the goal of this analysis to 
verify authenticity.  Using these methods, the inability to detect differences should not be 
confused with verification of authenticity. 
GC-MS analysis is also proposed as part of this scheme because the data can be quite 
informative and is not redundant to photography, infrared, or Raman analysis.  However, the 
challenges related to time and value to the field analyst should be considered before inclusion of 
GC-MS in the field-testing scheme is finalized. 
Something else to consider is that when using this analytical scheme, the tablet sample 
rather than the packaging needs to be analyzed.  Methods like radio frequency identification tags 
are useful at tracking and tracing drugs through the supply chain (Rudolf & Bernstein, 2004), but 
this technology is usually applied to packaging and is not useful in situations where packaging 
has been removed or repackaging occurs.  Alternative methods that require analysis of the 
sample contained within the packaging are necessary. 
Database Management 
The methods described as part of this analytical workflow for analysis of samples in the 
field provide physical and chemical information about samples analyzed.  The primary goal, 
especially for the field analyst, is to detect and identify non-authentic samples.  However, data 
collected can provide much more value if it is stored in a database for retrieval and review by 
forensic scientists or other law-enforcement personnel.  The methods proposed are well suited 
for analysis in the field.  The data is relatively easy to collect quickly.  The technologies used 
allow for interpretation of the physical and chemical nature of the sample.  The ability to 
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maintain this data in a searchable database format is powerful because it enables offline 
processing and review of large amounts of data from remote and potentially distant locations.  
This capability is well suited to the challenge of counterfeit drugs.  These goods come from 
different regions of the world, and the place of manufacture is frequently geographically distant 
from the place of sale or consumption.  The ability to collect data from different geographical 
locations, combine them into a single database, and then review and process to evaluate trends 
and perform other interpretations is invaluable.  There are some anticipated challenges in 
managing a database of this magnitude.  Creation, implementation, and maintenance of the 
database each offer unique challenges that need to be addressed. 
The way in which the database is formatted during its creation is important and, 
ultimately, will be directly related to its success.  The goal is for the forensic scientist to be able 
to take data from the database and review this data in as simple and straightforward a manner as 
possible.  Therefore, it will be important to be able to search the database using many different 
search criteria.  For instance, in one situation it may be important to search based upon data 
collection site, or time and date of data collection, while in another the critical search criterion 
may be the purported drug product.  The anticipated use and users should be considered during 
database creation so that the database is as user friendly as possible.  In addition, a method for 
inclusion into the database of customs documents and other appropriate paperwork should be 
considered. 
Another important factor to consider during database creation is file formats for data 
storage.  It is important that if handheld devices from different instrument manufacturers of the 
same technology will be contributing to the database, it should be required that files written be 
converted to a general data format that is not dependent upon which manufacturer’s instrument 
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was used to collect the file.  For instance, infrared data could be collected and reviewed in the 
field using the proprietary software that generates a pass/fail response and then converted to a 
general infrared data file format like *.spc or *.csv when the file is written to the database.  
Determination of the best database format for each technology, as well as other data processing 
requirements should be considered in detail during the creation of the database. 
Other items for consideration during creation of the database include networking 
capabilities and security, speed of internet, availability of internet cabling at anticipated field 
sites, user interface, and other factors that impact data collection in the field like efficiency and 
simplicity. 
Implementation of a program to analyze and centrally store data from different locations 
seems complicated, but is manageable.  Practically, the field analyst’s job may be as simple as 
collecting data using a handheld instrument, reading off a result and sending the file to the 
database.  Training is important so that useful data is collected.  For instance, photographs taken 
need to be in focus and at a uniform magnification.  If not, their value is limited.  For spectral 
files, the spectrum collected needs to be of an appropriate quality so that when compared with 
data collected from other sites, effective comparisons may be made. 
It is also important to manage the amount of data collected and keep the data collection as 
uniform as possible from site to site.  Although it is nice to be able to collect every piece of data 
and make available to the user every possible option for data processing and review, this would 
be an overwhelming training burden and would likely not be successful.  Handheld cameras and 
infrared and Raman spectrometers currently available are capable of meeting the field 
challenges.  However, field analysis with GC-MS is more complicated and requires more time 
for analysis than infrared and Raman measurements.  Modifications to workflow in the field 
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would need to be made to streamline them into the process, specifically considering sample 
preparation time to generate chemical profiles of residual-solvent and organic-volatile profiles.  
As previously stated, the use of GC-MS to establish a sample’s residual-solvent profile may not 
be appropriate at high-volume border crossings, but at locations where data collection of this 
type is possible, inclusion in the database would provide very valuable insight as to the chemical 
composition of the sample, as well as its method of manufacture.  GC-MS files, although 
complex, can be simplified into a common data format so transfer of the data would be possible. 
Maintenance of the database would be required.  Aside from maintenance issues related 
to the server and other hardware, networking and service provider issues need to be addressed.  
A plan for management of software changes and bug fixes need to be in place.  In addition, it 
would be beneficial to have routine audits of data entered into the database.  This would verify 
that data collected in the field meets minimum quality standards so that meaningful results are 
possible when data is accessed by the forensic scientists and other users for review. 
Admissibility in Court 
Forensic scientists are typically considerate of whether or not the testing they perform 
will be admissible in court.  The question of admissibility in court is complicated to answer when 
considering the testing and workflow provided in this analytical scheme.  When considering 
analytical testing in the field to determine authenticity, the answer to this question is not usually 
dependent upon the fundamental technology of the instrument, but rather on the methods and 
procedures in place for use, maintenance, and workflow when using the instrument, as well as on 
the training and education of the analyst. 
The methods used in this research for field analysis of suspected counterfeit drugs using 
infrared, Raman and GC-MS technologies provide the end user with the ability to distinguish an 
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authentic from a non-authentic sample.  These three technologies have all been successfully 
admitted in court when tested against the standards for the detection and identification of drugs 
when used in a laboratory setting. (State of Arizona, Appellee, v. Ronald Michael Lucero, 
Appellant, 2004; The People of the State of New York, Plaintiff, v. Donald Roraback, Also 
Known as Donald Reed, Also Known as Tom Reed, Defendant, 1997; Warner Chilcott 
Laboratories Ireland Limited, et al., Plaintiffs, v. Impax Laboratories, Inc., et al., Defendants. 
Warner Chilcott Laboratories Irealnd Limited, et al., Plaintiffs, v. Mylan Pharmaceuticals Inc., et 
al., Defendants., 2012)  For all three technologies, instrument design and the type of data 
generated between lab-based and field-portable instruments is consistent.  This would lend 
support for the admissibility of these field-portable technologies in court.  However, there are 
many factors that need to be considered if results collected from a field user were to be 
admissible in court including maintenance and calibration, instrument performance testing, user 
training and experience, standards for comparison, and purpose of testing. 
Proper maintenance and calibration allows the end user to be confident the instrument is 
performing in accordance with manufacturer specifications.  It is critical that these functions be 
documented, and that a record of all maintenance performed is available for review.  Procedures 
should be in place to verify that this is the case.  Procedures should also be in place to verify that 
as soon as an instrument fails performance testing, these issues are addressed.  It is reasonable to 
expect that these criteria could be met when deploying these instruments in the field.  Infrared, 
Raman, and GC-MS portable instruments are quite robust, and it is reasonable to assume that 
when using commercially available instruments, maintenance and calibration requirements in the 
field would not be too great a burden to meet. 
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Instrument performance testing is also very important for field-portable instruments.  
When using infrared and Raman systems, this type of testing is fast and easy and could easily be 
incorporated into the workflow for these instruments in the field.  For GC-MS systems, the 
methods used to verify performance are a little bit more complicated and may require more time 
for this aspect of the workflow.  This requirement of time would further burden an already time-
consuming field method.  However, the value of this data collected, as previously described, is 
high and likely worth the investment of time required in situations where time for analysis is 
available. 
User training and experience is a big factor impacting admissibility of scientific evidence 
because users of the technology may not have a strong background in a scientific discipline.  
Typically, end users are not scientists, but are expected to be able to interpret scientific evidence.  
Field-portable instruments are intended to be easy to use and designed to generate results rather 
than data.  In fact, most field users rely on the match factor generated by the handheld instrument 
rather than concern themselves with interpreting a spectrum.  However, extensive training on the 
theory and design of the technology and the instrument or on the process used to generate match 
factors is not usually extensive.  Therefore, the field analyst is not acting as a scientist in their 
approach to the evidence, but rather as a technician.  This does not mean that the evidence is 
inherently inadmissible (Kumho Tire Company, Ltd., et al., Petitioners v. Patrick Carmichael, 
etc., et al., 1999).  However, it does present challenges in court when considering the individual 
who performs the test and his or her suitability to testify in court.  It would be prudent to 
establish procedures that verify that the person determining that a sample is non-authentic 
understands how the instrument works, what aspects of the sample are being tested, what the 
data means, and other things an expert witness should understand about the method and 
123 
technology.  There are ways to address this.  For instance, a scientist could be assigned to 
supervise all non-authentication determinations.  This person could be responsible to review the 
data in real time and verify the data and results used to determine authenticity are accurate.  
Field-portable instruments and the workflow described in this dissertation are not used to verify 
authenticity, but rather to detect non-authentic samples.  The supervisory scientist could 
represent the data when presented in court. 
It is not reasonable to expect that standards for comparison would be available for testing 
during field analysis, or that time would be available in the field to perform such testing.  When 
performing analysis in the field, end users are forced to rely on electronic libraries of data 
available on the handheld unit.  This is not necessarily a problem because the quality of the 
library used can be secured and verified prior to deployment of the instrument.  However, it is 
typical for an analyst working in the lab to not make analysis determinations based upon a 
library-search result, but rather to use these electronic databases to identify unknowns.  The lab 
analyst identifies an unknown by comparison with a library spectrum.  They then will typically 
prepare a standard of the unknown and analyze the sample using the same methods they use to 
analyze the unknown sample for direct comparison of the standard with their unknown, and to 
evaluate whether or standard spectrum is incongruous with the unknown spectrum.  This 
paradigm would likely extend to field applications and would be a problem for admissibility of 
field-testing results.  It is important that these points be considered if results for field tests are to 
be admissible in court. 
One of the most important items to consider when determining whether data from field-
portable instruments is admissible in court is the purpose of the field test.  In this analytical 
scheme presented, data collected in the field would be used to demonstrate that a sample is not 
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authentic.  It is reasonable to expect that infrared, Raman, and GC-MS methods would all be 
capable of performing this function effectively.  However, it is important that the analyst 
understands the value and the limitations of the instrument, the technology, and the test.  It is 
also important that the testing be performed accurately, and in accordance with established 
methods and procedures. 
When meeting the standards for admissibility of evidence in court in the United States, it 
is likely, as previously referenced, that field-portable infrared, Raman, and GC-MS methods 
would meet the standards for admissibility.  However, challenges to admissibility would be faced 
based upon the systems and procedures in place to describe the workflow, the standards used for 
comparison, and the training and experience of the analyst.  These points are important to 
consider, but it is reasonable to expect that when these issues are considered and addressed, 
court-admissible field tests for the detection of non-authentic samples is possible. 
Summary 
Analysis of pharmaceutical tablets using this analytical scheme would enable the field 
analyst to identify non-authentic samples rapidly and reliably.  The availability of this data 
collected in the field in a searchable database format would be very valuable to forensic 
scientists.  A significant challenge to forensic science is the determination of source or origin of 
these illicit goods.  It seems that any attempt at sourcing requires access to data from many 
different samples in order to identify patterns in the samples and the data to ultimately link non-
authentic samples to each other.  Collection of such data is time consuming and challenging for 
various reasons.  Data compiled from field analysis using appropriate methods as detailed in this 
dissertation would be very beneficial.  This research shows the methods proposed in this 
analytical scheme for testing in the field may be used to determine source or origin of non-
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authentic samples.  An accessible database would enable forensic scientists to apply these 
methods to large numbers of samples and generate meaningful investigative information about 
the source and origin of non-authentic samples.  
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CHAPTER 12.  PHARMACEUTICAL DEVELOPMENT IN THE UNITED STATES 
Drug development in the United States is regulated by the United States FDA.  The 
mission of FDA's Center for Drug Evaluation and Research (CDER) is to ensure that drugs 
marketed in the United States are safe and effective. (Food and Drug Administration, 2014)  
Although the mission of CDER is safety, it is important to recognize that drug development (as 
regulated by FDA) is inseparably intertwined with the patenting system and protection of IP 
rights.  Pharmaceutical innovation and the patenting of new drugs and inventions are part of the 
business strategy of pharmaceutical development (Thakur & Ramacha, 2012), and mechanisms 
are in place throughout the regulated drug-development life cycle to allow IP owners to protect 
their inventions. 
Patent protection is the primary incentive to pharmaceutical innovators to develop new 
medicines.  Patent protection ensures market exclusivity for a specified period of time.  This 
market exclusivity is guaranteed under FDA regulation for drugs sold in the United States upon 
FDA approval.  This period of market exclusivity is when most of the financial investment in 
development is recouped. (Melethil, 2005)  For instance, Lipitor® total sales were well over 
$100 billion before its patent expired. (Phelps, 2012)  Failure to protect IP rights by allowing the 
infiltration of counterfeit and substandard drugs that violate IP rights threatens the future of 
pharmaceutical innovation because it minimizes the incentives to invest in the development of 
new drugs.  In terms of profitability, backing blockbuster drugs over many decades made big 
pharma what it is today, but as time goes on, it has become evident that the risks of this strategy 
are increasing and the rewards decreasing. (Phelps, 2012)  Lack of incentive to innovate could 
have devastating consequences on public health because new drugs are needed to address the 
continually changing needs of public health.  A review of some of the aspects of FDA regulation 
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of the drug-development process, especially related to the granting and protection of IP rights, is 
presented for consideration. 
Drug Applications 
Approval to sell pharmaceuticals in the United States is usually granted through one of a 
few types of applications.  The first is a new drug application (NDA); the second is an 
abbreviated new drug application (ANDA).  Pharmaceutical innovators that bring a new drug to 
the market will typically submit their request for approval using an NDA.  Generic 
manufacturers requesting approval to market generic versions of approved drugs will submit 
their request for approval using an ANDA.  A third type of application, sometimes referred to as 
a section 505(b)(2) application, is different from both the NDA and ANDA.  This type of 
application has significant IP considerations.  Section 505(b)(2) applications are specific for 
applications that contains full reports of investigations of safety and effectiveness, but where at 
least some of the information required for approval comes from studies not conducted by or for 
the applicant, and for which the applicant has not obtained a right of reference (IP claim).  In 
comparison, NDA filings contain full reports of investigations of safety and effectiveness 
conducted by or for the applicant; ANDA filings do not contain full reports of investigations of 
safety and effectiveness, but rather contain information to show that the proposed product is, 
among other things, identical to a previously approved product in active ingredient, dosage form, 
strength, route of administration, labeling, quality, performance characteristics, and intended use.   
The requirements for these three different applications are dramatically different and are briefly 
reviewed. 
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New Drug Application 
The NDA is the formal step a drug sponsor takes to ask that the FDA consider approving 
a new drug for marketing in the United States.  An NDA includes all animal and human data and 
analyses of the data, as well as information about how the drug is manufactured and behaves in 
the body.  Once an NDA is received by FDA, the FDA has 60 days to decide whether to file it so 
that it can be reviewed.  The FDA can refuse to file an application that is incomplete.  For 
example, some required studies may be missing. (Food and Drug Administration, 2014) 
Once an NDA is filed, an FDA review team of medical doctors, chemists, statisticians, 
microbiologists, pharmacologists, and other experts evaluate whether the studies the sponsor 
submitted show that the drug is safe and effective for its proposed use.  "Safe" in this sense 
means that the benefits of the drug appear to outweigh the known risks.  The review team 
analyzes study results and looks for possible issues with the application such as weaknesses of 
the study design or analyses.  Reviewers determine whether they agree with the sponsor's results 
and conclusions, or whether they need any additional information to make a decision.  Approval 
to market is granted after the NDA and labeling are approved, and facility inspections are 
completed. (Food and Drug Administration, 2014) 
Although the NDA is the formal request a drug sponsor makes to FDA for approval to 
market a drug in the United States, the process of drug development and the sponsors 
interactions with FDA begin years before an NDA is filed.  Initially, researchers work to either 
synthesize or identify new drugs viable for development.  Many drugs may be synthesized, but 
only a small number are deemed viable for testing in animals.  Most drugs that undergo testing in 
animals never make it to human testing and review by the FDA.  Further to this, hundreds more 
fail in clinical trials. (Phelps, 2012) 
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Permission to test drugs in humans (which is a required step before submitting an NDA) 
is only granted after an investigational new drug (IND) application has received FDA approval.  
Drug sponsors submit an IND to the FDA to request permission to test the drug in humans.  
During the IND approval process, the FDA scrutinizes everything about the drug from the design 
of clinical trials, to the severity of side effects, to the conditions under which the drug is 
manufactured.  Sponsors, which may be companies, research institutions, or other organizations 
taking responsibility for developing a drug, must show the FDA results of preclinical testing in 
laboratory animals, as well as what they propose to do for clinical testing.  At this stage, the FDA 
decides whether it is reasonably safe for the drug sponsor to move forward with clinical testing. 
Once an IND application is approved, the drug sponsor spends years in development to 
pass through the various phases of clinical trials to ultimately submit an NDA.  Clinical trials can 
begin only after an IND is reviewed by the FDA and a local institutional review board (IRB). 
The board is a panel of scientists and non-scientists in hospitals and research institutions that 
oversee clinical research.  IRB’s approve the clinical-trial protocols, which describe the type of 
people who may participate in the clinical trial, the schedule of tests and procedures, the 
medications and dosages to be studied, the length of the study, the study's objectives, and other 
details.  IRB’s make sure the study is acceptable, that participants have given consent and are 
fully informed of their risks, and that researchers take appropriate steps to protect patients from 
harm. 
The process of NDA approval is time consuming and expensive.  DiMasi and colleagues 
estimated average out-of-pocket direct cost per new drug is $403 million United States dollars 
(2000 dollars).  Capitalizing out-of-pocket costs to the point of marketing approval at a real 




























re 68.  Summ
e result of a




























 in cost estim








 are some th
s is in the h
ates depen
 costs, the pr
ug-developm
ss for drugs





















Abbreviated New Drug Application 
An ANDA contains data which, when submitted to FDA's CDER, Office of Generic 
Drugs (OGD), provides for the review and ultimate approval of a generic drug product.  The 
OGD is responsible for providing regulatory oversight to expedite the availability of safe, 
effective, high-quality generic drugs to patients.  The OGD also provides guidance to the 
regulated industry on a wide variety of clinical, scientific, and regulatory matters relating to 
generic drugs.  Part of the mission of the OGD is to maintain the public’s confidence in an FDA 
as it continues to meet the ever-changing needs of public health. 
Once an ANDA is approved, an applicant may manufacture and market the generic drug 
product in the United States to provide a safe, effective, low-cost alternative to the American 
public.  A generic drug product is defined as one that is comparable to an innovator drug product 
in dosage form, strength, route of administration, quality, performance characteristics, and 
intended use. 
Generic drug applications are termed "abbreviated" because drug sponsors are generally 
not required to include animal and human data to establish safety and effectiveness.  Instead, 
generic applicants must scientifically demonstrate that their product is bioequivalent (i.e., 
performs in the same manner as the innovator drug).  One way scientists demonstrate 
bioequivalence is to measure the time it takes the generic drug to reach the bloodstream in 24 to 
36 healthy volunteers.  This gives them the rate of absorption, or bioavailability, of the generic 
drug, which they can then compare to that of the innovator drug.  The generic version must 
deliver the same amount of active ingredients into a patient's bloodstream in the same amount of 
time as the innovator drug.  ANDA reviewers focus on bioequivalence data, chemistry and 
microbiology data, requests for plant inspection, and drug labeling information. 
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The costs to bring generic drugs to the market are significantly lower than they are for 
new drugs.  A primary reason for this is because many of the expensive and risky aspects 
required of an NDA filing are not a factor when seeking approval to market generics.  Drug 
discovery and proof of safety and efficacy are major components of the NDA life cycle that are 
risky and expensive.  They are not required steps for a generic drug sponsor.  In addition, much 
of the marketing and advertising costs for generics are lower than they are for new drugs. (Food 
and Drug Administration, 2014) 
505(b)(2) Application 
A 505(b)(2) application may be submitted for a new chemical entity (NCE) when some 
part of the data necessary for approval is derived from studies not conducted by or for the 
applicant and to which the applicant has not obtained a right of reference.  For an NCE, this data 
is likely to be derived from published studies, rather than FDA's previous finding of safety and 
effectiveness of a drug.  It is important to note that if the applicant had a right of reference to all 
of the information necessary for approval, even if the applicant had not conducted the studies, 
the application would be a considered an NDA. 
A 505(b)(2) application may also be submitted for applications based upon changes to a 
previously approved drug product.  The application may rely on FDA’s finding of safety and 
effectiveness of the previously approved product, coupled with the information needed to 
support the change from the approved product.  The additional information could be new studies 
conducted by the applicant or published data.  This use of section 505(b)(2), described in the 
regulations at 21 CFR 314.54, was intended to encourage innovation without creating duplicate 
work and reflects the same principle as the ANDA, i.e., it is wasteful and unnecessary to carry 
out studies to demonstrate what is already known about a drug. 
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An applicant should file a 505(b)(2) application if it is seeking approval of a change to an 
approved drug that would not be permitted using an ANDA, because approval will require the 
review of clinical data.  However, section 505(b)(2) applications should not be submitted for 
duplicates of approved products that are eligible for approval using an ANDA.  In addition, an 
applicant may submit a 505(b)(2) application for a change in a drug product that is eligible for 
consideration pursuant to a suitability petition under Section 505(j)(2)(c) of the Act. 
Although a 505(b)(2) applications is not applicable to all drug applications, there are 
situations when this option is useful.  Some examples include (1) applications for pediatric drugs 
where results of studies performed on adults may be extrapolated to apply to pediatric patients, 
(2) instances of bioequivalence where alternative formulations and new dosage strengths may be 
assessed on the basis of evidence of bioequivalence, instances where modified release dosage 
forms may be approved on the basis of pharmacokinetic data linking the new dosage form to an 
approved immediate-release dosage form, and (3) in situations of different doses, regimens, or 
dosage forms where blood levels and exposure are not very different.  In these instances, it may 
be possible to conclude that a new dose, regimen, or dosage form is effective on the basis of 
pharmacokinetic data alone. 
Drug Development and Patent Protection 
The research and development required to gain approval to market a drug in the United 
States is dramatically different depending upon whether the drug is innovative or generic.  
Regardless of which application and subsequent development process is followed, however, 
FDA regulation holds the value of IP rights to be fundamental.  Mechanisms for protection of 
these rights through enforcement and legal action are integrated throughout all application 
processes. 
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Pharmaceutical innovators seeking approval to market drugs in the United States using 
the NDA typically are performing development for drugs they’ve either patented or licensed 
from a patent holder.  Patents are granted and protected for a specified amount of time.  FDA 
regulations require drugs be approved before they are sold in the United States.  Therefore, the 
earlier in the development process the inventions are patented, the shorter the amount of market 
exclusivity time (because the longer the patented invention will be in the approval process.)  
Loss of market-exclusivity time due to time spent gaining approval to market is an inherent 
consideration of the drug-development process in the United States.  The Hatch-Waxman Act 
addresses these details and will be considered in chapter 14.  At this point, though, it is important 
to understand that it is typical that drugs approved through the NDA process are patented, and 
patenting strategies attempt to reconcile time lost in development with protection of market-
exclusivity time. 
The approach to patents and IP rights when seeking approval to market generic drugs 
using the ANDA process is extremely different than it is for the NDA process.  As part of the 
ANDA process, generic manufacturers attempt to demonstrate bioequivalence of innovative 
drugs that are patent protected so that these patented inventions become available to the public 
on the date the patent expires.  Using bioequivalence as the basis for approving generic copies of 
drug products was established as part of the Hatch-Waxman Act.  Typically, it is not legal to 
practice patented inventions until after patents expire.  In the case of pharmaceutical patents, this 
is not the case.  Giving generic drug sponsors rights to practice patented inventions are also an 
inherent consideration of the Hatch-Waxman Act.  Fundamentally, though, generic drug 
sponsors are required to adhere to laws governing patented inventions.  The ANDA process 
requires that patent holders are advised of potential infringements of their inventions. 
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To begin the FDA approval process, the generic applicant must: 1) certify in its ANDA 
that the patent in question is invalid or is not infringed by the generic product (known as 
"paragraph IV certification"); and 2) notify the patent holder of the submission of the ANDA.  If 
the patent holder files an infringement suit against the generic applicant within 45 days of the 
ANDA notification, FDA approval to market the generic drug is automatically postponed for 30 
months, unless, before that time, the patent expires or is judged to be invalid or not infringed.  
This 30-month postponement allows the patent holder time to assert its patent rights in court 
before a generic competitor is permitted to enter. 
Patents and IP rights are also integrated with section 505(b)(2) applications.  The filing or 
approval of a 505(b)(2) application may be delayed due to patent or exclusivity protections 
covering an approved product.  Section 505(b)(2) applications must include patent certifications 
described at 21 CFR 314.50(i) and must provide notice of certain patent certifications to the 
NDA holder and patent owner under 21 CFR 314.52.  The certifications are required and force 
the 505(b)(2) applicant to directly address their impact on the IP of others.  
The drug-development process in the United States is complicated, but it is important to 
recognize the value placed upon IP rights and their protection during this process.  These rights 
are fundamental in developed societies, and violation of them when considering pharmaceutical 
innovation is a significant threat to public health.  Sale of counterfeit drugs violates these IP 
rights.  Sale of drugs in the United States without FDA approval is illegal and poses a significant 
threat to public health.  Marketing of substandard drugs throughout the world undermines the 




CHAPTER 13.  PATENTS AND SOCIETY 
As described in chapter 12, IP and IP-rights protection are fully integrated in the process 
of gaining approval to market a drug for sale in the United States, regardless of which 
application route the drug sponsor pursues.  This type of integration demonstrates the value 
developed societies like the United States place upon IP.  IP fosters innovation and promotes 
society.  The patenting system is an important part of the drug-development process.  A brief 
review of patenting in the United States and patenting related to drug applications to FDA is 
considered. 
The first issued patent in the American colonies was granted in 1641.  The first United 
States patent was granted in 1790.  A patent in the United States is an IP right granted by the 
government of the United States to an inventor “to exclude others from making, using, offering 
for sale, or selling the invention throughout the United States, or importing the invention into the 
United States” for a limited time in exchange for public disclosure of the invention when the 
patent is granted. (The United States Patent and Trademark Office, 2014) 
Patents are granted to inventions that are novel and nonobvious.  They are a trade 
between society and the invention owner that provides benefit to both parties.  The inventor 
benefits because they enjoy market exclusivity for a specified period of time.  This market 
exclusivity provides financial incentive to the IP owner, and may be considered reward for the 
contribution their invention will make to society.  In the pharmaceutical industry, the potential to 
recoup the initial investment required to develop the invention during this time of market 
exclusivity is a significant incentive.  This is because the process to achieve FDA approval to sell 
a pharmaceutical in the United States is long, risky, and expensive.  Society benefits from the 
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patented invention because details of the best practice of the invention are available for all 
members of society to use upon patent-term expiration. 
Disclosure and details of the best practice of the invention is required as part of the 
patenting process.  However, even though the details of the invention are available for review at 
the time the patent is granted, patent law forbids the practice of the invention until the patent 
term expires.  This is fundamental to patent law in the United States, and the concept dates back 
in patent history as far as 1474 to the Venetian Senate Act. 
The Venetian Act lays out all the essential features of a modern patent statute including 
an established procedure to determine infringement, as well as a remedy for infringement.  It 
covers “devices”; states that they must be registered with a specific administrative agency; it says 
that they must be “new and useful”, “reduced to perfection”, and “not previously made in this 
Commonwealth”.  The Venetian Act also provides a fixed patent term of ten years.  Interestingly, 
the Venetian Act reserved to the Republic the right to use any invention without compensating 
the inventor.  This is an early attempt to reconcile individual interest with the good of the 
community.  It implies that the inventor’s protection, provided by the grace of the state, ought 
naturally to be subject to the needs of the state. (Merger, 1997) 
Patents, patent terms, and patent law for drug-related and medical-device inventions in 
the United States are different than they are for all other types of patents.  The reason for this 
difference is because society in the United States recognizes the balance between pharmaceutical 
innovation and providing access to affordable medication.  To account for this balance, 
pharmaceutically relevant patents allow for time spent gaining FDA approval.  Patent law for 
pharmaceutically relevant patents also allow for legal infringement of patented inventions when 
the purpose of such infringement is to provide generic alternatives upon patent-term expiration.  
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These differences in patent law are a result of the Hatch-Waxman Act.  Patent terms and legal 
infringement of patent inventions related to the pharmaceutical industry are described in this 
chapter.  The impact of the Hatch-Waxman Act will be discussed in chapter 14. 
Patent Terms 
Normally, patent terms are for 20 years.  It is expected that for a normal patent, the 
patent-application process may take up to three years.  Since the patent term begins on the initial 
date of the patent application, the effective term of a normal patent for market exclusivity is 
usually about 17 years. (Pensabene & Gregory, 2013)  Prior to the Hatch-Waxman Act, patent 
terms were the same in the drug-development world, but the effective time for market exclusivity 
was usually shorter due to the inability of the patent owner to market until FDA approval.  
Gaining this approval would usually take years.  Patents for inventions related to drug 
development now compensate for market exclusivity time lost gaining regulatory approval.  
Patent-term extension is provided for patents covering certain products and methods, including 
human drug products, that are subject to FDA approval. (35 U.S.C. § 156; Eli Lilly and 
Company, Petition v. Medtronic, Inc., 1990)  The patent’s term can be extended by a maximum 
of five years or 14 years of effective patent life, whichever is less. Specifically, the patentee is 
entitled to a credit for the time the FDA was reviewing the first drug application. (Pensabene & 
Gregory, 2013) 
Legal Infringement 
To balance the extension in patent term for pharmaceutically relevant compounds, 
practice of the patented invention is allowed in some circumstances.  Specifically, practice of the 
invention is allowed when the goal of the practice is to develop a generic alternative that can be 
provided to the consumer on the date of patent-term expiration.  Prior to this change in the patent 
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system, generic manufacturers were required to wait until patent-term expiration before they 
could begin the process of developing generic alternatives.  This led to an effective extension of 
market exclusivity prior to the Hatch-Waxman Act and, therefore, generic (more affordable) 
alternatives took longer to reach the public. 
It is clear the benefit to society of pharmaceutical innovation resulting from IP protection 
cannot be overlooked.  Innovative drugs have eradicated many diseases and improved quality-of-
life standards throughout the world. (International Task Force for Disease Eradication, 1993)  
The patenting system is an integral part of the drug-development process.  This system promotes 
pharmaceutical innovation and offers long-term benefits to society.  
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CHAPTER 14.  THE DRUG PRICE COMPETITION AND PATENT TERM 
RESTORATION ACT OF 1984 
The patenting of pharmaceuticals in the United States went through a significant change 
as a result of the Hatch-Waxman Act.  This Act establishes certain rights and procedures in 
situations where a company seeks FDA approval to market a generic product prior to the 
expiration of a patent or patents relating to a brand-name drug upon which the generic is based.  
Congress enacted this law to facilitate the entry of lower-priced generic drugs, while maintaining 
incentives for pharmaceutical companies to invest in developing new drugs. 
There were two related issues that were addressed by the Hatch-Waxman Act.  First, 
when new drugs were discovered and patents applied for, the patent was issued before the FDA 
regulatory approval process for the new drug was complete.  Thus, the patent term would begin 
to run, but the patent owner could not market the product until the FDA approval process was 
completed.  As a result, patent owners seeking FDA approval would lose time in market 
exclusivity due to regulatory requirements.  Second, generic drugs could not begin development 
until patent terms expired.  Under Roche v. Bolar (Roche Products, Inc. Appellant, v. Bolar 
Pharmaceutical Co., Inc., Appellee, 1984), the testing of a generic equivalent to a patented drug 
for the purpose of obtaining the FDA’s approval was deemed infringement.  Accordingly, a 
competitor hoping to produce a generic product had to wait until the patent expired before it 
could begin the often-lengthy process of obtaining FDA approval.  Thus, from the time the 
patent expired until a competitor obtained FDA approval, the patent owner enjoyed an effective 
extension of market exclusivity.  The Hatch-Waxman Act reconciled these two related issues and 
fundamentally changed the patenting system in the United States. 
With regard to the first issue, patent terms under the Hatch-Waxman Act for 
pharmaceutically relevant inventions were extended.  Most United States patents have a 20-year 
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term measured from the original application’s filing date.  Since the application process for most 
patents (non-drug) typically takes about three years, a patent’s effective life is usually about 17 
years from its issuance.  This term is subject to patent-term adjustment for USPTO delays during 
patent prosecution that shrink the effective life below 17 years. (35 U.S.C. § 154(b)) 
Virtually all drugs approved through the NDA process are covered by one or more 
patents.  The effective patent term for patents covering a new drug is typically much shorter than 
17 years because the time-consuming FDA approval process typically occurs during part of the 
patent term.  As a result, branded drug companies do not enjoy the full benefit of the patent until 
the FDA approves the drug and sales can begin. (Pensabene & Gregory, 2013)  As a partial 
remedy, the Hatch-Waxman Act provides a patent-term extension for patents covering certain 
products and methods, including human drug products, which are subject to FDA approval. (35 
U.S.C. § 156; Eli Lilly and Company, Petitioner v. Medtronic, Inc., 1990)  The patent’s term can 
be extended by a maximum of five or 14 years of effective patent life, whichever is less.  
Specifically, the patentee is entitled to a credit for the time the FDA was reviewing the first drug 
application. (35 U.S.C. § 156(a) and 35 U.S.C. § 156(f)(1)(A) and (2)(A)) 
With regard to the second issue, the Hatch-Waxman Act allowed provisions to benefit 
generic drug sponsors.  The first provision was that the generic drug sponsor did not have to file 
an NDA to be granted approval to market the generic drug; they could file an ANDA.  The 
importance of this was that requirements for an ANDA filing were different than for the NDA 
filing, and it was expected that the approval time and cost to gain approval via the ANDA 
process would be significantly less.  Under an ANDA, a generic drug company must establish 
that the generic drug is effectively a duplicate of the branded, NDA drug, which is referred to as 
the Reference Listed Drug (RLD).  Generic manufacturers were no longer required to perform 
142 
clinical testing to prove safety and efficacy.  Specifically, the generic drug company must show 
that the proposed generic drug: 
1. Has the same active ingredient, route of administration, dosage form, strength, 
and intended use as the RLD.  It also must have the same labelling, except that the generic drug 
company sometimes may remove information related to a patented method or use subject to 
exclusivity from its label.  However, the generic drug is not required to have the same inactive 
ingredients as the RLD (21 U.S.C. § 355(j)(2)(A)). 
2. Is bioequivalent with the RLD so that it performs in the same manner as the RLD 
in the body.  Generally, a drug is bioequivalent when it delivers the same amount of active 
ingredient in a patient’s bloodstream over the same amount of time as the RLD.  Different but 
analogous rules apply to drugs that are not delivered in the bloodstream, for example, by topical 
application (21 U.S.C. § 355(j)(8)). 
Additionally, the generic manufacturer must file a certification regarding patents listed in 
the Orange Book (also known as Approved Drug Products with Therapeutic Equivalence 
Evaluations).  A Paragraph-IV Certification states that the patent is invalid or will not be 
infringed and begins a process by which that question may be answered by the courts prior to 
expiration of the patent.  Under the Hatch-Waxman Act, FDA approval of an ANDA is 
automatically stayed for 30 months when a patent owner files a patent infringement lawsuit 
within 45 days of receiving a Paragraph-IV notification.  During the stay, the FDA is prohibited 
from approving another ANDA.  Additionally, the first ANDA is granted a 180-day exclusivity 
period, as an incentive whereby the generic company does not have competition from other 
generic companies and can both establish market share and charge a higher price.  This higher 
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price is quite an incentive because the prices charged are usually only slightly below the branded 
drug and are a time of high profit for the generic manufacturer. 
The second provision of the Hatch-Waxman Act to the benefit of generic manufacturers 
is with regard to practice of a patented invention.  Typically, the patented invention may not be 
practiced until patent-term expiration.  In these cases, though, the Hatch-Waxman Act allows 
generic drug sponsors to practice the invention if the intention is to bring a generic drug to the 
market.  What this practically means is that the generic manufacturer no longer has to wait until 
patent-term expiration to begin their development and, therefore, could be ready to market their 
generic product on the date of patent-term expiration.  It is important to recognize that this 
privilege that is extended to generic drug sponsors to legally infringe unexpired patents is unique 
to specific types of patents.  
There are other details of the Hatch-Waxman Act that are important and have changed 
the business of pharmaceutical development.  It is clear that the intention of the Act was to 
balance pharmaceutical innovation with access to affordable medication.  There have, however, 
been many unexpected consequences.  For instance, especially in more recent years, there have 
been more patent applications by generic companies and increased generic research and 
development for branded products.  Although clearly not a goal of Hatch-Waxman, generics 
innovate, often obtaining “design-around” patents or a more efficient manufacturing process, 
new formulations, or new forms of the API. (Rumore, 2009)  Conversely, although there are 
more ANDAs filed than ever, there are an increased number of “me-too” ANDAs and ANDAs 
for products which already have a generic version. (Silver, 2007) 
Although the net effect of Hatch-Waxman on pharmaceutical innovation is ambiguous, 
its effect on generic drug development has been explicit, and the effect on consumers has been 
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beneficial.  It will be argued in later chapters that the long-term benefits to the consumer are not 
as clearly beneficial.  One thing is for sure.  The Act has instigated a flurry of litigation this is 
costly.  The Hatch-Waxman Act resulted in increased ANDA applications and Paragraph-IV 
challenges, especially since 1998.  There has also been a high success rate for patent 
invalidation, particularly formulation and polymorph patents.  Since the Hatch-Waxman Act, 
virtually all top-selling drugs not covered by patent face generic competition; whereas pre–
Hatch-Waxman, only 35% had generics available.  Similarly, today more than 70% of 
prescriptions are for generics, whereas prior to the Act generic prescriptions numbered 15%. 
(Rumore, 2009)  In addition to substantial generic penetration, Saha and colleagues also reported 
on the generic-to-brand price ratio.  Their analysis indicated that the average generic-to-brand 
price ratio for the drugs in their sample set falls continuously following generic entry.  
Furthermore, as the entry rate slows down after the first year, so does the decline in the price 
ratio.  A month after the first generic entry, the average price of generics for all 40 drugs 
evaluated was 76% of the brand price; by the end of the first year it was 54%; by the end of the 
second year it was 41%. (Saha, Grabowski, Birnbaum, Greenberg, & Bizan, 2006)  Under the 
Hatch- Waxman Act, the average length of patent extension is three years.  Overall, there have 
been some reduced returns on new drugs, but product life cycles have not changed significantly. 
(Rumore, 2009) 
The impact of the Hatch-Waxman Act upon pharmaceutical development has been 
significant.  Not only was the drug-development process impacted, but also the fundamental 
rights of IP owners were changed to accommodate the balance between innovation and 
accessibility of the public to needed drugs.  There is no question it has increased the availability 
of generic drugs to that market.  Whether it will continue to foster innovation is still to be seen.
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CHAPTER 15.  ENFORCEMENT OF INTELLECTUAL PROPERTY RIGHTS 
Enforcement of IP rights in the pharmaceutical industry, especially as related to the 
availability of counterfeit, substandard and illegal-imitation drugs, is an important issue that is 
complex.  Even in the United States enforcement can be challenging.  In other regions of the 
world where societies are less developed and IP is not valued, enforcement can be daunting.  It 
seems appropriate, therefore, to discuss the challenges of enforcement in developed societies like 
the United States separate from enforcement in underdeveloped societies. 
Enforcement of Intellectual Property Rights in the United States 
In the United States, IP rights are granted and infringement criteria are established.  This 
is especially true during drug development and approval where patent litigation amongst 
innovative and generic drug companies is common.  In addition, the United States has a highly 
regulated drug-supply chain which minimizes the introduction of counterfeit and other illegal 
pharmaceuticals into the legitimate marketplace.  Finally, the functional legal system of the 
United States provides a mechanism to enforce instances of IP-rights violation.  This is not to say 
they are always enforced; just that the framework within which they can be enforced is 
established. 
FDA and other regulations make it very difficult, although not impossible, for counterfeit 
and other illegal pharmaceuticals to infiltrate the legitimate supply chain within the United 
States.  It is reasonable for a consumer in the United States to expect that, assuming they 
purchase within authorized pharmacies, the pharmaceuticals they receive are what they are 
purported to be.  This is not to say that counterfeit and other illegal pharmaceuticals are not 
available in the United States, but rather that within the regulated supply chain, they are not 
encountered with great frequency. 
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The internet in recent years has made it significantly easier for the American consumer to 
encounter counterfeit and substandard drugs.  Unregulated website pharmacies have added a new 
dimension to the trade of these goods.  Online purchasing has become more common in the 
United States.  However, not all people understand that purchasing medication online is different 
from purchasing other consumer goods online.  Online purchases of pharmaceuticals are very 
risky, especially if the consumer is unaware of what to look for to detect fraud or other illegal 
activities when making these purchases.  Purchases of pharmaceuticals online may result in the 
receipt of drugs that are counterfeit, the wrong dose, not approved by FDA, not stored properly 
during shipment, may contain unsafe ingredients, or have expired. (AWARxE Consumer 
Protection Program, 2014) 
During drug development, the Hatch-Waxman Act works reasonably well to enforce IP 
rights.  The primary legal actions taken during this time include litigation triggered by a 
Paragraph-IV Certification, where a patent holder believes their patent rights have been violated 
by an ANDA filing.  The patent holder has the right to file a patent infringement suit against the 
generic applicant and, essentially, will halt the approval of the ANDA for a period of at least 30 
months.  This 30-month stay allows time for the patent-infringement claims to be reviewed in a 
court of law.  This mechanism for enforcement is quite powerful, and enforcement of patent 
protection in these cases is possible. 
For the patentee, the primary reward for winning a Hatch-Waxman Act patent litigation is 
continued enjoyment of any unexpired exclusivity. The typical remedies for a prevailing patentee 
include (1) an order directing the FDA not to approve the ANDA before the expiration of the 
relevant patents and any other exclusivity, or (2) an injunction against future infringement.  
Money damages also may be available if the ANDA filer made actual sales. (Pensabene & 
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Gregory, 2013)  In exceptional cases, attorney fees also are available to a prevailing patentee. (35 
U.S.C. § 271(e)(4)) 
For a generic drug company, the primary reward for victory is the ability to enter the 
market before patent expiration without patent-infringement liability.  A prevailing generic drug 
company that has tentative approval usually can immediately gain final approval and enter the 
market.  If not, the prevailing generic drug company can enter the market once any other 
exclusivity has expired.  This is typically the 180 days of exclusivity held by a first filer.  A 
prevailing generic drug company also may obtain attorney fees in an exceptional case. 
(Pensabene & Gregory, 2013) 
There are some reported abuses of the Hatch-Waxman Act and loopholes that have made 
for some interesting legal actions.  Some of these loopholes have been closed.  One such 
example of a closed loophole is with regard to the 30-month-stay provision related to Paragraph-
IV Certification.  Once pharmaceutical companies began to realize the advantageous nature of 
the 30-month stays, they also began looking for ways to extend them beyond the 30-month 
period. (Eurek, 2003)  According to a study conducted by the Federal Trade Commission (FTC) 
in 2002, one of the most common ways that patent-holding companies were able to further delay 
the market entry of generic drugs was through multiple patent listings in the Orange Book, which 
is the FDA’s official list of all approved products.  The FTC study identified several instances in 
which brand-name companies listed patents in the Orange Book after an ANDA had already 
been filed by a generic manufacturer.  The effect of these later listings is that the generic 
applicant was then required to recertify that the later-listed patent is also invalid or not infringed, 
and notify the patent holder of the recertification.  In essence, the generic applicant was required 
to repeat the ANDA process for the later-listed patent.  It was estimated that abuses of this kind 
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resulted in billions of dollars in additional sales to the patent holders. (Federal Trade 
Commission, 2002) 
The Hatch-Waxman Act was amended several times to close this and other loopholes, as 
well as to decrease generic drug approval times. (Medicare Prescription Drug, Improvement, and 
Modernization Act, 2003)  Additionally, over the years, the FDA issued many guidance 
documents clarifying the Hatch-Waxman Act with the goals of reducing generic approval time, 
improving ANDA application quality to avoid multiple review cycles, and avoiding time-
consuming legal delays which delayed competition. (Rumore, 2009) 
There are still many legal strategies that are used by brand owners and generic sponsors 
to gain or maintain market exclusivity.  One such strategy is the “at-risk” product launch by 
generic companies.  This strategy involves launching the generic product prior to a district court 
decision and injunction.  In Sanofi- Synthelabo and Bristol-Myers Squibb v. Apotex (Sanofi-
Synthelabo, Inc.; and Bristol-Myers Squibb Sanofi Pharmaceuticals Holding Partnership, 
Plaintiffs, -against- Apotex Inc.; and Apotex Corp., Defendants, 2006), three months prior to the 
FDA’s approving the ANDA, the generic company notified Sanofi that it would launch the 
generic Plavix® product “at risk.”  The generic was launched stocking pharmacy shelves over 
the course of approximately three weeks, while Sanofi filed for a preliminary injunction.  Three 
weeks later, an injunction was granted with Apotex being “at risk” that it would lose some of the 
180-day exclusivity period and the market share associated with it.  Even though the court ruled 
in favor of Sanofi, it denied Sanofi’s request to recall the product that had already been 
distributed prior to the injunction.  During the three-week distribution that occurred as a result of 
the at-risk launch, Apotex supplied enough of the generic drug pharmacy’s to maintain 
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domination over Plavix for five months.  Apotex received hundreds of millions of dollars in 
revenue for this at-risk launch. (Pechersky, 2007) 
In spite of this and other “legal strategies” that have changed the business of drug 
development in the United States as a result of the Hatch-Waxman Act, it is important to 
recognize that this law is intended to balance innovation with access to affordable medicines.  
Fundamentally, the United States legal and regulatory system affords patent owners with the 
tools they need to enforce IP rights.  This is clearly the case when it comes to patent litigation 
surrounding drug approvals. 
Patent infringement related to other kinds of sales of pharmaceutical is a little bit more 
difficult to manage than it is for infringement related to legal sales of pharmaceutical within the 
United States.  For example, generic versions of VIAGRA ordered online that are shipped to the 
consumer located in the United States from overseas are illegal.  In this case, the generic 
VIAGRA is illegal because it is sold in the United States without FDA approval.  It is also illegal 
because it violates the IP rights of Pfizer, the brand owner.  These are related, but fundamentally 
different reasons they are illegal, and each violation has different implications.  With regard to 
lack of FDA approval, the primary implication of this problem is that the safety and efficacy of 
the drug is truly unknown.  With regard to the IP-rights violations of Pfizer, this is a problem that 
is monetary and social.  However, it is difficult to prosecute against the infringer primarily due to 
jurisdictional issues. 
As an example, sample SING1 analysed as part of this research was purportedly (by 
package labelling) manufactured in India, shipped from Singapore (by postmarking), and 
received in the United States.  What is the appropriate jurisdiction within which to file action?  
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Jurisdiction issues challenges not only IP rights in the pharmaceutical industry, but also other 
industries as well. (Dean, 2013) 
It seems one of the best ways, at least in theory, to enforce IP rights protection for 
violations against United States patents is by way of trade agreements.  In the 1980’s the United 
States was undergoing a transformation from an industrial to an information economy.  Waning 
industrial competitiveness hurt United States companies and international trade.  The United 
States began searching for new areas of commerce which would help it maintain 
competitiveness.  IP emerged as "a new basis of comparative advantage." (Subramanian, 1991)  
There were several IP-related industries, namely the entertainment industry (records and 
movies), pharmaceutical industry, and the computer industry who were becoming extremely 
important contributors to the United States economy.  Computer technology, for example, was a 
huge growth industry during the mid-1980s.  During this time, personal computers hit the 
market, computer programs became hot items, and computer software emerged as a commercial 
product with a high level of economic return. (Halbert, 1997)  The United States worked to 
protect its IP interests and as a result has become the international advocate for strong IP-rights 
protection.  This advocacy has been the motivating force behind the inclusion of IP rights in the 
general agreement on tariffs and trade (GATT), the United States-Canada free-trade agreement, 
and the North American free-trade agreement. (Halbert, 1997) 
In 2009, the Commissioner of the USPTO stated that his office works closely with the 
Office of the United States Trade Representative (USTR) and other agencies to establish, on a 
bilateral and multilateral basis, workable treaty commitments and trade agreements.  For 
example, Commerce worked with the USTR on matters concerning the IP chapter for several 
free trade agreements (FTAs) during FY 2008, most notably negotiation of the IP chapter of the 
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United States-Malaysia FTA, Costa Rica’s implementation of the Dominican Republic-Central 
America-United States FTA, Peru’s implementation of the United States-Peru Trade Promotion 
Agreement, as well as implementation of the United States-Chile FTA.  Commerce also 
contributed to the development of the United States’ World Trade Organization (WTO) dispute 
settlement case against China relating to deficiencies in its IP rights enforcement regime.  In 
addition, the USPTO co-chair’s the IP Rights Working Group in the United States-China Joint 
Commission on Commerce and Trade (JCCT), the United States’ ongoing trade dialogue with 
China. (Stoll, 2009) 
It can be argued that unless trade agreements mandate the consideration of IP rights by 
foreign countries, there is virtually no recognition of such rights. (Bird, 2006)  For instance, in 
China and India, coercion attempts by the United States centered on trade agreements were used 
to get these countries to recognize IP rights.  While there is genuine concern about whether or 
not coercion attempts garner real benefit in the long term, infringement of IP rights in these 
countries is a significant problem for brand owners. (Bird, 2006)  Brazil faced overwhelming 
pharmaceutical industry pressure and governmental threats of sanctions from the United States to 
improve its patent protection for drug products and processes.  Brazil finally gave up its 
resistance by discussing IP rights at the GATT, joined the trade-related aspects of IP rights 
(TRIPS) agreement, and now possesses a functioning patent approval system that is fairly 
consistent with the minimum standards of protection required by TRIPS. (Schulz & Wu, 2004) 
The TRIPS agreement is quite comprehensive in its understanding of the complexity of 
the IP-protection problem, especially within the pharmaceutical industry.  The agreement 
requires all WTO Member States to grant patents for pharmaceutical products or process 
inventions for a minimum of 20 years. (Velásquez & Boulet, 1999)  Prior to the agreement, 
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many Member States granted no rights at all, or had terms as short as five years.  It also provides 
time for developing countries to modify and enact laws that made them compliant with the 
agreement.  The agreement also allows the use of compulsory licenses, a provision that 
demonstrates an understanding of the need for some consideration of public-health crises (even if 
at the expense of an individual’s right to own property).  Compulsory licensing enables a 
competent government authority to license the use of a patented invention to a third party or 
government agency without the consent of the patent holder.  Article 31 of the Agreement sets 
forth a number of conditions for the granting of compulsory licenses.  These include a case-by-
case determination of compulsory-license applications, the need to demonstrate prior 
(unsuccessful) negotiations with the patent owner for a voluntary license, and the payment of 
adequate remuneration to the patent holder.  Where compulsory licenses are granted to address a 
national emergency or other circumstances of extreme urgency, certain requirements are waived 
in order to hasten the process, such as that for the need to have had prior negotiations to obtain a 
voluntary license from the patent holder. (World Health Organization, 2014) 
Enforcement of Intellectual Property Rights in Underdeveloped Societies 
Even in the best of cases where IP-rights protections are in place like for Member States 
of the TRIPS agreement, enforcement of these rights is not common. (Bird, 2006)  Interestingly, 
it has been proposed that although social benefits may arise from patent protection through the 
discovery of new drugs, the TRIPS agreement standards derive from those of industrialized 
countries and are not necessarily appropriate for the development level of all countries. 
(Velásquez & Boulet, 1999)  As previously mentioned, IP rights are fundamental in a developed 
society like the United States, but their value is not always appreciated.  
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It is likely the best chance for success of IP-rights enforcement on a global scale is by 
way of trade agreements.  However, there are other efforts taking place that may lead to the 
improvement of IP-rights enforcement.  The USPTOs Attaché Program was formally instituted 
in 2006 for the benefit of United States economic and political interests abroad to promote the 
value and importance of strong IP protection and enforcement in selected, high-profile countries 
where United States IP challenges are greatest.  In partnership with Commerce’s more broadly 
scoped Foreign Commercial Service and the Department of State, the IP Attachés are sent out to 
strengthen global IP protection and enforcement overseas.  The IP-rights experts support United 
States embassies and consulates on IP-rights issues, including devising strategies to stop 
counterfeiting and piracy, and supporting United States government efforts to improve the 
protection and enforcement of IP rights.  The Attachés also advocate United States IP policies, 
coordinate training on IP rights matters, and assist United States businesses that rely on IP-rights 
protection abroad. These Attachés serve at posts in Brazil, Russia, India, China, Thailand, and 
the United States Missions in Geneva. (Stoll, 2009) 
Although hopeful, it seems lofty to expect that IP-rights enforcement related to 
pharmaceuticals in countries of extreme poverty will improve in the short term.  The unfortunate 
aspect of this realization is that these environments are the ones where counterfeit drugs pose the 
greatest short- and long-term threat to public health. (USP Council of the Convention Section on 
Global Public Health, USP Council of Experts International Health Expert Committee, USP 
Regionalization Team, Heyman, & Williams, 2011)  The administration of counterfeit or 
substandard drugs is the norm in these regions of the world.  In fact, without the availability of 
counterfeit or substandard drugs, no drugs at all would be available for these citizens, which can 
be considered a problem if government has a moral responsibility to guarantee its citizens a right 
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to a healthy life. (Gewertz & Amado, 2004)  Some researchers have proposed charging 
counterfeiters with manslaughter when a patient’s death can be directly linked to performance of 
a counterfeit medication. (Newton, et al., 2006)  This approach may help curb the influx of 
counterfeit goods because it would increase the risk counterfeiters take when supplying these 
harmful drugs.  Currently, the risk/reward ratio for counterfeiters in these regions of the world is 
so low that there is no incentive to deter these criminals from engaging in these activities. 
(Thomas, 2011)  There have been instances where safe medications have been delivered to these 
regions of the world, but abuses in these situations are also a big problem that frequently lead to 
the diversion of these goods from their intended recipients. (Médecins Sans Frontières Australia, 
2014) 
It seems fair to say that public health is the most significant factor when considering the 
counterfeit-drug problem, but coupled with this public-health aspect is the need for developed 
societies to support innovation by enforcing IP rights.  Extending this to underdeveloped and 
extremely poor countries is important.  Enforcement is challenging, and in many regions of the 
world mechanisms are in place to support this enforcement. 
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CHAPTER 16.  FUNDING OF PHARMACEUTICAL RESEARCH 
Funding of pharmaceutical research comes from a variety of different sources including 
private industry, government, not-for-profit organizations, and individual donors.  The cost of 
research and development, by all accounts, is high.  In 2003, DiMasi and colleagues reported in 
the Journal of Health Economics that the pre-approval cost estimate for development of a drug in 
the United States is $802 million (year 2000 United States dollars). (DiMasi, Hansen, & 
Grabowski, 2003)  Since this time, this number has been cited frequently. 
In addition to the cost estimate, these authors determined that the average successfully 
developed new molecular entity (NME) in the study’s sampled required 4.3 years for discovery 
and preclinical development, and another 7.5 years for clinical trials and FDA approval.  
Approval itself took an average of 1.5 years.  Thus, developing an NME and bringing it to 
market required 11.8 years, on average. (DiMasi, Hansen, & Grabowski, 2003)  Table 11 
summarizes estimated costs calculated in the study, as well as average research length for both 
preclinical and clinical phases of development.  The study surveyed drugs from a representative 
set of therapeutic classes, but it excluded some types of new drugs that have lower average 
research and development costs.  In addition, the estimate may not be representative of research 
and development costs for smaller pharmaceutical firms which did not participate in the survey 
on which the study was based.  However, by focusing on NME’s, the study did base its cost 
estimate on the types of drugs that have been the source of most pharmaceutical breakthroughs. 
(Congressional Budget Office, 2006) 
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Table 11.  Estimated costs calculated by DiMasi et al.  Reprinted 
from Congressional Budget Office Report, Research and 
Development in the Pharmaceutical Industry, 2006. 
Although this study is widely cited, it is not without its critics.  Light and Warburton 
discuss various reasons for the problems with the calculation of this $802-million value.  They 
state, among other things, that this cost figure, like the ones that preceded it, is based on 
confidential, unsystematic data, and has dubious scientific validity. (Light & Warburton, 2005)  
They state that given the many independent sources of variability, any point estimate is 
misleading.  Reporting that research and development costs of major new drugs range from $300 
million to $1.3 billion rather than a single average point estimate, therefore, is more informative. 
(Light & Warburton, Setting the record straight in the reply by DiMasi, Hansen and Grabowski, 
2005) 
While the exact cost of pharmaceutical research and development is an elusive number to 
determine, it is clear that regardless of how costs are calculated, the numbers are high and 
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usually in the hundreds of millions of dollars. (Adams & Brantner, 2006; Light & Warburton, 
2011)  For every successful new drug, a firm will have had many failed drug projects that did not 
survive clinical trials or that never won approval from the FDA.  Estimates of average research 
and development costs per drug include the costs of those failures. (Congressional Budget 
Office, 2006) 
These high costs have been used by the pharmaceutical industry for decades to justify 
high sale prices. (Melethil, 2005)  When you follow the money, it seems that the largest 
percentage of research and development costs is, indeed, paid by industry.  Government makes a 
significant contribution, though.  Health-related research receives the second largest amount of 
federal support for research and development (behind only defense-related research).  That 
support has been steadily growing for several decades.  Spending on research by the National 
Institutes of Health (NIH)—by far the primary recipient of government funding for health-related 
basic research—was $5.8 billion (in 2005 dollars) in 1970.  This figure more than doubled to 
$12.3 billion by 1990.  By 2004, it reached $28.5 billion.  In comparison, spending reported on 
research and development by the members of the Pharmaceutical Research and Manufacturers of 
America (PhRMA) was just two-thirds the size of NIH’s spending in 1980.  PhRMA’s research 
and development spending surpassed NIH’s in 1987 and has remained higher since then, 
although both grew at similar rates in the late 1990s and early 2000s.  Figure 69 shows the 
spending data from 1970 to 2004. (Congressional Budget Office, 2006) 
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Figure 69.  Research and development spending between 1970 and 
2004 for PhRMA members and NIH. 
Government funding has a very strong role in pharmaceutical research and development, 
but it tends to have a different role than funding from private industry.  Much of the government 
funding is for the basic research on disease mechanisms that underlie the search for new drugs.  
Although the distinction between basic and applied research and development is not always 
clear, it is useful to think of basic research as generating information or knowledge that is not 
readily embodied in physical products.  Federally supported basic research in genomics, 
molecular biology, and other life sciences has greatly expanded the drug industry’s technological 
opportunities, stimulating private investment in pharmaceutical research and development. 
(Congressional Budget Office, 2006) 
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The rationale for government funding of basic scientific research is simple; if such 
research was left solely to the private sector, too little of it would be done.  The benefits to 
society from doing additional basic research and development (beyond what firms alone would 
conduct) far outweighs the costs.  A company’s incentive to invest in research and development 
is limited to its own expected returns.  In the case of basic research and development, those 
returns can be particularly low compared with the social benefits.  It can be difficult for private 
companies to capture more than a small fraction of the total social value of their basic research.  
A basic research discovery cannot be patented unless the inventor can credibly describe the 
discovery’s “specific and substantial” utility. (Congressional Budget Office, 2006)  It seems the 
role government funding plays is to create new knowledge and new tools and produce large 
numbers of highly trained researchers, all of which are a direct and important input to private-
sector research. (Cockburn & Henderson, 2001) 
Some argue that since government funding can be linked to drug products that provide 
profit to private industry, government should share in the profits.  This approach has historically 
not been met with success.  Prior to 1980, invention rights supported by government agencies 
belonged strictly to the federal government.  Nobody could exploit such research without tedious 
negotiations with the federal agency concerned.  Worse, companies found it near impossible to 
acquire exclusive rights to a government-owned patent.  Without these rights, few firms were 
willing to invest millions more of their own money to turn a raw research idea into a marketable 
product.  The result was that inventions and discoveries made in American universities, teaching 
hospitals, national laboratories, and non-profit institutions sat in warehouses gathering dust.  Of 
the 28,000 patents that the American government owned in 1980, fewer than 5% had been 
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licensed to industry.  Although taxpayers were footing the bill for 60% of all academic research, 
they were getting hardly anything in return. (Innovation's golden goose, 2002) 
The transfer of rights from the government to the inventor and university came about in 
1980 with the Bayh-Dole Act.  The philosophy behind the Act was the belief that the solution lay 
with the individual and that the best thing government could do to provide incentives for success 
was get out of the way of these individuals. (Stevens, 2004)  Government would then benefit in 
two ways.  First, the therapeutic value of new medications would be considered a primary benefit 
to government. (Congressional Budget Office, 2006)  Second, even though rights were 
transferred from government to individual researchers and universities, some financial benefits to 
government were written into the law to help the government get better results from their 
funding than had historically been the case.  Even so, the government has not had much success 
collecting on these financial incentives primarily due to its own administrative issues. (Gerth & 
Stolberg, 2000) 
The Bayh-Dole Act was designed to push federally financed research from the university 
laboratory into the marketplace.  Scientists who made discoveries using taxpayer money were 
required to file invention reports with the government.  Universities were directed to license 
patented inventions to companies that would commercialize them.  The law was originally 
passed to aid small businesses, but later it was modified so that even big companies could 
benefit.  If a company did not develop a product quickly enough, the government could revoke 
the company's license and hand the job over to a competitor. It could also take control of an 
invention to alleviate "health or safety needs," the law said. (Gerth & Stolberg, 2000) 
Once an invention is on the market, the law grants the government the right to buy it 
without paying customary royalties.  At the same time, other laws enable federal agencies to put 
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taxpayer-financed inventions out to competitive bidding.  For example, the government could 
give other companies (besides the developer) the opportunity to manufacture and sell at a lower 
price, but only to the government.  However, in the first 20 years after the Bayh-Dole bill 
became law, the government had not taken advantage of these provisions.  One reason is because 
the government already buys drugs cheaply by purchasing them in bulk.  More importantly, even 
if federal officials wanted to use the Bayh-Dole Act to get medicines at still cheaper prices, they 
could not because they do not keep track of products, including drugs that are invented with 
taxpayer money.  In addition, a preliminary report by the inspector general's office of the 
Department of Health and Human Services found that as many as 22 percent of discoveries 
financed by the health institutes were not reported by universities, as is required.  More than 
2,000 inventions developed with government money were reported to the health institutes in 
1999, but agency officials said in interviews that they had no idea which, if any, companies had 
licensed those inventions, or how they were being used. (Gerth & Stolberg, 2000) 
In spite of the government’s inability to fully collect financially from the drug products it 
funds, the Bayh-Dole Act did invigorate industry.  Coming out of World War II, the United 
States was unchallenged in its political and economic leadership of the free world.  However, by 
the end of the 1970s it was clear that United States industry had lost its international 
competitiveness to Europe and, particularly, to Japan. This process had started with the success 
of the United States programs to rebuild its Allies and former enemies and was completed by the 
impact of the oil shocks of the 1960s and 1970s on an economy dependent on cheap domestic 
energy.  Examples of the loss of competitiveness abounded.  The United States lost leadership 
roles in both mature industries, such as automobiles and televisions, and emerging industries, 
such as memory chips.  In addition, Japanese companies dominated in industries based on 
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American and European innovations, such as video cassette recorders and compact discs.  The 
Bayh-Dole Act was intended to reverse this trend toward non-competitiveness.  It is unlikely that 
anyone in the technology-transfer community would dispute its importance. (Stevens, 2004) 
Although initially the concern with this Act was that the government would provide 
investment and not reap reward, it seems the most important criticism is the impact it has had on 
academic institutions and their role in society.  Many scientists, economists, and lawyers believe 
the Act distorts the mission of universities, diverting them from the pursuit of basic knowledge, 
which is freely disseminated, to a focused search for results that have practical and industrial 
purposes.  Whether that is a bad thing is a matter of debate. (Bayhing for blood or Doling out 
cash? Intellectual property, 2005) 
What is not in dispute is that it makes American academic institutions behave more like 
businesses than neutral arbiters of truth.  For example, a study published in 2003 by Jerry and 
Marie Thursby of Emory University and the Georgia Institute of Technology, respectively, 
reported that a survey of industry licensing executives shows 27% of their university licenses 
include clauses that allow deletion of information from papers before submission, and 44% ask 
for publication delay (3.9 months on average) (Thursby & Thursby, 2003) 
Moreover, there is ample evidence that scientific research is being delayed, deterred, or 
abandoned due to the presence of patents and proprietary technologies.  Researchers (and 
particularly their minders in university patent-licensing offices) are increasingly reluctant to 
share materials and knowledge with others unless such sharing is accompanied by legal 
agreements about "reach-through" royalties on potential findings and the right to restrict 
publication of results.  A study released by the American Association for the Advancement of 
Science noted that 35% of academic biotechnology researchers experience difficulties getting 
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hold of patented technologies that they need for their work, even though non-commercial 
research is supposed to be exempt from the normal restrictions of patents.  The question is just 
how "non-commercial" is such research?  Lawsuits between universities and researchers over 
patents and royalties are now common. (Bayhing for blood or Doling out cash? Intellectual 
property, 2005) 
Even industry is starting to complain about a gold-digger mentality among academic 
administrators.  The most notorious example is Columbia University, which tested the 
boundaries of the law by seeking to re-patent a technique whose patent had already expired.  The 
patent was for a technology called co-transformation that is used to place external DNA into 
cells, and is important in making certain drugs.  Columbia eventually backed down, but only in 
the face of both public criticism and a series of writs from biotechnology companies. (Bayhing 
for blood or Doling out cash? Intellectual property, 2005) 
Another case ensnared the University of Utah, which licensed its patent on a gene 
underlying hereditary breast cancer exclusively to one company, Myriad Genetics.  That gave 
Myriad Genetics a monopoly on diagnostic testing for the disease, which was controversial 
enough.  Then the firm started suing universities that were using its technology in follow-up 
research, bringing the non-commercial research exemption still further into question. (Bayhing 
for blood or Doling out cash? Intellectual property, 2005) 
Funding has changed in recent years.  Neither federal nor private support for research and 
development is likely to return to the trend that produced a tripling in support between 1995 and 
2005.  As a portion of gross domestic product, research and development expenditures are 
declining in the United States and Europe, whereas they are increasing at an accelerated rate in 
China, South Korea, and India. (Moses III & Dorsey, 2012)  In 2009, privately funded 
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biomedical research comprised $70 billion (65%) of the $110 billion total. (Dorsey, et al., 2010)  
The NIH budget has not kept pace with inflation.  The result is justified concern over the support 
of institutions and researchers who must conduct critical early-stage investigations to validate 
new approaches to diseases of high prevalence and high morbidity such as common cancers, 
autism, and dementia, for which the public health burden (and costs) are increasing, and effective 
prevention or treatment are elusive. (Moses III & Dorsey, 2012) 
New drugs have revolutionized the treatment of ulcers, stroke, and various psychiatric 
conditions.  They have dramatically improved the quality of life of asthma sufferers.  They have 
brought the symptoms of AIDS under control for a significant fraction of the infected population.  
Some cancers are now reliably curable by drug therapy, and new drugs for hypertension and high 
cholesterol are proving instrumental in the treatment of heart disease, still the largest killer of 
Americans.  Drugs "in the pipeline" promise major advances in the treatment of arthritis, 
Alzheimer's disease, many kinds of cancers and a variety of other chronic conditions. (Cockburn 
& Henderson, 2001)  These innovations are expensive.  Cost required to invent and develop 
these innovations is a serious consideration. 
The cost of innovation is expensive and drug companies argue that without profit 
incentive, the risks would be too high to invest in development.  However, there is concern by 
some that the amount of profit of some successful pharmaceutical companies is too high making 
it impossible for some patients to be treated.  In 2013, a group of over 100 oncologists discussed 
the exorbitant cost of innovative cancer medications in a commentary piece in the journal Blood 
of the American Society of Hematology. (Experts in Chronic Myeloid Leukemia, 2013)  They 
propose that these costs are not justified and may even be immoral.  The authors report that the 
annual sale of imatinib, a blockbuster drug used to treat chronic myelogenous leukemia, was 
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approximately $4.7 billion dollars in 2012.  They propose this targeted cancer therapy may have 
set the pace for the rising costs of cancer drugs.  Initially priced at $30,000 per year when it was 
released in 2001, the annual cost in 2012 at $92,000, in spite of the fact that all research costs 
were accounted for in the original proposed price and recovered within the first two years the 
drug was on the market. (Experts in Chronic Myeloid Leukemia, 2013) 
The doctors who signed on to the commentary are not alone in their criticism of pricing 
by pharmaceutical companies.  Some of these doctors said they were inspired by physicians at 
the Memorial Sloan-Kettering Cancer Center in New York, who refused in 2012 to use a new 
colon cancer drug, Zaltrap®, because it was twice as expensive as another drug without being 
better.  After those doctors publicized their objections in an Op-Ed article in The New York 
Times (Bach, Saltz, & Wittes, 2012), Sanofi, which markets Zaltrap, effectively cut the price in 
half. (Pollack, 2013) 
Development for cancer therapy's tend to be higher than for other types of innovative 
drugs, but It is important that the pricing of these goods by pharmaceutical manufacturers be 
considered when evaluating cost.  A determination of what is unreasonable profit should be 
considered when the consequence of high prices is that access to life-saving medication is 
denied.  In the case of the drug imatinub, it is clear that profits are high. 
Pfizer, the manufacturer of VIAGRA, has also been experiencing increase in profits in 
recent years.  Table 12 shows Pfizer’s profit in the form of net income attributable to Pfizer Inc. 
(% of revenues) for the years 2011 through 2013.  This value increased from 16.4% to 26.7% 
from 2011 to 2012, up to 42.7% for the year 2013. (Pfizer Inc. and Subsidiary Companies, 2013) 
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Table 12.  Analysis of the consolidated statements of income of 
Pfizer for the years 2011 through 2013. 
Pfizer stock prices have also increased steadily over the past five years.  Over the past ten 
years, these stock prices were at their lowest in the year 2009 (approximately $12.5 per share) 
and at their highest in the year 2004 (approximately $35 per share).  Current stock prices are 
approximately $30 per share. (Pfizer, 2014)  Pfizer stock prices for the past 10 years are shown 
in figure 70. 
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Figure 70.  Historical stock chart of Pfizer stock. 
Pricing and evaluation of profit is an important consideration.  Incentive to invest in 
pharmaceutical innovation is critical and impacted by counterfeit drugs.  However, review of the 
profit margins need to be considered.  Pharmaceutical companies have been criticized for their 
practices used to set sale prices by educated health-care professionals with regard to certain types 
of innovative drugs. (Bach, Saltz, & Wittes, 2012; Experts in Chronic Myeloid Leukemia, 2013)  




CHAPTER 17.  LONG-TERM THREAT OF COUNTERFEIT DRUGS TO PUBLIC 
HEALTH 
Counterfeit drugs pose a serious long-term threat to public health.  The theft of this 
pharmaceutical IP is reducing the financial incentive to drug companies to invest in innovative 
research.  If investors in these private firms can’t rely upon the legal and justice systems to 
enforce their IP rights, it is likely they will no longer invest in this expensive and risky business.  
The United States government has historically shown that it does not have the capability to bring 
a new and innovative pharmaceutical product to the market without support from private 
industry.  In addition, government funding of research in the basic sciences will likely not be as 
strong as it has been in the past.  This will require additional funding from private investments in 
an environment that is much less likely to rally investors. 
There is no question that pharmaceutical innovation is a valued and necessary component 
of developed society.  Patenting and protection of patent rights has provided incentive to 
investors.  Patenting is an integral part of the drug-development process in the United States.  
The patent system is fully integrated with federal regulations throughout the process, and laws 
are in place that balance the patent owner’s rights with the value of their innovations to society.  
Further, government funding supports basic research and transfers to patent inventors the rights 
of the work product of these funds. 
Laws are also in place to allow for enforcement of IP rights in the United States.  These 
laws, coupled with extensive FDA regulation designed to provide a safe and effective drug 
supply chain, have made the short-term issues of counterfeit drugs in the United States less 
problematic than in other regions of the world.  In these other regions, trade agreements or other 
methods to establish patent protection must be enforced so that the financial incentive to private 
investors is maintained. 
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The United States has taken a leadership role in the development of pharmaceutical 
innovations that have benefitted the rest of the world.  While it has had success in the United 
States with protection of these rights, infringement throughout much of the world is rampant.  
This infringement cuts into profits of pharmaceutical innovators, and minimized the rewards to 
investors.  Without private investment, the United States will likely move away from the 
leadership role it has taken.  This will seriously threaten the future of pharmaceutical innovation.  
There is currently no reasonable replacement to serve in the role the United States takes as 
pharmaceutical innovators.  In an environment where infringement of IP rights related to these 
innovations throughout the world is accepted, the system upon which pharmaceutical innovation 
is built will not sustain itself.  The burden of payment for pharmaceutical innovation will need to 
be shared more evenly with societies in other regions of the world. 
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CHAPTER 18.  THE VALUE AND CONTRIBUTION OF THIS RESEARCH TO 
FORENSIC SCIENCE AND CRIMINAL JUSTICE 
Counterfeit drugs are a problem for criminal justice.  Theft of intellectual property in the 
pharmaceutical industry has caused sickness and death (Newton, et al., 2006; World Health 
Organziation, 2008; Wondemagegnehu, 1999).  It is necessary that the perpetrators of these 
crimes are brought to justice.  In some cases, threats to health and safety are short term; in others 
they are long term.  This research describes these threats in detail. 
The problem is complex, and there are many important factors that need to be considered 
to successfully address the problem.  Public-health challenges, drug-development challenges, 
legal challenges, and financial considerations are all important aspects of the problem that need 
to be understood.  The counterfeit-drug problem integrates forensic science, patent law, 
enforcement of patent rights, pharmaceutical innovation, and public-health issues.  This research 
is valuable to criminal justice because it details these aspects so that appropriate solutions to the 
problem can be proposed. 
This research defines the problem counterfeit drugs present and why they are a problem 
for the criminal justice system.  It also describes the complexity the problem.  The critical 
aspects of each of these topics related to the counterfeit-drug problem are presented.  
Understanding these topics is needed by the criminal justice system to understand the 
complicated nature of the counterfeiting problem, and why IP rights in the pharmaceutical 
industry are so vitally important and need to be enforced.  This research summarizes in a 
systematic way, all of these integral aspects of the counterfeit-drug trade providing the 
background necessary to understand and address this problem. 
This project is also important to forensic science.  Forensic science is the application of 
the natural sciences to matters of the law.  The laws in effect at any given time are usually 
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influenced by or derived from those of previous periods. (De Forest, Gaensslen, & Lee, 1983)  
Laws in the United States related to drug development and pharmaceutical innovation have 
changed dramatically since 1980.  These changes, coupled with the advent of the internet and 
other globalization that has taken place over this same time period, have forged a new discipline 
within the field of forensic science.  Societal and public-health needs require that forensic 
scientists and other practitioners of justice provide the tools to successfully investigate, identify, 
and adjudicate criminal violators of IP rights, especially with regard to pharmaceuticals.  It 
defines the challenges faced by the field of forensic science and proposes methods that may be 
used to address these challenges.  This will enable forensic scientists to provide support to law 
enforcement and other members of the legal system to successfully investigate and adjudicate 
these crimes. 
Forensic scientists are tasked with providing investigative leads to identify counterfeiters, 
as well as with providing scientific assessments of evidence that can be used during adjudication 
of these crimes.  This research explored the use of field-portable instruments based upon 
technologies with high discrimination potentials to help forensic scientists meet these goals.  
Detection in the field is an important capability because when decisions about a product’s 
authenticity can be quickly made at a port of entry, that article can be confiscated before it enters 
the legitimate supply chain.  The ability to stop the entry minimizes risk to the consumer. 
This research also proposed a method to help scientists share data collected in the field, 
helping to define the role forensic scientists play in the solution to this problem.  One of the 
major challenges to forensic scientists when establishing provenance of counterfeit drugs is the 
limited sample set available for analysis.  The method proposed as a result of this research would 
allow users across the globe to share useful scientific data from samples tested.  Forensic 
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scientists would then have access to large numbers of samples from distant regions of the world.  
These shared data could be used for comparisons, to evaluate trends, and perform other types of 
data review useful in establishing provenance. 
  
173 
CHAPTER 19.  REFERENCES 
 
Acampora, A., Ferranti, P., Malorni, A., & Milone, A. (1991). Mass spectrometry in forensic 
chemistry: 1. Pigment identification by direct mixture analysis in a case of bank note 
falsification. Journal of Forensic Sciences, 36(2), 579-586. 
Adams, C., & Brantner, V. (2006, March). MarketWatch: Estimating the cost of new drug 
development: Is it really $802 million? Health Affairs, 420-428. 
doi:10.1377/hlthaff.25.2.420 
Adar, F., Delhaye, M., & DaSilvia, E. (2003, March). Evolution of instrumentation for detection 
of the Raman effect as driven by available technologies and by developing applications. 
Waters Symposium, Pittcon. Orlando, FL. 
Alabdalla, M. A. (2005). Chemical characterization of counterfeit Captagon tablets seized in 
Jordan. Forensic Science International, 185-188. doi:10.1016/j.forsciint.2004.08.004 
Almog, J. (2006). Forensic science does not start in the lab: The concept of diagnostic field tests. 
Journal of Forensic Sciences, 51(6), 1228-1234. doi:10.1111/j.1556-4029.2006.00256.x 
Anzanello, M. J., Ortiz, R. S., Limberger, R., & Mariotti, K. (2014). A framework for selecting 
analytical techniques in profiling authentic and counterfeit Viagra and Cialis. Foresic 
Science International, 235, 1-7. doi:org/10.1016/j.forsciint.2013.12.005 
Arnó, J., Frunzi, M., Kittredge, M., & Sparano, B. (2014). Advancements in the safe 
identification of explosives uisng a Raman handheld instrument (ACE-ID). SPIE. 
Baltimore: SPIE. 
Arnó, J., McNeish, A., Munro, W., Frunzi, M., Weber, C., & Levy, D. (2013, June 4). Advances 
in handheld FTIR chemical identification for counter terrorism and defence. Stockholm: 




AWARxE Consumer Protection Program. (2014, April 17). Online pharmacies: How to protect 
yourself from illicit online pharmacies. Retrieved from AWARxE Consumer Protection 
Program Web site: http://www.awarerx.org/get-informed/safe-acquisition/online-
pharmacies 
Bach, P. B., Saltz, L. B., & Wittes, R. E. (2012, October 14). In cancer care, cost matters. The 
New York Times, pp. Op-Ed. Retrieved from 
http://www.nytimes.com/2012/10/15/opinion/a-hospital-says-no-to-an-11000-a-month-
cancer-drug.html 
Baechler, S., Terrasse, V., Pujol, J. P., Fritz, T., Ribaux, O., & Margot, P. (2013). The systematic 
profiling of false identity documents: Method validation and performance evalaution 
using seizures known to originate from common and different sources. Forensic Science 
International, 232, 180-190. doi:10.1016/j.forsciint.2013.07.022 
Baer, I., Gurny, R., & Margot, P. (2007). NIR analysis of cellulose and lactose - Application to 
ecstasy tablet analysis. Forensic Science International, 234-241. 
doi:10.1016/j.forsciint.2006.06.056 
Baldry, I. K., Bland-Hawthorn, J., & Robertson, J. G. (2004, February 16). Volume phase 
holographic gratings: Polarization properties and diffraction efficiency. Publications of 
the Astronomical Society of the Pacific, 1-8. 
Barden, S. (1998, June). Volume phase holographic gratings. NOAO Newsletter(54). Retrieved 
from National : http://www.noao.edu/noao/noaonews/jun98/node4.html 
Bartle, E. K., & Watling, R. J. (2007). Provenance determination of Oriental porcelain using 
laser ablation-inductively coupled plasma-mass spectrometry. Journal of Forensic 
Sciences, 341-348. doi:10.1111/j.1556-4029.2006.00364.x 
175 
Bayhing for blood or Doling out cash? Intellectual property. (2005, December 24). The 
Economist, 377(8458), p. 109. Retrieved from 
http://go.galegroup.com/ps/i.do?id=GALE%7CA139962124&v=2.1&u=cuny_johnjay&it
=r&p=AONE&sw=w&asid=b89beebe0deffa712e21f86baf3213d1 
Been, F., Roggo, Y., Degardin, K., Esseiva, P., & Margot, P. (2011). Profiling of counterfeit 
medicines by vibrational spectroscopy. Forensic Science International, 211, 83-100. 
doi:org/10.1016/j.forsciint.2011.04.023 
Bird, R. C. (2006). Defending intellectual property rights in the BRIC economies. American 
Business Law Journal, 43(2), 317-363. 
Blossom, D. B., Kallen, A. J., Patel, P. R., Elward, A., Robinson, L., Gao, G., . . . Sasisekharan, 
R. (2008). Outbreak of adverse reactions associated with contaminated heparin. The New 
England Journal of Medicine, 2674-2684. 
Bogdanich, W., & Hooker, J. (2007, May 6). From China to Panama, a trail of poisoned 
medicine. New York Times, p. 1. Retrieved from 
http://www.nytimes.com/2007/05/06/world/americas/06poison.html?pagewanted=all&_r
=0 
Božičević, M. S., Gajović, A., & Zjakić, I. (2012). Identifying a common origin of toner printed 
counterfeit banknotes by micro-Raman spectroscopy. Forensic Science International, 
223, 314-320. doi:10.1016/j.forsciint.2012.10.007 
Brzezinski, J. L., & Craft, D. L. (2012). Characterization of microorganisms isolated from 
counterfeit toothpaste. Journal of Forensic Sciences, 55(3), 738-741. 
Cao, Y., Gao, T., Fan, L., & Yang, Q. (2012). A robust detection algorithm for copy-move 
forgery in digital images. Forensic Science International, 214, 33-43. 
doi:org/10.1016/j.forsciint.2011.07.015 
176 
Carrabba, M. M., Spencer, K. M., Rich, C., & Rauh, D. (1990). The utilization of a holographic 
Bragg diffraction filter for Rayleigh line rejection in Raman spectroscopy. Applied 
Spectroscopy, 44(9), 1558-1561. 
Carruthers, B. G., & Ariovich, L. (2004). The sociology of property rights. Annual Review of 
Sociology, 23-46. doi:10.1146/annurev.soc.30.012703.110538 
Cockburn, I., & Henderson, R. (2001). Publicly funded science and the productivity of the 
pharmaceutical industry. In A. B. Jaffe, J. Lerner, & S. Stern, Innovation and Policy and 
the Economy, Volume 1 (pp. 1--34). MIT Press. Retrieved from URL: 
http://www.nber.org/books/jaff01-1 
Cockburn, R., Newton, P. N., Agyarko, E. K., Akunyili, D., & White, N. J. (2005, April). The 
global threat of counterfeit drugs: Why industry and governments must communicate the 
dangers. PLOS Medicine, 2(4), 302-308. doi:10.1371/journal.pmed.0020100 
Congressional Budget Office. (2006). Research and Development in the Pharmaceutical 
Industry. Congress of the United States. 
de Cássia Mariotti, K., Ortiz, R. S., Sousa, D. Z., Fröehlich, P. E., & Limberger, R. P. (2013). 
Trends in counterfeits amphetamine-type stimulants after its prohibition in Brazil. 
Forensic Science International, 229, 23-26. doi:10.1016/j.forsciint.2013.03.026 
De Forest, P. R., Gaensslen, R., & Lee, H. C. (1983). Forensic Science: An Introduction to 
Criminalistics. New York: McGraw-Hill, Inc. 
Dean, O. (2013, April 25). Determining jurisdiction in cross-border cases. Istanbul: Conference 
Presentation - Seventh Global Congress on Combatting Counterfeiting and Piracy. 
DiMasi, J. A., Hansen, R. W., & Grabowski, H. G. (2003). The price of innovation: New 
estimates of drug development costs. Journal of Health Economics, 22, 151-185. 
doi:10.1016/S0167-6296(02)00126-1 
177 
Dorsey, E. R., de Roulet, J., Thompson, J. P., Reminick, J. I., Thai, A., White-Stellato, Z., . . . 
Moses III, H. (2010). Funding of US biomedical research. Journal of the American 
Medical Association, 303(2), 137-143. 
Effron, B., & Tibshirani, R. J. (1993). An Introduction to the Boot Strap. New York: Chapman & 
Hall, Inc. 
Eli Lilly and Company, Petitioner v. Medtronic, Inc., 496 U.S. 661 (Supreme Court of the United 
States June 18, 1990). 




Eurek, S. E. (2003, August 19). Hatch-Waxman report and accelerated market entry of generic 
drugs: Is faster necessarily better? Duke University School of Law (Student). Retrieved 
from http://scholarship.law.duke.edu/cgi/viewcontent.cgi?article=1087&context=dltr 
Experts in Chronic Myeloid Leukemia. (2013, May 30). 121(22), 4439-4442. doi:10.1182/blood-
2013-03-490003 
Faucon, B., & Whalen, J. (2012, April 5). Fake Avastin took murkey path to US. Wall Street 
Journal Online. Retrieved from 
http://online.wsj.com/news/articles/SB10001424052702303302504577323500453577094 
Fedchak, S. (2014). Presumptive Field Testing Using Portable Raman Spectroscopy: Research 
and Development on Instrumental Analysis for Forensic Science. Las Vegas Metropolitan 
Police Department. National Institute of Justice. 
Federal Food, Drug, and Cosmetic Act. (1938, June 25). 
178 
Federal Trade Commission. (2002). Generic drug entry prior to patent expiration: An FTC 
study. Federal Trade Commission. Retrieved from 
http://www.law.fsu.edu/gpc2007/FTCGenericDrugStudy.pdf 
Fernández, F. M., Cody, R. B., Green, M. D., Hampton, C. Y., McGready, R. M., 
Sengaloundeth, S., . . . Newton, P. N. (2006). Characterization of solid counterfeit drug 
samples by desorption electrospray ionization and direct-analysis-in-real-time coupled to 
time-of-flight mass spectrometry. ChemMedChem, 702-706. 
doi:10.1002/cmdc.200600041 
Fiore. (2012, August 30). Viagra from online sources mostly fake. MedPage Today. Retrieved 
from http://www.medpagetoday.com/meetingcoverage/smsna/34493 
Food and Drug Administration. (2010). FDA update regarding generic drug user fees. Food and 
Drug Administration. Retrieved from 
http://www.fda.gov/downloads/drugs/newsevents/ucm237641.pdf 
Food and Drug Administration. (2014, April 14). FDA's drug review process: Continued. 
Retrieved from Food and Drug Administration Web site: 
http://www.fda.gov/Drugs/ResourcesForYou/Consumers/ucm289601.htm 
Food and Drug Administration. (2014, April 16). Generic drugs: Same medicine, lower costs. 
Retrieved from Food and Drug Administration Web site: 
http://www.fda.gov/ForConsumers/ConsumerUpdates/ucm340343.htm 
Food and Drug Administration. (2014, April 17). How drugs are developed and approved. 
Retrieved from Food and Drug Administration Web site: 
http://www.fda.gov/Drugs/DevelopmentApprovalProcess/HowDrugsareDevelopedandAp
proved/default.htm 
Food and Drug Administration. (2014, April 14). The FDA's drug review process: Ensuring 
drugs are safe and effective. Retrieved from Food and Drug Adminstration Web site: 
http://www.fda.gov/drugs/resourcesforyou/consumers/ucm143534.htm 
179 
Frunzi, M. (2014, April 8). Personal communication. Danbury, CT. 
Gerth, J., & Stolberg, S. G. (2000, April 23). Medicine merchants: Birth of a blockbuster; drug 
makers reap profits on tax-backed research. The New York Times, p. 1. 
Gewertz, N., & Amado, R. (2004). Intellectual property and the pharmceutical industry: A moral 
crossroads between health and property. Journal of Business Ethics, 55(3), 295-308. 
Retrieved from http://www.jstor.org/stable/25123392 
Halbert, D. (1997). Intellecual property piracy: The narrative construction of deviance. 
International Journal for the Semiotics of Law, X(28), 55-78. 
Hancock, B. C., & Zografi, G. (1997). Characteristics and significance of the amorphous state in 
pharmaceutical systems. Journal of Pharmaceutical Sciences, 86(1), 1-12. 
Harris, G. (2014, February 15). Medicines made in India set of safety worries. The New York 
Times, p. A1. Retrieved from http://www.nytimes.com/2014/02/15/world/asia/medicines-
made-in-india-set-off-safety-worries.html 
Hensley, S. (2013, May 6). Pfizer goes direct with online Viagra sales to men. Retrieved from 
http://www.npr.org/blogs/health/2013/05/06/181577694/pfizer-goes-direct-with-viagra-
sales-to-men 
Hida, M., & Mitsui, T. (2001). Classification of prepaid cards based on multivariate treatment of 
data obtained by x-ray fluorescence analysis. Forensic Science International, 119, 305-
309. 
Hida, M., Mitsui, T., & Minami. (1997). Forensic investigation of counterfeit coins. Forensic 
Science International, 89, 21-26. 
180 
Hida, M., Sato, H., Sugawara, H., & Mitsui, T. (2001). Classification of counterfeit coins using 
multivariate analysis with x-ray diffraction and x-ray fluorescence methods. Forensic 
Science International, 129-134. 
Innovation's golden goose. (2002, December 14). The Economist, 365(8303). Retrieved from 
http://go.galegroup.com/ps/i.do?id=GALE%7CA98852279&v=2.1&u=cuny_johnjay&it
=r&p=AONE&sw=w&asid=8fb7c75a50db6b281cad6c7cf0b21991 
International Task Force for Disease Eradication. (1993). Morbidity and Mortality Weekly 
Report. International Task Force for Disease Eradication. Retrieved from 
http://www.cartercenter.org/resources/pdfs/news/health_publications/itfde/updated_disea
se_candidate_table.pdf 
Jung, C. R., Ortiz, R. S., Limberger, R., & Mayorga, P. (2012). A new methodology for detection 
of counterfeit Viagra and Cialis tablets by image prcessing and statistical analysis. 
Forensic Science International, 216, 92-96. doi:org/10.1016/j.forsciint.2011.09.002 
Kaiser Optical Systems, Inc. (2014, April 16). Introduction to Volume Phase Holographic (VPH) 
Transmission Gratings and Applications. Retrieved from Kaiser Optical Systems, Inc. 
Web site: http://www.kosi.com/Holographic_Gratings/vph_ht_overview.php 
Kauppila, T. J., Flink, A., Haapala, M., Laakkonen, U.-M., Aalberg, L., Ketola, R. A., & 
Kostiainen. (2011). Desorption atmospheric pressure photoionization-mass spectrometry 
in routine analysis of confiscated drugs. Forensic Science International, 210, 206-212. 
doi:org/10.1016/j.forsciint.2011.03.018 
Keire, D. A., Ye, H., Trehy, M. L., Ye, W., Kolinksi, R. E., Westenberger, B. J., . . . Al-Hakim, 
A. (2011). Characterization of currently marketed heparin products: Key tests for quality 
assurance. Analytical and Bioanalytical Chemistry, 399, 581-599. doi:10.1007/s00216-
010-4023-y 
Kelland, K. (2014, March 6). Climate change could mean more malaria in Africa, South America 
. Thompson Reuters. Retrieved from http://in.reuters.com/article/2014/03/06/health-
malaria-climate-idINL6N0M34FZ20140306 
181 
Kumho Tire Company, Ltd., et al., Petitioners v. Patrick Carmichael, etc., et al., 97–1709 
(Supreme Court of the United States March 23, 1999). 
Labadie, J. (2012). Forensic pharmacovigilence and substandard or counterfeit drugs. 
International Journal of Risk & Safety in Medicine, 24, 37-39. doi:10.3233/JRS-2012-
0551 
Lammert, S. A., Plass, W. R., Thompson, C. V., & Wise, M. B. (2001). Design, optimization and 
initial performance of a toroidal rf ion trap mass spectrometer. International Journal of 
Mass Spectrometry, 212, 25-40. 
Lammert, S. A., Rockwood, A. A., Wang, M., & Lee, M. L. (2006). Miniature toroidal radio 
frequency ion trap mass analyzer. Journal of the American Society for Mass 
Spectrometry, 17(7), 916-922. doi:10.1016/j.jasms.2006.02.009 
LaPorte, G. M., Stephens, J. C., & Beuchel, A. K. (2010). The examination of commercial 
printing defects to access common origin, batch variation, and error rate. Journal of 
Forensic Sciences, 55(1), 136-140. doi:10.1111/j.1556-4029.2009.01211.x 
Light, D. W., & Warburton, R. (2011). Demythologizing the high costs of pharmceutical 
research. BioSocieties , 6, 34-50. doi:10.1057/biosoc.2010.40 
Light, D. W., & Warburton, R. N. (2005). Extraordinary claims require extraordinary evidence. 
Journal of Health Economics, 1030-1033. doi:10.1016/j.jhealeco.2005.07.001 
Light, D. W., & Warburton, R. N. (2005). Setting the record straight in the reply by DiMasi, 
Hansen and Grabowski. Journal of Health Economics, 24, 1045-1048. 
doi:10.1016/j.jhealeco.2005.07.003 
Loewy, M. (2007). Deadly imitations. Perspectives in Health, 11(1), 16-21. 
182 
Logan, B. K., Reinhold, L., Xu, A., & Diamond, F. X. (2012). Identification of synthentic 
cannabinoids in herbal incense blends in the United States. Journal of Forensic Sciences, 
57(5), 1168-1180. doi:10.1111/j.1556-4029.2012.02207.x 
Lopatka, M., & Vallat, M. (2011). Surface granularity as a discriminating feature of illicit 
tablets. Forensic Science International, 210, 188-194. 
doi:org/10.1016/j.forsciint.2011.03.008 
Médecins Sans Frontières Australia. (2014, April 16). Médecins Sans Frontières Australia. 
Retrieved from Médecins Sans Frontières Australia Web site: 
http://www.msf.org.au/from-the-field/field-news/field-news/article/haiti-medical-
supplies-running-out-as-delivery-planes-are-diverted.html 
Medicare Prescription Drug, Improvement, and Modernization Act. (2003). 
Melethil, S. (2005). Patent issues in drug development: Perspectives of a pharmaceutical 
scientist-attorney. The AAPS Journal, 7(3), E723-E727. doi:10.1208/aapsj070372 
Merger, R. P. (1997). Patent Law and Policy (Second ed.). Charlottesville, VA: Michie Law 
Publishers. 
Moses III, H., & Dorsey, E. R. (2012). Biomedical research in an age of austerity. Journal of the 
American Medical Association, 308(22), 2341-2342. 
Nam, Y. S., Keun, K. I., Lee, Y., & Lee, K.-B. (2012). Quantitative monitoring of corticosteroids 
in cosmetic products manufactured in Korea using LC-MS/MS. Forensic Science 
International, 220, e23-e28. doi:org/10.1016/j.forsciint.2011.12.011 
Neuhauser, A. (2014, March 7). Study: Global warming could spark malaria outbreaks. US News 




Newton, P. N., Green, M. D., Fernández, F. M., Day, N. P., & White, N. J. (2006). Counterfeit 
anti-infective drugs. The Lancet Infectious Diseases, 6, 602-613. 
Newton, P., McGready, R., Fernandez, F., Green, M., Sunjio, M., Bruneton, C., . . . White, N. 
(2006). Manslaughter by fake artesunate in Asia -Will Africa be next? PLoS Medicine, 
3(6), 752-755. 
Ortiz, R. S., de Cássia Mariotti, K., Fank, B., Limberger, R. P., Anzanello, M. J., & Mayorga, P. 
(2013). Counterfeit Cialis and Viagra fingerprinting by ATR-FTIR spectroscopy with 
chemometry: Can the same pharmaceutical powder mixture be used to falsify two 
medicines? Forensic Science International, 282-289. doi:10.1016/j.forsciint.2013.01.043 
Ortiz, R. S., de Cássia Mariotti, K., Holzschuh, M. H., Romão, W., Limberger, R. P., & 
Mayorga, P. (2013). Profiling counterfeit Cialis, Viagra and analogs by UPLC-MS. 
Forensic Science International, 229, 13-20. doi:10.1016/j.forsciint.2013.03.024 
Otieno-Alego, V., & Speers, N. (2011). Counter Terrorism and Homeland Security. In J. M. 
Chalmers, H. G. Edwards, & M. D. Hargreaves (Eds.), Infrared and Raman Spectroscopy 
in Forensic Science (p. 208). Hoboken, NJ: Wiley. 
Overton, G. (2010, August 23). Photonic applied: Handheld Spectrometers: Spectrometer 
miniaturization redefines real-time sensing. LaserFocusWorld. Retrieved from 
http://www.laserfocusworld.com/articles/2010/08/photonics-applied-handheld-
spectrometers-spectrometer-miniaturization-redefines-real-time-sensing.html 
Park, M., & Ahn, S. (2012). Quantitative analysis of sildenafil and tadalafil in various fake drugs 
recently distrubuted in Korea. Journal of Forensic Sciences, 1-4. doi:10.1111/j.1556-
4029.2012.02164.x 
Patterson, R., Mabe, P., Mitchell, E. N., & Cory, W. (2012). Lifestyle illicit drug seizures: A 
routine ESI-LC-MS method for the identification of sildenafil and vardenafil. Forensic 
Science International, 222, 83-88. doi:org/10.1016/j.forsciint.2012.05.003 
184 
Pensabene, L. B., & Gregory, D. (2013). Hatch-Waxman Act: Overview. Practical Law 
Company. 
Pérez-Bernal, J. L., Amigo, J. M., Fernández-Torres, R., Bello, M. A., & Callejón-Mochón, M. 
(2011). Trace-metal distribution of cigarette ashes as marker of tobacco brands. Forensic 
Science International, 204, 119-125. doi:doi:10.1016/j.forsciint.2010.05.014 
Petraco, N. D. (2014, April 7). Personal communication. New York, NY. 
Pfizer. (2014, April 26). Pfizer Investor Information. Retrieved from Pfizer: 
http://www.pfizer.com/investors 
Pfizer Inc. and Subsidiary Companies. (2013). Appendix A: 2013 Finanical Report. Pfizer Inc. 
and Subsidiary Companies. Retrieved from 
http://www.pfizer.com/files/investors/presentations/FinancialReport2013.pdf 
Phelps, K. V. (2012, August 9). Taking the 505(b)(2) Route. Drug Discovery & Development. 
Retrieved from http://www.dddmag.com/articles/2012/08/taking-505b2-route 
Pills for birth control seized as counterfeit. (1984, November 16). p. B6. Retrieved from 
http://ez.lib.jjay.cuny.edu/docview/122428823?accountid=11724 
Pollack, A. (2013, April 25). Doctors denounce cancer drug prices of $100,000 a year. The New 
York Times. Retrieved from http://www.nytimes.com/2013/04/26/business/cancer-
physicians-attack-high-drug-costs.html?pagewanted=all&_r=0 
Pomfret. (2006, July 15). Bribery at border worries officials: Mexican smugglers intensify efforts 




Reffner, J. A., & Martoglio, P. A. (1995). Uniting Microscopy and Spectroscopy. In H. J. 
Humecki, Practical Guide to Infrared Microspectroscopy (pp. 41-84). New York: Marcel 
Dekker, Inc. 
Roche Products, Inc. Appellant, v. Bolar Pharmaceutical Co., Inc., Appellee, 733 F. 2d 858 
(United States Court of Appeals for the Federal Circuit April 23, 1984). 
Romão, W., Vaz, B. G., Lalli, P. M., Izabel, M., S, B. M., Correa, D. N., . . . Eberlin, M. (2012). 
Analyzing Brazlian vehicle documents for authenticity by easy ambient sonic-spray 
ionization mass spectrometry. Journal of Forensic Sciences, 57(2), 539-543. 
doi:10.1111/j.1556-4029.2011.02005.x 
Rudolf, P. M., & Bernstein, B. G. (2004). Counterfeit drugs. New England Journal of Medicine, 
350(14), 1384-1386. 
Rumore, M. M. (2009, August 15). The Hatch-Waxman Act--25 years later: Keeping the 
pharmaceutical scales balanced. Pharmacy Times Supplement. Retrieved from 
http://www.pharmacytimes.com/publications/supplement/2009/GenericSupplement0809/
Generic-HatchWaxman-0809 
Sacchetti, M. (2013). Thermodynamics of water-solid interactions in crystalline and amorphous 
pharmaceutical materials. Journal of Pharmaceutical Sciences, 1-12. 
doi:10.1002/jps.23806 
Saha, A., Grabowski, H., Birnbaum, H., Greenberg, P., & Bizan, O. (2006). Generic competition 
in the US pharmaceutical industry. International Journal of the Economics of Business, 
13(1), 15-38. doi:10.1080/13571510500519905 
Samms, W. C., Jiang, Y. J., Dixon, M. D., Houck, S. S., & Mozayani, A. (2011). Analysis of 
alprazolam by DART-TOF mass spectrometry in counterfeit and routine drug 
identfication cases. Journal of Foensic Sciences, 56(4), 993-998. doi:10.1111/j.1556-
4029.2011.01767.x 
186 
Sanofi-Synthelabo, Inc.; and Bristol-Myers Squibb Sanofi Pharmaceuticals Holding Partnership, 
Plaintiffs, -against- Apotex Inc.; and Apotex Corp., Defendants, 488 F. Supp. 2d 317 
(United States District Court for the Southerin District of New York August 31, 2006). 
Schulz, C., & Wu, M. (2004). The TRIPS agreement and intellectual property protection in 
Brazil. Proceedings of the Annual Meeting (American Soceity of International Law). 98, 
pp. 100-106. American Society of International Law. Retrieved from 
http://www.jstor.org/stable/25659903 . 
Sen, A. (2012, June 25). India, Brazil & China Defend Generic Drugs. Economic Times (E-
Paper Edition). Retrieved from http://articles.economictimes.indiatimes.com/2012-06-
25/news/32409062_1_counterfeit-medicines-fake-drugs-generic-drugs 
Senior, K. (2008). Global health-care implications of substandard medicines. The Lancet 
Infectious Diseases, 8(11), 666. 
Shakoor, O., Raylor, R. B., & Behrens, R. H. (1997). Assessmet of the incidence of substandard 
drugs in developing countries. Tropical Medicine & International Health, 2(9), 839-845. 
doi: 10.1046/j.1365-3156.1997.d01-403.x 
Shwe, T. N., Nyein, M. M., & Yi, W. M. (2002). Blood culture isolates from children admitted 
to medical unit III Yangdon's Children's Hospital, 1998. Southeast Asian Journal of 
Tropical Medicine & Public Health, 33(4), 764-771. 
Siddiqui, Z., & Chatterjee, S. (2014, March 13). FDA bans imports from Sun Pharma plan in 
India crackdown. Thomson Reuters. Retrieved from 
http://www.reuters.com/article/2014/03/13/us-sun-pharma-india-fda-
idUSBREA2C09S20140313 
Silver, R. (2007). A wall street perspective on generics. European Generic Medicines 
Association. 13th EGA Annual Conference. Retrieved from 
http://www.ieis.org.tr/ieis/assets/media/images/toplanti/13yil/sunumlar/R_SilverS.pdf 
187 
Siraj, A. S., Santos-Vega, M., Bouma, M. J., Yadeta, D., Ruiz Carrascal, D., & Pascual, M. 
(2014, March 7). Altitudinal changes in malaria incident in highlands of Ethiopia and 
Columbia. Science, 343, pp. 1154-1158. doi:10.1126/science.1244325 
Smiths Detection. (2014, April 14). Retrieved from Smiths Detection Web site: 
http://www.smithsdetection.com/index.php/technologies/gas-chromatography-mass-
spectrometry.html 
Smiths Detection. (2014, April 14). Smiths Detection GC-MS Product Solutions. Retrieved from 
Smiths Detection Web site: http://www.smithsdetection.com/index.php/products-
solutions/chemical-identification/57-chemical-identification/hazmatid-elite.html#.U0x-
UkHD-P8 
Soltaninejad, K., Faryadi, M., Akhgari, M., & Bahmanabadi, L. (2007). Chemical profie of 
counterfeited buprenorphine vials seized in Tehrran, Iran. Forensic Science International, 
172, e4-e5. 
State of Arizona, Appellee, v. Ronald Michael Lucero, Appellant, 207 Ariz. 301; 85 P.3d 1059; 
2004 Ariz. App. LEXIS 35; 422 Ariz. Adv. Rep.11 (Court of Appeals of Arizona, 
Division One, Department B March 23, 2004). 
Staton, T. (2012, May 21). FDA in line for new foreign-inspecrion powers. FiercePharma. 
Retrieved from http://www.fiercepharma.com/story/fda-line-new-foreign-inspection-
powers/2012-05-21 
Stevens, A. J. (2004). The enactment of Bayh-Dole. Journal of Technology Transfer, 29, 93-99. 
Stoll, R. L. (2009, December 9). Protecting intellectual propety rights in a global economy: 
Current trends and future challenges. Statement of Robert L. Stoll, Commissioner for 
Patents, Commissioner for Patents, before the Subcommittee on Government 
Management, Organization and Procurement Committee on Oversight and Government 
Reform. Washington, D.C. 
188 
Subramanian, A. (1991). The international economics of intellectual property right protection: A 
welfare-theoretic trade policy analysis . World Development, 945-956. 
Sugawara, S. (2007). Passport examination by polarized infrared spectra. Journal of Forensic 
Sciences, 52(4), 974-977. doi:10.1111/j.1556-4029.2007.00487.x 
Sugawara, S. (2008). Passport examination by a confocal-type laser profile microscope. Forensic 
Science International, 178, 40-45. doi:org/10.1016/j.forsciint.2008.02.004 
Suzuki, M. (2008). Determination of a simple and non-destructive examination of counterfeit 
coins using acoustic characteristics. Forensic Science International, e5-e8. 
doi:org/10.1016/j.forsciint.2007.10.004 
Thakur, V. P., & Ramacha, S. (2012, September). Pharmaceutical business strategy: A generics 
perspective. Journal of Intellectual Property Rights, 484-496. Retrieved from 
http://nopr.niscair.res.in/bitstream/123456789/14773/1/JIPR%2017(5)%20484-496.pdf 
The People of the State of New York, Plaintiff, v. Donald Roraback, Also Known as Donald 
Reed, Also Known as Tom Reed, Defendant, 174 Misc.2d 641; 666 NYS 2d 397; 1997 
NY Misc.Lexis 528 (Supreme Court of New York, Sullivan County November 18, 1997). 
The United States Patent and Trademark Office. (2014, April 17). The United States Patent and 
Trademark Office. Retrieved from The United States Patent and Trademark Office Web 
site: http://www.uspto.gov/patents/ 
Thomas, P. (2011, December 14). PharmaView: Fake drugs: Why business is booming. 
PharmaManufacturing. Retrieved from 
http://www.pharmamanufacturing.com/articles/2011/161/ 
Thursby, J. G., & Thursby, M. C. (2003, August 22). University licensing and the Bayh-Dole 
Act. Science, 301, p. 1052. 
189 
Trouiller, P., Torreele, E., Olliaro, P., White, N., Foster, S., Wirth, D., & Pécoul, B. (2001). 
Drugs for neglected diseases: A failure of the market and a public health failure? Tropical 
Medicine & International Health, 6(11), 945-951. doi:10.1046/j.1365-3156.2001.00803.x 
United Nations Office on Drugs and Crime. (2014, April 14). United Nations Office on Drugs 




USP Council of the Convention Section on Global Public Health, USP Council of Experts 
International Health Expert Committee, USP Regionalization Team, Heyman, M. L., & 
Williams, R. L. (2011). Ensuring global access to quality medicies: Role of the US 
Pharmacopeia. Journal of Pharmaceutical Sciences, 100(4), 1280-1287. 
doi:10.1002/jps.22391 
Varmuza, K., & Filmozer, P. (2009). Introduction to Multivariate Statistical Analysis in 
Chemometrics. Boca Raton, FL: Taylor & Francis Group, LLC. 
Velásquez, G., & Boulet, P. (1999). Globalization and access to drugs: Implications of the 
WTO/TRIPS agreement. World Health Organization. 
Venhuis, B. J., Blok-Tip, L., & de Kaste, D. (2008). Designer drugs in herbal aphrodisiacs. 
Forensic Science International, 177, e25-e27. doi:org/10.1016/j.forsciint.2007.11.007 
Warner Chilcott Laboratories Ireland Limited, et al., Plaintiffs, v. Impax Laboratories, Inc., et al., 
Defendants. Warner Chilcott Laboratories Irealnd Limited, et al., Plaintiffs, v. Mylan 
Pharmaceuticals Inc., et al., Defendants. , Civ. No. 2:08-cv-06304 (WJM), Civ. No 2:09-
cv-02073 (WJM), Civ. No. 2:09-cv-01233 (WJM) (United States District Court for the 
District of New Jersey April 30, 2012). 
Wasatch Photonics. (2014, April 14). Wasatch Photonics Raman Product Solutions. Retrieved 
from Wasatch Photonics Web site: http://wasatchphotonics.com/systems/vph-
spectrometers/raman-flourescence/stroker-785l/ 
190 
Wax, P. M. (1995). Elixirs, diluents, and the passage of the 1938 Federal Food, Drug and 
Cosmetic Act. Annals of Internal Medicine(122), 456-461. 
Willard, H. H., Merritt Jr., L. L., Dean, J. A., & Settle Jr., F. A. (1988). Instrumental Methods of 
Analysis (Seventh ed.). Belmont, CA: Wadsworth, Inc. 
Wondemagegnehu, E. (1999). Counterfeit and substandard drugs in Myanmar and Viet Nam - 
Report of a study carried out in cooperation with the governments of Myanmar and Viet 
Nam. Geneva: World Health Organzation. Retrieved from 
http://apps.who.int/medicinedocs/pdf/s2276e/s2276e.pdf 
World Health Organization. (2014, April 26). The Doha Declaration on the TRIPS Agreement 
and Public Health. Retrieved from World Health Organzation: 
http://www.who.int/medicines/areas/policy/doha_declaration/en/ 
World Health Organziation. (2008). Counterfeit Drugs Kill! Rome: IMPACT - International 
Medical Products Anti-Counterfeiting Taskforce. 
 
